<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
- ---
EXCHANGE ACT OF 1934
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
- --- EXCHANGE ACT OF 1934
For the Year Ended December 31, 1999 Commission File Number: 0-16937
SUMMIT TECHNOLOGY, INC.
-----------------------
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 04-2897945
------------------------ ------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
21 HICKORY DRIVE, WALTHAM, MASSACHUSETTS 02451
-------------------------------------------------------------
(Address of principal executive officer) (Zip Code)
(781) 890-1234
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: none
Securities registered pursuant to Section 12(g) of the Act:
Common Stock and Common Share Purchase Rights
----------------------------------------------------------
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. X YES NO
-- --
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
Based on the closing price for the registrant's voting stock on March 24, 1999,
the aggregate market value of such voting stock held by non-affiliates of the
registrant was approximately $462.8 million on said date. The number of
shares of the registrant's Common Stock, $.01 par value, outstanding on March
24, 1999 was 46,867,723.
DOCUMENTS INCORPORATED IN TEXT BY REFERENCE
Certain portions of the Company's Proxy Statement for the 2000 Annual Meeting of
Stockholders (the "Proxy Statement") are incorporated by reference into Part III
of this Report.
<PAGE> 2
PART I
ITEM 1. BUSINESS
GENERAL
We are a leading worldwide manufacturer and supplier of excimer laser
systems and related products used to perform procedures that correct common
refractive vision disorders such as nearsightedness, farsightedness and
astigmatism. We also sell contact lenses and other vision products by mail order
through our Lens Express subsidiary.
Our operations presently consist of two operating segments: (i) vision
correction, which includes manufacturing, selling and servicing laser systems
and related products to correct vision disorders and collecting per procedure
license fees from users of our systems and (ii) contact lenses and related
products sold via mail order by Lens Express.
We continue to evaluate our operations and strategies, which may result
in the acquisition of one or more additional businesses, or dispositions of all
or part of one or more of our businesses.
INDUSTRY OVERVIEW
LASER VISION CORRECTION
Laser vision correction is a surgical procedure for correcting
disorders such as nearsightedness, farsightedness and astigmatism using an
excimer laser. This procedure uses ultraviolet laser energy to remove tissue
from the surface of, and thus sculpt, the cornea into a predetermined shape.
Because the excimer laser is a cold laser, it is possible to ablate, or remove,
precise amounts of corneal tissue without causing thermal damage to surrounding
tissue. The goal of laser vision correction is to eliminate or reduce a person's
reliance on corrective eyewear.
Today, there are two principal methods for performing laser vision
correction with excimer laser systems: photorefractive keratectomy, or PRK, and
a form of PRK known as laser in-situ keratomileusis, or LASIK. In a PRK
procedure, tissue is removed from the outermost surface of the cornea, just
beneath the epithelium. In a LASIK procedure, the ophthalmologist uses a device
called a microkeratome to surgically create a thin, hinged flap of corneal
tissue. The flap is folded back, the laser energy is directed to the corneal
surface exposed beneath the flap, and the flap is folded back into place. The
LASIK procedure generally involves less post-operative discomfort and faster
visual results than PRK, often resulting in a high degree of immediate patient
satisfaction.
In both PRK and LASIK procedures, an ophthalmologist determines the
exact correction required to be made to the cornea, typically using the same
examination used to prescribe eyeglasses and contact lenses. Required
corrections are then programmed into the excimer laser system's computer.
During a procedure, the excimer laser system emits laser pulses, each
of which lasts several billionths of a second, to remove submicron layers of
corneal tissue. The average procedure lasts approximately 15 to 60 seconds.
Cumulative exposure to the laser light is less than one second. The entire
procedure, including patient preparation and post-operative dressing, generally
lasts no more than thirty minutes.
Following the procedure, an ophthalmologist may prescribe topical
pharmaceuticals to promote corneal healing and to alleviate discomfort.
Post-procedure responses vary depending upon the individual patient and the type
of
-2-
<PAGE> 3
procedure performed. Individuals undergoing laser vision correction may
experience discomfort for approximately 24 hours, and blurred vision for
approximately 48 to 72 hours, after the procedure. Although many patients
experience improvement in vision without the use of eyeglasses or contact lenses
within a few hours or days of the procedure, it can take up to two to six months
for the correction to stabilize and for the full benefit of the procedure to be
realized.
REFRACTIVE VISION CORRECTION MARKET(1)
The market for products and services to correct common refractive vision
disorders such as nearsightedness, farsightedness and astigmatism is large and
growing. Market Scope estimates that 50% of the U.S. population, or
approximately 140 million Americans, presently use eyeglasses or contact lenses.
In 1999, U.S. optical retail sales (excluding laser vision correction)
totaled approximately $15 billion, most of which consisted of sales of
eyeglasses, contact lenses and other vision correction products. Eyeglasses and
contact lenses are large, mature segments of this market.
Laser vision correction is a small, but fast growing segment of the vision
correction market. Since 1996, according to Market Scope, total industry
procedure volume in the United States has doubled each year, increasing from
105,000 procedures in 1996, to 215,000 procedures in 1997, to 480,000 procedures
in 1998 to 950,000 procedures in 1999. Market Scope predicts that over 1.5
million procedures will be performed in the United States in 2000. Based on
presently existing treatment modalities, some of which are not yet FDA-approved,
and on demographic considerations such as age, income and type of correction
needed, Market Scope estimates that there are approximately 37 million people in
the United States who would make excellent candidates for laser vision
correction.
Laser vision correction's rapid growth in the United States is also
reflected in the expansion of excimer laser installations, in the rise in
average annual procedure volume per laser and in the increasing number of
ophthalmologists now practicing refractive surgery. Market Scope predicts a U.S.
installed base of 1,210 systems by the end of 2000, up from 899 systems at the
end of 1999, 476 systems at year end 1998, and 365 systems at year end 1997.
Average procedures per laser center per year are predicted to increase to 1,856
in 2000, up from 1,416 in 1999, 1,102 in 1998 and 542 in 1997.
Similarly, out of a total of approximately 14,000 practicing
ophthalmologists in the United States, Market Scope estimates that the number
identifying themselves as refractive surgeons will be approximately 4,000 by the
end of 2000, up from 3,400 at the end of 1999, just over 2,000 in 1998 and 1,000
in 1997. We believe U.S. ophthalmologists are receptive to laser vision
correction because of the potential for excellent clinical results and high
patient satisfaction, and because laser vision correction is an attractive
source of revenue that does not usually involve Medicare and managed care
reimbursement complexities. For this reason, we believe that many U.S.
ophthalmologists are transitioning their practices from Medicare reimbursed
cataract surgery to laser vision correction.
We believe the accelerating popularity of laser vision correction in the
United States has been driven, in part, by the increased patient satisfaction
associated with the LASIK procedure. In October, 1999, we became the first
commercial manufacturer to obtain an FDA approval for LASIK when our
Infinity(TM) system (formerly known as the Apex Plus) was approved to treat
high degrees of nearsightedness and astigmatism using LASIK. Applications for
approval of our LADARVision system to treat nearsightedness, farsightedness and
astigmatism using LASIK, and of our Infinity system to treat farsightedness and
astigmatism using LASIK, are presently pending before the FDA. On March 17,
2000, the FDA Ophthalmic Advisory Panel unanimously recommended approval of our
LADARVision system for treatment of farsightedness with or without astigmatism
and mixed astigmatism using LASIK, with conditions. While the FDA is not bound
by the Panel's recommendations,
(1) Apex Plus(TM), CustomCornea(TM), emphasis(R) Disc, LADARVision(R),
OmniCard(R), and SKBM(TM) Microkeratome are our trademarks and registered
trademarks. Other trademarks used in this Report are the property of their
respective holders.
In addition, the data concerning the laser vision correction industry that
we cite throughout this Annual Report on form 10-K are based upon information
published in Refractive Market Perspective, an independent publication that
follows the refractive vision correction market, and on information from a
presentation made in April 1999 by Mr. David R. Harmon of MarketScope, the
publisher of Refractive Market Perspectives, before the American Society of
Cataract and Refractive Surgery. We believe that this information is the most
reliable data currently available about our industry. However, we have not
independently verified any of the data and we cannot assure their accuracy or
completeness.
-3-
<PAGE> 4
they are accorded significant weight. Despite the fact that we do not presently
have LASIK approvals over the full range of treatment modalities, and that
certain other manufacturers have no LASIK approvals, U.S. ophthalmologists are
not prohibited from performing LASIK procedures using equipment that has been
approved for PRK. We believe the vast majority of laser vision correction
procedures now being performed in the United States are LASIK procedures.
Other alternatives for correcting refractive vision disorders include
radial keratotomy, which involves reshaping the cornea with a series of scalpel
cuts, and surgically implantable rings, which were recently approved by the FDA.
A holmium laser system has been developed for farsightedness. This system would
involve reshaping the cornea using thermal energy, in contrast to our cold
excimer laser system. This system was recommended for approval by the FDA's
Ophthalmic Advisory Panel in January 2000.
DEVELOPMENT OF THE LASER VISION CORRECTION INDUSTRY
In October 1995, we were the first manufacturer to receive FDA approval
to market an excimer laser system for PRK. Our initial approval was for the
correction of low to moderate nearsightedness. VISX, our principal competitor,
received PRK approval for low to moderate nearsightedness in March 1996. FDA
approvals have been a critical aspect of U.S. industry development, as expanded
treatment approvals also expand the pool of laser vision correction candidates
to whom the procedure can be marketed.
FDA approvals have also been a key competitive element in the industry. A
manufacturer with broader FDA approval ranges can address a wider patient
population. In the U.S. market, VISX obtained approval to expand its labeling to
include astigmatism in April 1997, approximately one year before we obtained
astigmatism approval for the Apex Plus. VISX obtained approval to treat higher
degrees of nearsightedness in January 1998 and to treat farsightedness in
November 1998. We believe that VISX's lead in obtaining these labeling
expansions has helped it achieve early dominance in the laser vision correction
industry, with an estimated 75-80% share of total U.S. procedure volume in 1999.
Our applications for approval of the Infinity system to treat farsightedness
using PRK, and higher degrees of nearsightedness and astigmatism using LASIK,
were approved by the FDA in October, 1999. In December of 1999, VISX obtained
FDA approval to treat high nearsightedness and astigmatism using LASIK. Thus, at
December 31, 1999, the VISX system and our Infinity system possessed roughly
equivalent FDA labeling. Our application for approval of the Infinity system to
treat farsightedness with or without astigmatism using LASIK, and of the
LADARVision(R) system to treat nearsightedness, farsightedness and astigmatism
using LASIK, are presently pending before the FDA. On March 17, 2000, the FDA's
Ophthalmic Advisory Panel unanimously recommended approval of our LADARVision
system for treatment of farsightedness with or without astigmatism, and mixed
astigmatism, using LASIK, with conditions. The Panel's recommendation was for up
to +6.0 diopters of farsightedness and an astigmatism range of up to -6.0
diopters. Final acceptance of the Panel's recommendation by the FDA would result
in our systems having the broadest range of approvals of any FDA approved
excimer laser system.
Although FDA approval requirements create a significant barrier to entry into
the U.S. laser vision correction field, Nidek, LaserSight and Bausch & Lomb have
also obtained FDA approval of their systems to treat varying degrees of
refractive error. The table below summarizes the currently approved treatment
ranges with PRK and LASIK for all excimer laser systems currently approved by
the FDA. The labeling for each device contains a more detailed description of
the ranges summarized below.
-4-
<PAGE> 5
<TABLE>
<CAPTION>
Manufacturer-Device Disorder Current Approval Range
<S> <C> <C>
- -------------------------------- ------------------------ ------------------------------------------------------
Summit-Infinity/Apex Plus PRK Myopia Up to -7.0 Diopters
PRK Astigmatism-Myopia Up to -6.0 Diopters of Myopia with up to -4.0 Diopters of
Astigmatism and Spherical equivalent limited to below -6.0
Diopters
PRK Hyperopia Up to +4.0 Diopters
LASIK-Expanded Up to -14.0 Diopters of Myopia, with up to
Astigmatism-Myopia -5.0 Diopters of Astigmatism
- -------------------------------- ------------------------ ------------------------------------------------------
Summit-Autonomous LADARVision PRK Astigmatism-Myopia Up to -10 Diopters of Myopia with up to -4.0 Diopters of
Astigmatism
- -------------------------------- ------------------------ ------------------------------------------------------
VISX-StarS2 PRK Myopia Up to -12.0 Diopters
PRK Astigmatism-Myopia Up to -12.0 Diopters of Myopia with up to -4.0 Diopters
of Astigmatism
PRK Hyperopia Up to +6.0 Diopters
LASIK-Expanded
Astigmatism-Myopia Up to -14.0 Diopters of Myopia, with up to -5.0 Diopters of
Astigmatism
- -------------------------------- ------------------------ ------------------------------------------------------
Nidek EC 5000 PRK Myopia Up to -13.0 Diopters
PRK Astigmatism-Myopia Up to -8.0 Diopters of Myopia with up to -4.0 Diopters of
Astigmatism
- -------------------------------- ------------------------ ------------------------------------------------------
LaserSight-LSX PRK Myopia Up to -6.0 Diopters
- -------------------------------- ------------------------ ------------------------------------------------------
Bausch & Lomb-Technolas 217 LASIK Astigmatism-Myopia Up to -7.0 Diopters of Myopia with up to -3.0 Diopters
of Astigmatism
- -------------------------------- ------------------------ ------------------------------------------------------
</TABLE>
The development of the laser vision correction industry has also been
technology and patent driven. In addition to regulatory hurdles, we believe new
entrants will need to obtain licenses to key patents owned by us and by VISX. In
1992, we and VISX entered into a patent pooling partnership -- Pillar Point
Partners -- intended to resolve our patent disputes, enable each company to
develop and commercialize its products free of infringement and offer
comprehensive licenses to
-5-
<PAGE> 6
other FDA-approved manufacturers. Pillar Point Partners was dissolved in 1998 by
mutual agreement. As part of that dissolution, we exchanged royalty-free patent
cross-licenses with VISX. Thus, any new entrants who want to obtain licenses to
these patents must now negotiate separately with us and with VISX if they wish
to obtain licenses to our respective patents.
The laser vision correction industry today addresses only a small portion
of the population with refractive vision disorders. Current excimer laser
systems have just begun to penetrate the large market of individuals with
refractive vision disorders. We believe that manufacturers with a wide range of
FDA approvals who are able to successfully commercialize new technologies will
accelerate penetration of the laser vision correction market and allow the
capture of a greater portion of this market.
PRODUCTS
We currently offer the following laser vision correction systems and
related products:
INFINITY(TM) LS
The FDA has approved our Infinity LS excimer system (formerly known as
the Apex Plus) for sale in the United States to treat (i) low, moderate and high
degrees of nearsightedness, alone and with low to moderate astigmatism, using
PRK or LASIK, and (ii) low to moderate degrees of farsightedness, without
astigmatism, using PRK. We have filed applications with the FDA seeking approval
to treat farsightedness with or without astigmatism using LASIK. We sell the
Infinity LS in the U.S. and selected international markets. The Infinity LS is
the successor to our Apex Plus system. It has been re-engineered to include, or
be upgraded to include when available, several enhancements designed to improve
ergonomics and ease of use, including graphical user interface, projected
reticle microscope and two bottle gas handling system. On February 3, 2000, the
FDA approved our request to officially change the name of the Apex Plus to the
Infinity LS and all new production of this system is marketed under the Infinity
name. We may also refurbish and resell previously sold Apex Plus units that are
acquired through trade or similar means. These units, which do not include
Infinity enhancements, will continue to be sold as Apex Plus systems.
The Infinity LS is configured to treat nearsightedness using a mechanical
iris device that shapes light. It is also configured to treat farsightedness,
astigmatism and both nearsightedness or farsightedness with low to moderate
astigmatism using our emphasis Disc. Our emphasis Disc is a proprietary
single-use polymer disc that is used with the Infinity LS to treat a wide range
of refractive disorders. The disc is designed to create very smooth and precise
corneal ablations, without reliance on complicated optomechanics, resulting in
improved healing and enhanced refractive outcomes. This technology permits the
ophthalmologist to select a disc that is matched to the patient's refractive
error, in much the same way that an appropriate contact lens might be selected.
During a procedure, the shape of the disc is precisely replicated on the cornea.
We presently produce discs for correcting astigmatism, nearsightedness with
astigmatism, farsightedness and farsightedness with astigmatism. As part of the
Infinity approvals described above, the FDA has approved the disc in the United
States for treatment of low to moderate nearsightedness with astigmatism and low
to moderate farsightedness without astigmatism. The disc is included in our
clinical submissions for expanded Infinity indications. We are working to
develop additional applications for our emphasis Disc, including development of
patient-specific, customized discs for treatment of difficult or unusual cases.
The international version of the Infinity LS is configured to treat a full range
of refractive disorders, including astigmatism, farsightedness, high degrees of
nearsightedness and combinations of these disorders.
-6-
<PAGE> 7
Our U.S. list price for the Infinity LS is $375,000. Actual prices
charged to customers may vary, depending on a number of factors including
whether the system is new or refurbished, whether it is outfitted with any
optional upgrades and whether its purchase is bundled with other products and
services. The list price for our emphasis Disc is $25.00 in the United States
and $75.00 in international markets. Actual prices charged to customers for the
emphasis Disc may vary, depending upon a number of factors, including pricing
programs which combine emphasis Discs with other products and services.
We sell OmniCards(R) to facilitate the collection of per-procedure
license fees due in connection with use of the Infinity LS and its predecessor
systems in the United States. OmniCards are credit card-sized, data encrypted
plastic cards that must be inserted into the system to enable customers to
perform a procedure. These OmniCards must be purchased from us. OmniCards may be
encoded with a single procedure or with several procedures, and are priced based
on the number of procedures they permit. The card cannot be reused once the
permitted number of procedures have been performed. Prior to February 23, 2000,
the list price of OmniCards was $250.00 per procedure, with actual pricing
variable based on factors including volume discounts and promotions,
participation in one of our innovative bundled pricing programs which combine
OmniCards with other products and services, and whether the customer is or was
one of our clinical investigators. In response to competitive pressures, we
reduced the list price of OmniCards to $100 effective February 23, 2000. Actual
pricing may continue to vary based on the factors described above.
LADARVISION SYSTEM
The FDA has approved the LADARVision system for low to high levels of
nearsightedness alone or with low to moderate astigmatism. Our applications to
market the LADARVision system to treat a full range of refractive errors using
LASIK, including nearsightedness and farsightedness with or without astigmatism,
and mixed astigmatism, is presently pending before the FDA. On March 17, 2000,
the FDA's Ophthalmic Advisory Panel recommended approval of the LADARVision
system for treatment of farsightedness with or without astigmatism, and mixed
astigmatism, using LASIK, with conditions. The Panel's recommendation was for up
to +6.0 diopters of farsightedness and an astigmatism range of up to -6.0
diopters. The LADARVision system combines high-speed, laser radar eye tracking
with narrow beam corneal shaping. The LADARVision system is designed to address
a need for sophisticated eye tracking to compensate for eye movement during
surgery, including saccadic eye movements. Saccadic eye movements are very
rapid, involuntary and random in amplitude and direction and are not suppressed
or reduced by medication used during laser vision correction procedures. These
eye movements degrade predictability and visual quality from the procedure. The
LADAR eye tracker measures and adjusts more than 4,000 times per second. We
believe that the LADARVision system provides higher accuracy ablation by
virtually eliminating shaping error caused by eye movement. Additionally, the
narrow beam excimer provides a smooth ablation, and the LADARVision system's
shaping algorithms offer high speed ablations to minimize surgical duration
while retaining high pointing accuracy to achieve predictable shaping.
We believe the LADARVision system will yield more stable, predictable
results with less post-operative regression, thereby improving visual quality
and clinical outcomes for low to moderate levels of nearsightedness compared to
first generation excimer laser vision correction systems. We also believe
extensions of the LADARVision platform may yield even greater improvements in
patient results for vision disorders that require more complex corneal reshaping
such as farsightedness, higher degrees of nearsightedness and astigmatism and
combinations of these disorders.
Our proprietary software in the LADARVision system is a user-friendly,
32-bit Windows-based, graphical user interface incorporating high resolution,
real-time
-7-
<PAGE> 8
imaging of both the tracked and untracked eye images. The software is
designed with full patient database features and unique eye tracker information
available to identify and count surgical procedures.
Our current strategy is to offer these systems for sale at a list price
of $575,000 and a per procedure license fee of $150. Alternatively, customers
may elect to lease these systems on a per-procedure basis which includes
service, maintenance and licensing fees. System and per-procedure pricing may
vary based upon a number of factors, including the customer's procedure volume
commitment and other variables similar to those applicable to our other
products.
SKBM(TM) MICROKERATOME
Our SKBM(TM) microkeratome is a medical device designed exclusively for
use in ophthalmic surgery. It can be used in LASIK procedures to create a flap
on the anterior corneal surface or to dissect a thin layer of corneal tissue
that remains attached to the rest of the cornea via a small hinge of tissue. The
operator of the SKBM microkeratome can control and change the size of the hinge,
the blade traverse distance, the advancement speed of the steel blade, and the
oscillation speed of the blade by means of front panel settings. Our SKBM
microkeratome utilizes disposable, single-use blades. In December, 1998, we
received FDA clearance to market our SKBM microkeratome in the United States for
keratoplasty, corneal harvesting and microlamellar keratoplasty. The list price
of our SKBM microkeratome is $58,100. The list price of the disposable
microkeratome blade is $62.00 per blade. Actual prices charged to customers may
vary.
SALES AND MARKETING
Our sales and marketing efforts are focused on innovative and flexible
programs tailored to the particular needs of our customers -- ophthalmologists,
clinics and hospitals. We sell our excimer laser systems, microkeratomes and
related products in more than 50 countries through a direct sales force,
independent sales representatives and distributors. We sell our products on open
credit to select distributors and end users. In many instances we require a
letter of credit or a commitment from a third party lessor to secure payment.
Working alone or in conjunction with independent leasing companies, we offer our
U.S. customers a variety of innovative programs that bundle the price of all or
a combination of equipment, per-procedure license fees, emphasis Discs and
service into a single periodic payment. Under these programs, our customers may
elect to purchase their systems and related products and services directly,
lease to own, or accept systems on an all-inclusive per-procedure basis where we
retain ownership. Although our initial strategy was to offer LADARVision systems
solely on the latter basis, our experience has been that customers desire and
are receptive to a variety of LADARVision acquisition options, which we now
offer. At March 20, 2000, we had 31 people employed in sales and marketing. On
January 1, 2000, we formally integrated our Autonomous and Summit sales forces
into a single, unified sales force. The efforts of our sales force are augmented
by our senior executives, who participate in our Executive Champion program.
Under this program, nine of our senior executives take responsibility for our
top 50 customer accounts to make sure that these accounts are receiving the
utmost in customer attention.
Our sales force includes five refractive marketing representatives who
assist customers in developing programs and materials to help grow their laser
vision correction practices. We have developed marketing materials that
ophthalmologists can use to inform their patients about the benefits of laser
vision correction. We also offer an innovative patient financing program,
underwritten by an independent financing company which we have made available
only to our own customers. We use our web site for marketing purposes and have
established a "Find a Doctor" section where consumers can locate a doctor to
whom they can be referred for a laser vision correction procedure with one of
our excimer laser systems. We believe that practice marketing is often most
effective when it emphasizes the surgeon, rather than the
-8-
<PAGE> 9
equipment. Our marketing programs are structured to help our individual users
market their practices to prospective laser vision correction candidates.
PATENTS
There are a number of U.S. and foreign patents or patent rights covering
methods and apparatus for performing laser ablation of corneal tissue. We and
VISX own a large number of these patents. We believe that the patents we own and
the patents we license are valuable to our business and represent a key
competitive advantage in our industry.
Pillar Point Partners. Between 1992 and 1998, we were a partner with VISX
in a partnership called Pillar Point Partners. The partnership was formed in
1992 as a result of a dispute between us and VISX over U.S. patents covering
methods and apparatus for performing ultraviolet laser corneal surgery. In
forming the partnership, all U.S. patents that we then owned or were later
granted to us or VISX which could have precluded either company from making,
using or selling in the United States our excimer laser systems as designed on
that date were required to be exclusively licensed or offered for exclusive
license to Pillar Point Partners. Under the formation agreement, we and VISX
each contributed the exclusive right to make, use and sell apparatus and perform
(including the right to license others to perform) procedures covered by any of
our U.S. patents relating to ultraviolet laser corneal surgery. The partnership
arrangement did not cover foreign patents. The partnership's policy was to
license its patents to manufacturers and sellers of excimer laser systems in the
United States, including us and VISX, in return for per-procedure royalties and
royalties on equipment sales.
Along with VISX and Pillar Point Partners, we became involved in several
lawsuits with respect to Pillar Point Partners relating to royalties, patent
infringement by others and antitrust issues. On March 24, 1998, the Federal
Trade Commission commenced an administrative enforcement proceeding against us
and VISX alleging antitrust violations in connection with the partnership's
patent arrangements. The FTC also alleged that some of the patents licensed by
VISX to the partnership were fraudulently obtained by VISX. The FTC has not
challenged the validity of any of our patents. The FTC sought an order
dissolving Pillar Point Partners and requiring that VISX cease charging
royalties on the patents alleged by the FTC to have been fraudulently obtained.
In June 1999, an FTC administrative law judge issued a decision in favor of VISX
and the FTC has appealed this decision. In December, 1999 the FTC staff filed a
motion indicating they would drop their appeal because it appeared that one of
the key VISX patents at issue, the Trokel '388 patent, would emerge from a
patent office reexamination with strong claims. The FTC stated it would drop its
appeal at such time as the Patent and Trademark Office formally acted. To date,
the Patent and Trademark Office has not done so. In 1997, VISX commenced a
lawsuit against us and the partnership seeking a declaration that it did not
have to pay royalties to the partnership for LASIK procedures performed on VISX
systems in the United States. On February 17, 1998, VISX commenced another
lawsuit against us seeking a dissolution of the partnership. On June 4, 1998, we
settled all outstanding disputes and litigation with VISX. Under the settlement,
Pillar Point Partners was dissolved. In addition, we and VISX granted to each
other worldwide, royalty-free cross-licenses to all of our U.S. and foreign
patents in the field of laser ablation of corneal tissue. These cross-licenses
permit each of us to license each other's patents to users of our equipment.
Both of us have retained all rights to license our own patents to other
manufacturers. As part of the settlement, VISX paid us $35 million.
On December 6, 1999, the U.S. International Trade Commission (ITC)
issued an Initial Determination to the effect that the Nidek EC-5000 excimer
system did not infringe two VISX patents licensed to us and that one of those
patents, the Trokel '762 patent, was invalid and unforceable due to certain
alleged inventorship issues. On March 6, 2000, the ITC issued a Final
Determination upholding the non-
-9-
<PAGE> 10
infringement findings of the Initial Determination and taking no position as to
the validity or enforceability of the '762 patent.
Autonomous patents. Our Autonomous subsidiary has filed a total of
fifteen patent applications in the United States. Eight of the fifteen U.S.
patent filings have resulted in patents being issued. The earliest of these
patents will expire in 2014, and the latest will expire in 2017. Autonomous has
also filed numerous patent applications in foreign jurisdictions.
The patents and applications generally relate to the following areas:
- CustomCornea;
- a cartridge excimer laser device for high serviceability;
- fast response eye tracking;
- fast and accurate optical narrow beam delivery system with tracking;
- ablation with shot pattern, with minimal sensitivity to ablation
debris;
- the algorithm for shaping with arbitrary combinations of plus and minus
sphere and cylinder; and
- measuring vision defects of a human eye.
Other. In 1992, IBM granted us a non-exclusive license to its patent
covering excimer laser ablation of tissue. The terms of the license permit us to
sublicense our subsidiaries. We agreed to pay to IBM a royalty of 2%, net of
related expenses, on all excimer laser systems we sell or lease in the United
States and other countries that are covered by this license. LaserSight has
notified us that it has acquired IBM's rights under this license agreement. We
do not believe the transfer will materially affect our rights or obligations
under the license. In 1996, IBM granted Autonomous a non-exclusive license to
the same patent, providing for a royalty of 5% applicable to both sales and per
procedure usage fees, net of related expenses. We do not believe that this
license has been transferred by IBM. In December 1999, we terminated Autonomous'
IBM license. Going forward, we are treating Autonomous as a sublicensed
subsidiary under our 1992 license agreement. We have also entered into a license
agreement with Patlex Corporation under which we pay a royalty on various laser
components of our products.
RESEARCH AND DEVELOPMENT
We continually invest in research and product development to improve our
technology and enhance our current systems. As of March 20, 2000, we have 121
full-time employees committed exclusively to research, engineering, product
development and regulatory and clinical affairs. We spent $14.2 million in 1999,
$7.2 million in 1998, and $6.2 million in 1997 for research, engineering and
product development, including regulatory and clinical affairs. These figures do
not include amounts that Autonomous spent on these activities in 1998 and 1997,
which totaled $6.4 million in 1998 and $6.0 million in 1997.
Our current research and development projects include:
CustomCornea. We are developing CustomCornea, a patent pending
technology designed to further extend the precision and flexibility of
the LADARVision system by incorporating an advanced wavefront eye
measurement technology. The advanced eye measurement technology will
allow CustomCornea to determine the more subtle errors of the human
visual system. With this information, the LADARVision system can address
what we believe will be a
-10-
<PAGE> 11
growing demand for custom ablations specifically tailored for individual
patients, offering the promise of outstanding results that consistently
exceed 20/20. CustomCornea is also intended to offer correction of the
degrading effects of complex corneal topographical anomalies, including
irregular astigmatism. A successful clinical trial of the measurement
aspects of the CustomCornea technology was conducted during late 1997 on
approximately 100 eyes with a prototype device. In June 1999, the FDA
granted us clearance to commence clinical trials of the CustomCornea
technology with the LADARVision system to correct a full range of
refractive disorders using both PRK and LASIK. These clinical trials are
underway, with 23 eyes treated through March 22, 2000, and promising
results. At present we are the only manufacturer in active, FDA-approved
clinical trials with this type of technology. We believe that
CustomCornea corrections offer the promise of increased contrast
sensitivity, improved night vision and uncorrected visual acuity beyond
that offered by current technology.
Engineering improvements. We continue to spend significant amounts
on engineering to improve both the Infinity and LADARVision systems and
the SKBM microkeratome in order to enhance their performance in clinic
operation and to improve manufacturability and serviceability.
Operational performance improvements include not only enhancements in
electrical/electronic and optical performance, but also implementation of
physician requested features to further enhance ease of use. We are
finalizing our Infinity package upgrade with a new microscope for better
visualization, on-site energy calibration to ensure better energy
distribution and an easier-to-use graphical interface.
SYSTEM INSTALLATION, TRAINING AND SERVICE
We train our employees and distributors on how to properly install and
maintain our excimer laser systems. We believe that educating our customers and
informing them about system developments is an important way to ensure customer
satisfaction and desirable clinical results. After installation, one of our
clinical specialists will typically travel to a customer site to train the
ophthalmologist how to safely operate our excimer laser system and successfully
perform laser surgery. We have also developed an extensive set of written
materials to inform ophthalmologists about how our excimer laser system works.
We generally include installation, training and the first year of maintenance in
the purchase price of our excimer laser systems. After the initial year of
maintenance, we offer annual equipment maintenance contracts, at list prices
ranging from $45,000 to $70,000 depending on the type of system and level of
service selected. Prices may vary depending on various factors, including
the type of equipment and whether the price of service is bundled with other
products or services. We also maintain a 24-hour telephone call service for
emergency maintenance calls.
COMPETITION
The vision correction industry is subject to intense competition.
Our excimer laser systems compete with other excimer laser systems in the
United States and abroad. In the United States, there are presently four
manufacturers in addition to us that have obtained FDA approval to commercially
market and sell their excimer laser systems: Bausch & Lomb, LaserSight, Nidek
and VISX. Because Bausch & Lomb and LaserSight only recently obtained FDA
approval to enter the U.S. market, our principal competitors to date have been
VISX and Nidek.
Until the fourth quarter of 1999, the VISX system was FDA approved for
a broader range of treatment indications than our Infinity system, giving VISX a
competitive advantage in the U.S. marketplace. We estimate that in 1999
approximately 75-80% of U.S. laser vision correction procedures were performed
using VISX systems. In October of 1999, our Infinity system was FDA approved to
treat farsightedness and higher degrees of nearsightedness with or without
astigmatism
-11-
<PAGE> 12
using LASIK, resulting in substantially equivalent labeling of the Infinity and
VISX systems as of the end of 1999. On March 17, 2000, the FDA's Ophthalmic
Advisory Panel recommended approval of our LADARVision system for treatment of
farsightedness with or without astigmatism and mixed astigmatism, using LASIK.
The Panel recommended approval for up to +6.0 diopters of farsightedness, as
well as an astigmatism range of up to -6.0 diopters. Although the FDA is not
bound by the Panel's recommendation, it is typically accorded great weight. Our
applications for approval of the Infinity system for farsightedness with or
without astigmatism using LASIK and for the LADARVision system for
nearsightedness and astigmatism using LASIK are also pending.
On February 22, 2000, VISX announced that it was lowering its U.S. per
procedure licensing fee to $100. For obvious competitive reasons, the Company
responded by lowering its own U.S. per procedure licensing fee. Effective
February 23, 2000, the Company instituted a tiered pricing program for its U.S.
customers. The Company's Apex Plus/Infinity excimer laser system will be value
priced and will carry a per procedure licensing fee of $100. The emphasis(R)
disc used in conjunction with the Apex Plus/Infinity System for astigmatism and
hyperopic corrections will be priced at $25. LADARVision(R) system procedures
will be premium priced at $150 per procedure for purchased units. Actual prices
charged to customers may vary. Customers who have acquired Apex
Plus(TM)/Infinity(TM) and/or LADARVision(R) Systems utilizing a program which
bundles the licensing fee with other products and services will receive
adjustments to their programs to reflect the reduced pricing.
Competing manufacturers of excimer laser systems may have greater
financial resources than us, may be able to offer their products at a lower cost
or may develop products that involve a lower per-procedure cost. In 1998, Nidek
received approval from the FDA to market its system in the United States for up
to -13.0 diopters of nearsightedness and in September, 1999 received approval to
treat up to -4.0 diopters of astigmatism with -8.0 diopters or less of
nearsightedness. The Nidek system has not been approved to treat farsightedness.
Nidek has not been charging its customers per-procedure license fees. Nidek has
not obtained patent licenses from us or VISX and is presently the subject of
patent infringement suits brought by both companies.
Bausch & Lomb received approval of its Technolas 217 system in
February, 2000. The Bausch & Lomb system is approved for treatment of up to -7.0
diopters of nearsightedness with or without up to -3.0 diopters of astigmatism,
using LASIK. Bausch & Lomb offers a full line of ophthalmic surgical products,
and we believe it will try to leverage its existing presence in ophthalmology in
its efforts to gain market share. Bausch & Lomb has stated that it will charge
its U.S. customers $100 per procedure.
LaserSight received FDA approval of its LSX system in November, 1999
for treatment of up to -6.0 diopters of nearsightedness, with the ability to
treat up to -10.0 diopters of nearsightedness in the discretion of the treating
physician. LaserSight has stated that TLC Laser Eye Centers Inc., a
publicly-held operator of laser vision correction centers in the U.S. and
Canada, has invested approximately $20 million in LaserSight. TLC has stated
that it intends to equip some of its centers with the LSX system, as well as
with our LADARVision system and the Bausch & Lomb system. LaserSight has stated
that it will charge its U.S. customers $130 per procedure.
Neither Bausch & Lomb nor LaserSight have obtained patent licenses from
us or from VISX. VISX has commenced patent infringement litigation against
LaserSight, and LaserSight has countersued, seeking a declaration that certain
VISX patents are invalid and unenforceable.
On April 12, 1999, KeraVision announced it had received FDA approval to
market its Intacs surgically implantable corneal ring for correction of up to
- -3.0 diopters of nearsightedness. We cannot predict whether, or the extent to
which,
-12-
<PAGE> 13
corneal rings will ultimately garner significant market share in the vision
correction market but believe the manufacturer's claims that the procedure is
reversible may be attractive to some candidates. We believe that the ring's
market penetration to date has been limited.
Sunrise Technologies' application for FDA approval of its holmium laser
for treatment of .75 to 2.5 diopters of farsightedness was recommended by the
FDA's Ophthalmic Advisory Panel in January, 1999, with conditions. We believe
this system is designed only for treatment of farsightedness and involves
reshaping the cornea using thermal energy, in contrast to our cold excimer laser
system. We cannot predict the degree to which this system will achieve market
acceptance if it is commercially approved. The Sunrise Technologies system's
relatively small size and claimed ease of use may be attractive to many
ophthalmologists.
Competition in the Microkeratome Market
There is substantial competition in the microkeratome market. Bausch & Lomb
and Moria hold significant market share. In addition, there are several smaller
companies offering microkeratomes for sale. Microkeratomes compete based on
safety, efficacy, reliability, versatility, and price. Based on our experience
to date with the SKBM, we believe that it can compete effectively.
GOVERNMENT REGULATION
Medical device regulation. The FDA regulates the manufacture,
distribution and production of medical devices in the United States. Our
products are regulated as medical devices by the FDA under the Federal Food,
Drug, and Cosmetic Act. In order to sell such products in the United States, we
must obtain a premarket clearance or premarket approval by the FDA.
Noncompliance with applicable requirements can result in any one or more of the
following:
- fines;
- injunctions;
- civil penalties;
- recall or seizure of products;
- total or partial suspension of production;
- denial or withdrawal of premarket clearance or approval of devices;
- recommendations by the FDA that we not be allowed to enter into
government contracts; and
- criminal prosecution.
The FDA also has authority to request repair, replacement or refund of
the cost of any device manufactured or distributed by a company.
Medical devices are classified by the FDA as Class I, Class II or Class
III based upon the level of risk presented by the device and whether the device
is substantially equivalent to an already legally marketed Class I or II device.
Class III devices are subject to the most stringent regulatory review and cannot
be marketed for commercial sale in the United States until the FDA grants a
premarket approval, or PMA, for the device.
A PMA application must be filed if a proposed device is not substantially
equivalent to a legally marketed Class I or Class II device, or if it is a Class
III device for which the FDA requires PMAs. The process of obtaining approval of
a PMA
-13-
<PAGE> 14
application is lengthy, expensive and uncertain. It requires the submission of
extensive clinical data and supporting information to the FDA. Human clinical
studies may be conducted only under an FDA-approved investigational device
exemption and must be conducted in accordance with FDA regulations. In addition
to the results of clinical trials, the PMA application includes other
information relevant to the safety and efficacy of the device, a description of
the facilities and controls used in the manufacturing of the device, and
proposed labeling. After the FDA accepts a PMA application for filing and
reviews the application, a public meeting may be held before an FDA advisory
panel comprised of experts in the field.
After the PMA is reviewed and discussed, the panel issues a favorable, or
approvable, or unfavorable, or not approvable, recommendation to the FDA and may
recommend conditions. Although the FDA is not bound by the panel's
recommendations, it historically has given them significant weight. If the FDA's
evaluation of the PMA application is favorable, the FDA typically issues an
"approvable letter" requiring the applicant's agreement to comply with specific
conditions (e.g., changes in labeling) or to supply specific additional data
(e.g., longer patient follow up) or information (e.g., submission of final
labeling) in order to secure final approval of the PMA application. Once the
approvable letter is satisfied, the FDA will issue a PMA order for the approved
indications, which can be more limited than those originally sought by the
manufacturer. The PMA order can include postapproval conditions that the FDA
believes necessary to ensure the safety and effectiveness of the device
including, among other things, restrictions on labeling, promotion, sale and
distribution. Failure to comply with the conditions of approval can result in
enforcement action, including withdrawal of the approval. Products manufactured
and distributed pursuant to a PMA will be subject to extensive, ongoing
regulation by the FDA. The FDA review of a PMA application generally takes one
to two years from the date such application is accepted for filing but may take
significantly longer. The review time is often significantly extended by the FDA
asking for more information, including additional clinical trials or
clarification of information already provided in the submission. A number of
devices for which FDA approval has been sought by other companies have never
been approved for marketing.
Modifications to a device subject to a PMA may require approval by the
FDA of PMA supplements or new PMAs. We believe that our excimer laser systems
require a PMA or a PMA supplement for each of the surgical procedures which they
are intended to perform. The FDA may grant a PMA with respect to a particular
procedure only when it is satisfied that the use of the device for that
particular procedure is safe and effective. In granting a PMA, the FDA may
restrict the types of patients who may be treated.
FDA regulations authorize any interested person to petition for
administrative review of the FDA's decision to approve a PMA application.
Challenges to an FDA approval have been rare. We do not believe any PMA
application has ever been revoked by the agency based on such a challenge. We
are aware that at least two persons have filed a petition with the FDA calling
for reconsideration of the FDA's approval of our PMA for the Apex Plus. One of
these petitions was subsequently withdrawn, and we are unaware of any action
having been taken by the FDA on the other. If the FDA were to grant such a
petition, we could continue to market the device during the agency's
deliberations. If after a hearing, however, the FDA were to revoke its approval
of our PMA application, we would be required to cease marketing the device.
Devices deemed to pose relatively less risk are placed in either Class I
or II, which requires the manufacturer to submit a premarket notification
requesting 510(k) clearance, unless an exemption applies. The premarket
notification must demonstrate that the proposed device is "substantially
equivalent" in intended use and in safety and effectiveness to a legally
marketed "predicate device" that is either in Class I or II, or is a
"preamendment" Class III device (i.e., one that was in commercial distribution
before May 28, 1976) for which the FDA has not yet
-14-
<PAGE> 15
decided to require PMA approval. Our SKB microkeratome received premarket
clearance through the 510(k) process in December 1998.
After a device receives 510(k) clearance, any modification that could
significantly affect its safety or effectiveness, or that would constitute a
major change in its intended use, requires a new 510(k) clearance. The FDA
requires each manufacturer to make this determination in the first instance, but
the FDA can review any such decision. If the FDA disagrees with a manufacturer's
decision not to seek a new 510(k) clearance, the agency may retroactively
require the manufacturer to submit a premarket notification requiring 510(k)
clearance. The FDA also can require the manufacturer to cease marketing and/or
recall the modified device until 510(k) clearance is obtained.
We have obtained FDA approval to conduct several additional studies
involving subsets of patients under our Investigational Device Exemptions for
laser vision correction. In October 1999, the FDA approved our PMA applications
for use of the Infinity system (formerly known as Apex Plus) for treatment of
farsightedness using PRK and for treatment of higher degrees of nearsightedness
and astigmatism using LASIK. In December 1999, the FDA filed and granted
expedited review of our PMA application for use of our Infinity system to treat
farsightedness with or without astigmatism using LASIK. In October 1999, the FDA
filed our PMA application for use of the LADARVision system to treat
farsightedness with and without astigmatism and nearsightedness with and without
astigmatism using LASIK. On March 17, 2000, the FDA's Ophthalmic Advisory Panel
unanimously recommended approval of the LADARVision system, with conditions, for
treatment of farsightedness with and without astigmatism and mixed astigmatism
using LASIK. FDA determined not to submit to Panel the nearsightedness
indications included in the PMA, which are pending. In June 1999, the FDA
authorized us to begin clinical trials of our CustomCornea technology with the
LADARVision system. Through March 22, 2000, we have treated 23 eyes, with
promising results. Our CustomCornea investigational device exemption permits us
to treat both farsighted and nearsighted patients, alone or with astigmatism,
using both PRK and LASIK. We are also conducting clinical research at
international sites in the area of large zone myopia with astigmatism treatment
using LASIK.
Other regulatory requirements. Our products are subject to pervasive and
continuing regulation by the FDA. We are required under FDA guidelines to
manufacture our products in registered establishments and in accordance with its
Quality System Regulations and to list our devices with the FDA. These
regulations impose certain procedural and documentation requirements upon us
with respect to manufacturing and quality assurance activities. Our facilities
are also subject to periodic Quality System Regulations inspections by the FDA.
Labeling and promotional activities are subject to scrutiny by the FDA and by
the FTC. Current FDA enforcement policy prohibits the marketing of approved
medical devices for unapproved uses.
Our lasers are also subject to the Radiation Control for Health and
Safety Act administered by the Center for Devices and Radiological Health of the
FDA. The law requires laser manufacturers to file new product and annual reports
and to maintain quality control, product testing and sales records. In addition,
laser manufacturers must incorporate specified design and operating features in
lasers sold to end users and comply with labeling and certification
requirements. Various warning labels must be affixed to the laser depending on
the class of the product under the performance standard.
The manufacture, sale and use of our products is also subject to numerous
federal, state, local and foreign government laws and regulations relating to
such matters as safe working conditions, manufacturing practices, environmental
protection, fire hazard control and disposal of hazardous or potentially
hazardous substances.
-15-
<PAGE> 16
International regulatory requirements. We may need foreign regulatory
clearances to introduce our products in foreign countries.
LENS EXPRESS
In 1996, we acquired Lens Express, a leading mail order distributor of
contact lenses and related products in the United States. Lens Express' retail
sales consist of:
- new orders of contact lenses
- reorders of contact lenses
- eye care solutions sales
- lens case sales
- sunglass sales
- membership sales
- vitamin sales
- shipping and handling fees
Lens Express wholesales contact lenses and eye care solutions to
pharmacies and similar retail outlets. Lens Express also markets some eye care
programs to large employers as a cost effective alternative to more traditional
vision indemnity programs.
To purchase contact lenses through Lens Express, a customer simply
places a toll-free call to the Lens Express telephone number to place an order.
For customers without a valid prescription, Lens Express will supply the names
of ophthalmologists or optometrists located in a customer's immediate location
from its nationwide network of over 2,700 doctors who will provide an
examination and prescription. Lens Express cannot distribute contact lenses to a
patient without a verified prescription. Many states permit Lens Express to
obtain telephone verification from the patient's contact lens prescriber; other
states have stricter requirements, including at least one state which requires
that Lens Express obtain a written copy of the patient's prescription before
lenses may be shipped. Some practitioners resist verifying prescriptions to Lens
Express because they regard Lens Express as their competitor in the sale of
lenses to their customers. Approximately 79% of Lens Express' orders are shipped
within one business day of when the order is received. The balance cannot be
shipped within one business day either because the product is not in stock or
because Lens Express has not yet been able to verify the customer's
prescription.
We take orders on-line through Lens Express' world wide web site,
www.LensExpress.com. Lens Express' objective is to increase our Internet sales
significantly and become the leading Internet provider of contact lenses,
sunglasses and related products. Our strategy includes:
- reconstruction of our website with state-of-the-art, real time order
processing and other unique features and tools; and
- development of affiliations with other top Internet advertisers and
portals.
Several manufacturers of contact lenses have historically refused to
sell lenses to mail order distributors including Lens Express. Because of this,
Lens Express obtains most of its contact lens inventory from others. The price
Lens Express pays for its inventory is therefore higher in some cases than those
paid by practitioners, chains and others who are able to buy directly from the
manufacturers. Although Lens Express has been able to obtain most contact lens
brands at competitive prices in sufficient quantities on a regular basis, there
are some lens brands that are difficult and/or expensive for Lens Express to
obtain. This has resulted in Lens Express from time to time being unable to fill
some
-16-
<PAGE> 17
customer orders or filling them at little or no profit and has negatively
affected Lens Express' growth and profitability.
Most orders are shipped via priority mail and paid for with a credit
card. Lens Express has little collection or bad debt expenses.
Most of Lens Express' retail customers join the Lens Express Premium
Vision Program for a fee of $29 for three years or $40 for five years.
Membership in this program entitles a member to purchase contact lenses and
other products and devices at member prices. We have recently added a feature to
this program under which we promise not to increase member prices during the
term of membership. We have also added a feature under which each member is
entitled to rebates on future purchases based on past purchasing volume.
In February 2000, we began offering prescription eyeglasses by mail
order. It is too early to evaluate the results of this program.
Marketing and advertising. Lens Express' sales are highly dependent
upon the amount and effectiveness of its marketing and advertising. Lens Express
utilizes primarily television, print, radio, Internet, inserts and referrals.
These efforts have helped produce a database of over several million people who
have expressed an interest in purchasing contact lenses and have requested a
brochure from Lens Express. The use of a well-known celebrity spokesperson, in
combination with our reputation for quality, reliability and service, have
contributed to Lens Express' growth and expanding name recognition. Lens Express
has determined that the use of television represents the greatest opportunity
for customer awareness and, therefore, sales of Lens Express products and
services. Lens Express also uses promotions with major credit cards to market
its services and products. Periodically, Lens Express places coupons offering
replacement contact lenses at special discounts in credit card monthly
statements.
Government regulation. Although some states impose little or no
specific regulation of mail order dispensing of replacement contact lenses,
other states have stricter requirements. Burdensome regulatory requirements
imposed by certain states, such as prohibiting dispensing of replacement lenses
prior to receipt of a written prescription, make it more difficult and expensive
for Lens Express to sell replacement lenses in such states. There can be no
assurance that other states will not enact or impose laws or regulations that
prohibit mail order dispensing of replacement contact lenses or otherwise impair
Lens Express' ability to sell lenses and operate profitably.
Competition. The contact lens and solutions business is extremely
competitive. Lens Express' primary competition are
ophthalmologists/optometrists. Some of these practitioners are reluctant to
provide Lens Express with prescription information for their patients, which can
make it difficult for Lens Express to obtain the timely prescription
verification it requires in order to ship contact lenses. Some pharmacies have
recently begun to sell contact lenses directly to consumers. Several of the mass
merchandisers, such as Wal-Mart, Sam's, and Costco, have entered the optical
market offering lower prices than typically offered by chains and professionals.
There are approximately 15 mail order contact lens companies in the United
States, exclusive of Lens Express. Lens Express believes its principal mail
order competitor to be 1-800-CONTACTS. Lens Express believes that 1-800-CONTACTS
has stated that its practice is to fill orders even if it is unable to obtain a
valid prescription as required by applicable state laws and regulations. We
believe this practice, combined with extensive advertising, has enabled it to
make significant inroads into Lens Express' market share. A number of companies
offer vision care programs and indemnity plans which compete with the Lens
Express Premium Vision Program. Competition for eye care solutions is extremely
intense and price sensitive with generic or private label solutions providing a
cost advantage over traditional higher-priced branded products.
-17-
<PAGE> 18
EMPLOYEES
As of March 20, 2000, we had 566 full-time employees in the United
States, Ireland and other countries. Of these, 422 were employed in our excimer
laser systems business and 144 were employed by Lens Express. Of the laser
systems employees, 281 were employed at Summit and 141 were employed at our
Autonomous subsidiary. The following is a breakdown of the employees in our
excimer laser systems business by functional area:
- 113 in manufacturing;
- 120 in research, engineering, product development and regulatory and
clinical affairs;
- 80 in customer service;
- 31 in sales and marketing; and
- 78 in administration.
Of the total number of our employees, 481 are located in the United
States and 85 are located in Ireland and other parts of the world. None of our
employees is represented by a union or subject to a collective bargaining
agreement. We believe that our relations with our employees are good.
BACKLOG
As of March 22, 1999, the Company had no significant backlog.
CAUTIONARY STATEMENTS AND RISK FACTORS AFFECTING FUTURE OPERATING RESULTS
This report contains information about the Company's future business
prospects including, without limitation, statements about the size of the
potential markets for Laser Vision Correction and the Company's Excimer Systems,
the potential for per procedure license fees, FDA approvals, pending litigation,
and the success of Lens. These statements are considered "forward-looking"
within the meaning of the Private Securities Litigation Reform Act. These
statements are based on the Company's current plans and expectations and involve
risks and uncertainties that could cause actual future activities and results of
operations to be materially different from those set forth in the
forward-looking statements. The following cautionary statements identify
important factors that may cause actual results to differ materially from those
reflected in, or implied by, any such forward looking statements. The Company
expressly undertakes no duty to update any forward-looking statement.
PER PROCEDURE PRICE REDUCTIONS WILL IMPEDE OUR EFFORTS TO ACHIEVE CONSISTENT
PROFITABILITY
Due to competitive pressures, the Company reduced its U.S. per procedure
licensing fees, effective February 23, 2000. This price reduction could delay
the Company's efforts to achieve consistent profitability until at least 2001.
CHALLENGES TO OWNED OR LICENSED INTELLECTUAL PROPERTY COULD ADVERSELY AFFECT OUR
BUSINESS
Failure to maintain the protection afforded by our owned and licensed
patents would materially reduce our revenues. These patents might ultimately be
found to be invalid, or others might elect to infringe these patents or develop
substantially equivalent or competitive products. On February 6, 2000, the U.S.
International Trade Commission (ITC) issued an Initial Determination to the
effect that the Nidek EC-5000 excimer system did not infringe two VISX patents
licensed to the Company and
-18-
<PAGE> 19
that one of those patents, the Trokel '762 patent, was invalid and unforceable
due to certain alleged inventorship issues. On March 6, 2000, the ITC issued a
Final Determination upholding the non-infringement findings of the Initial
Determination and taking no position as to the validity or enforceability of the
'762 patent. On March 24, 1998, the FTC commenced an action challenging and
seeking to invalidate certain of the patents that VISX has licensed to us. We
have settled our part of this litigation. In June 1999, an FTC administrative
law judge issued a decision in favor of VISX and the FTC has appealed this
decision. In March 1999, a U.S. physician wrote us claiming to be a co-inventor
of two of our patents, both of which are the subject of infringement actions
that we have brought against Nidek and other alleged infringers. Alleged
infringers have responded or may respond by challenging the validity and
enforceability of these patents, such as Nidek has done in connection with the
VISX '762 patent. Further, Nidek or others may assert similar claims against
VISX's Trokel '388 patent, which we believe to be a fundamental patent in our
industry. Successful challenges to the validity and enforceability of any of our
patents or the patents licensed from VISX could significantly impair our ability
to collect per-procedure license fees. Even if an unlicensed party's products or
procedures infringe upon our patents, it is costly to enforce these rights.
Infringement actions require the diversion of funds from our operations and
require management to expend funds and effort that might otherwise be devoted to
our operations. Furthermore, we may not be successful in enforcing our patent
rights. Any failure by us to prevail in patent infringement actions against
others, or any success by others in invalidating, asserting ownership in, or
being found not to infringe patents owned or licensed by us, could impair our
ability to collect per-procedure fees and thus materially reduce our revenues.
There are a number of U.S. and foreign patents covering methods and
apparatus relating to corneal surgery that we neither own nor have the right
to use. If we were found to infringe a patent in a particular market, we may be
enjoined from making and selling, and our customers may be enjoined from using,
that product in the market or we may be required to obtain a fee-bearing
license, if available on acceptable terms. Alternatively, we might be required
to redesign the infringing aspects of these products. Any redesign efforts that
we undertake could be expensive and might require FDA review. Furthermore, the
redesign efforts could delay the reintroduction of these products into certain
markets, or may be so significant as to be impractical. If redesign efforts were
impractical, we could be prevented from manufacturing and selling the infringing
products, which would significantly harm our business.
COMPETITORS MAY NOT CHARGE THEIR CUSTOMERS PER-PROCEDURE FEES, OR MAY REDUCE
THEIR FEES, WHICH, IN TURN, COULD AFFECT OUR ABILITY TO CHARGE LICENSE FEES
We license a number of patents to our U.S. customers on a per-procedure
basis. We derive a substantial portion of our revenues from the per-procedure
fees we charge to license these patents. If competitors do not charge
per-procedure fees to users of their systems, or significantly reduce the amount
of such fees, we could be forced to reduce or eliminate the fees we charge,
which could significantly reduce our revenues. Nidek, one of our competitors,
does not charge per-procedure fees to users of its systems. On February 22,
2000, VISX announced a reduction in its per procedure fees, forcing the Company
to implement its own price reductions the following day. These reductions will
significantly reduce the Company's revenues through at least 2000.
COMPETITORS MAY ERODE OUR U.S. MARKET SHARE OR LIMIT OUR MARKET SHARE GAINS
The number of manufacturers offering laser vision correction systems and
related products has grown. In addition to us and VISX, Nidek obtained FDA
approval of its system in late 1998, LaserSight obtained FDA approval of its
system in late 1999, and Bausch & Lomb received FDA approval of its Technolas
217 system in the first quarter of 2000. Some of these competitors are larger
than we are and have greater resources to devote to selling and marketing their
products. If ophthalmologists perceive
-19-
<PAGE> 20
competitors' products to be technologically or economically superior to ours, we
could lose customers and market share to these competitors or encounter
difficulty increasing our market share.
ANY COMPETITOR WITH BROADER APPROVALS MAY HAVE A COMPETITIVE ADVANTAGE OVER US
In the United States, a manufacturer of laser vision correction systems
gains a competitive advantage by having its systems approved by the FDA for a
wider range of treatments. Although our Infinity LS system and the VISX system
possess roughly equivalent FDA approvals, the VISX system presently is approved
for a wider range of treatments than our LADARVision(R) system. The Nidek laser
vision correction system is approved for a higher degree of nearsightedness than
our LADARVision(R) system. The LADARVision(R) system is presently approved for
low to high degrees of nearsightedness alone and with moderate astigmatism. If
the FDA does not approve in a timely manner our pending applications for LASIK
treatment of farsightedness and astigmatism using the LADARVision(R) system, our
ability to compete effectively in the United States may be compromised.
WE ARE INVOLVED IN LITIGATION THAT HAS CONSUMED OUR TIME AND RESOURCES AND COULD
SUBJECT US TO SIGNIFICANT LIABILITIES
Since August 1996, stockholders have commenced multiple separate legal
actions against us and some of our directors and officers. In addition, there
are multiple state and federal antitrust lawsuits pending against us and VISX
relating to the Pillar Point Partners arrangement that existed between the two
companies from 1992 to 1998. All these lawsuits seek substantial monetary
damages for alleged violations of securities or antitrust laws. Defending
against these lawsuits has consumed, and will continue to consume, considerable
resources, including management time and attention, which has been diverted from
operating our business. If the plaintiffs are successful, their recoveries could
have a significant negative effect on our cash position. Litigation is
inherently uncertain and an adverse resolution of these actions may have a
material adverse effect on our financial position and operating results in the
period in which they are resolved.
OUR RELIANCE ON SOLE SOURCE SUPPLIERS FOR CRITICAL COMPONENTS COULD JEOPARDIZE
OUR OPERATIONS
We purchase the optical module for the LADARVision system and other
components of our products from sole source suppliers. If these sole source
suppliers were to cease providing these components, we would be required to
locate and contract with substitute suppliers, which we may not be able to do in
a timely manner. Any interruption in our ability to manufacture and service
excimer laser systems or microkeratomes on a timely basis would reduce our
revenues, could increase our costs and might jeopardize our customer
relationships.
NEW PRODUCTS AND TECHNOLOGIES COULD DECREASE DEMAND FOR OUR PRODUCTS OR MAKE
THEM OBSOLETE
In addition to competing with eyewear, excimer laser vision correction
systems compete with newer technologies such as intraocular lenses, corneal
rings and surgical techniques using different types of lasers. KeraVision has
recently received FDA approval for its corneal ring and has begun to market this
product commercially in the United States. A holmium laser for the treatment of
farsightedness manufactured by Sunrise Technologies is scheduled for
consideration by the FDA's Ophthalmic Advisory Panel in March 2000. To the
extent that any of these or other new technologies are perceived to be
clinically superior or more economical than excimer laser vision correction,
they could decrease demand for our excimer laser systems or render these
products obsolete. If one or more competing technologies achieve broader market
acceptance or render the Infinity or the LADARVision system obsolete, we may
lose customers and revenues.
-20-
<PAGE> 21
OUR FAILURE TO TIMELY OBTAIN REGULATORY APPROVALS FOR PRODUCTS AND TO COMPLY
WITH FDA REGULATIONS COULD ADVERSELY AFFECT OUR BUSINESS
Our excimer laser systems and related products are regulated medical
devices under the Federal Food, Drug, and Cosmetic Act. New product
introductions, expanded treatment types and levels for approved products, and
significant design or manufacturing modifications require a premarket clearance
or approval by the FDA prior to commercialization in the United States. The FDA
approval process, which is lengthy and uncertain, requires underlying clinical
studies and substantial commitments of financial and management resources.
Failure to obtain or maintain regulatory approvals and clearances in the United
States and other countries, or significant delays in obtaining these approvals
and clearances, could prevent us from marketing our products for either approved
or expanded indications or treatments, which could significantly reduce our
future revenues.
USE OF UNAPPROVED SYSTEMS COULD REDUCE OUR REVENUES
We are aware that some U.S. physicians are performing refractive
procedures with laser vision correction systems that have not been approved by
the FDA, including earlier versions of our systems originally sold in
international markets as well as so-called "homemade" or "black box" systems.
Pursuing these potential infringers could be costly and might not result in any
significant recoveries. Continued use or additional sales of these systems will
reduce our system sales and per-procedure revenues. In addition, any adverse
clinical consequences resulting from the use of these systems could adversely
affect consumer acceptance of laser vision correction generally.
ILLEGAL TAMPERING WITH SYSTEM CONFIGURATIONS COULD REDUCE OUR REVENUES
Some U.S. users of the Apex excimer laser systems have tampered with the
software and hardware configuration of their systems to defeat the card reading
system that facilitates the collection of per-procedure license fees. Continued
loss of per-procedure fees will reduce our revenues.
CHANGES IN THE U.S. ECONOMY AND CONSUMER SPENDING COULD ADVERSELY AFFECT THE
VOLUME OF U.S. PROCEDURES
Laser vision correction is an elective procedure that involves greater
immediate expense than eyeglasses or contact lenses. The procedure is not
typically covered by insurance. A significant adverse change in the U.S. economy
may cause consumers to re-assess their spending choices and reduce the demand
for laser vision correction. Any such shift would have an adverse effect on the
volume of laser
-21-
<PAGE> 22
vision correction procedures performed and on our collection of per-procedure
licensing fees.
OUR LENS EXPRESS OPERATIONS ARE SUBJECT TO ADDITIONAL RISKS THAT COULD REDUCE
OUR PROFITABILITY
Our Lens Express operations are subject to risks beyond our control,
including:
- lack of consistent sources of supply;
- inability to obtain suitable advertising spots in selected media at
cost-effective prices;
- state regulations; and
- competition from other contact lens providers.
Because some contact lens manufacturers do not sell contact lenses
directly to Lens Express, Lens Express must obtain product through indirect
channels. Lens Express may not be able cost effectively to obtain sufficient
quantities of product through indirect channels at the times it requires. If
unable to obtain product from indirect suppliers, or if forced to do so on
unfavorable terms, Lens Express' revenues and profitability would be adversely
affected. Lens Express' operations are subject to numerous state laws and
regulations that govern the dispensing of replacement contact lenses. Some
states have strict requirements that prohibit dispensing replacement lenses
without receipt of a written prescription, which makes it more difficult and
expensive for Lens Express to sell replacement contact lenses in those states.
In addition, these regulations place Lens Express at a competitive disadvantage
versus competing mail order sellers that are able to avoid or ignore these laws
and regulations. Our principal competitor has stated publicly that it does not
comply with these regulations. Other states may enact or impose laws or
regulations that prohibit mail order dispensing of replacement contact lenses or
otherwise impair Lens Express' ability to sell lenses and operate profitability.
In addition, the contact lens dispensing industry is subject to intense
competition. Lens Express may lose market share to other contact lens providers
electing to pursue a marketing strategy which, like that of Lens Express,
emphasizes convenience and price, or to discount chains, wholesale clubs and
other competitors.
INADEQUACY OR UNAVAILABILITY OF INSURANCE MAY EXPOSE US TO SIGNIFICANT LIABILITY
The testing and use of our products entail an inherent risk of physical
injury to patients and physicians and expose us to potential product liability
and other damage claims. In addition, our products have high voltage power
supplies and use corrosive gases. Although we maintain product liability
insurance, a product liability claim assessed against us could exceed our
insurance coverage. Adequate product liability insurance may not continue to be
available, either at existing or increased levels of coverage, on commercially
reasonable terms. Even if a claim is covered by insurance, the costs of
defending a product liability, malpractice, negligence or other action, and the
assessment of damages in excess of insurance coverage, could entail significant
expense and damage our reputation.
THE MARKET PRICE OF OUR STOCK HISTORICALLY HAS BEEN VOLATILE
The volatility of our common stock imposes a greater risk of capital
losses on stockholders when compared to less volatile stocks. The market price
of our common stock may be significantly affected by factors such as:
- the announcement or introduction of technological innovations or new
products by us or our competitors;
-22-
<PAGE> 23
- quarter-to-quarter variations in our operating results and changes in
earnings estimates by analysts;
- market conditions in the technology, healthcare and other growth
sectors;
- changes in U.S. or foreign governmental regulations or regulatory
approval processes;
- developments or disputes relating to patent or proprietary rights; and
- public concern about the safety and efficacy of the procedures for
which the excimer laser system is used.
Moreover, the possibility exists that the stock market, and in particular
the securities of technology companies such as us, could experience extreme
price and volume fluctuations unrelated to operating performance. These
fluctuations may have a material adverse effect on the market price of our
common stock.
CONCERNS ABOUT THE SAFETY AND EFFICACY OF OUR PRODUCTS COULD LIMIT OUR FUTURE
REVENUES
Physicians and consumers may have a number of concerns about the safety
and efficacy of laser vision correction procedures, including the predictability
and stability of results. Potential complications and side effects include:
- post-operative discomfort, including pain, itching, tearing and dryness
of the eye;
- corneal haze, which is an increase in the cornea's light scattering
properties, during healing;
- glare and halos produced by bright lights;
- decreases in contrast sensitivity that can cause night vision
difficulties;
- temporary increases in intraocular pressure or pupil enlargement in
reaction to post-procedure medication;
- fluctuations in refractive capabilities during healing;
- decreases in vision with corrective eyewear;
- unintended over- or under-corrections;
- disorders of corneal healing;
- corneal scars and corneal ulcers;
- induced regular or irregular astigmatism that can cause blurred or
double vision or shadow images;
- drooping of the eyelid; and
- inflammation of the iris.
In addition, we have had limited commercial experience with our SKBM
microkeratome, which, if misused or defective, could cause significant injury
when cutting a patient's cornea. Long-term follow-up data may reveal additional
complications associated with our products. The responses of potential
candidates,
-23-
<PAGE> 24
physicians and others to information about complications could materially affect
market acceptance for laser vision correction, which in turn would materially
harm our business.
ITEM 2. PROPERTIES
MANUFACTURING
Summit's manufacturing operations consist of assembly, inspection and
testing of parts and system components to assure performance and quality.
Assembly of the Infinity system takes place at our facility in Cork, Ireland. We
have also begun production of certain LADARVision system components at that
facility. Assembly of the LADARVision system takes place at our facility in
Orlando, Florida. Most parts and system components are manufactured and supplied
by outside vendors. We conduct a series of final integration and acceptance
tests prior to shipping a completed system.
The laser component in the LADARVision system has been custom designed
and, until recently, was sourced solely from a single U.S. specialty
manufacturer. We now manufacture this component exclusively at our Cork, Ireland
facility.
In addition to the excimer laser, the most significant component of the
LADARVision system is the optical module. We have outsourced the manufacture of
the LADARVision optical module to a sole source supplier. If this supplier is
unable to meet our demand, our ability to build LADARVision systems would be
adversely affected.
We manufacture our emphasis Discs at both our Waltham and Cork
facilities. Our SKB microkeratome is presently manufactured both in our Cork
facility and in Germany by a contract manufacturer that also supplies our single
use microkeratome disposable blades. We presently intend to continue dual
sourcing of this product.
FACILITIES
We presently lease approximately 50,000 square feet of manufacturing and
office space in Waltham, Massachusetts, under a lease expiring in 2005. We also
lease an approximately 25,000-square-foot manufacturing facility in Cork,
Ireland, under a lease expiring in 2026. We believe that we have the capacity to
manufacture a sufficient number of our products to satisfy demand. We also have
the manufacturing space to produce products in greater volumes. Any significant
increase in manufacturing capacity will require the hiring and training of
qualified manufacturing personnel.
Our Autonomous subsidiary leases approximately 64,000 square feet of
office/manufacturing/warehouse space in two roughly contiguous buildings in
Orlando, Florida. These facilities consist of approximately 25,250 square feet
covered by a lease that expires in 2007 and approximately 39,000 square feet
covered by a lease that expires in 2010. An ancillary warehouse lease consists
of approximately 5,050 square feet and is covered by a lease that expires in
2000, with renewal opportunities.
Our Lens Express subsidiary leases approximately 38,000-square-feet of
office/warehouse space in the Fort Lauderdale, Florida area under a lease
expiring in August 2002.
ITEM 3. LEGAL PROCEEDINGS
The Company is a party to various litigation matters as described
below. The Company has denied, or will deny, the substantive allegations in each
of these actions, and intends to defend them vigorously. The Company may be
served with additional complaints of a similar nature in the future. The Company
may not prevail
-24-
<PAGE> 25
in the pending or any possible additional actions, and the resolutions of the
actions, individually or in the aggregate, may have a material adverse effect on
the Company's financial position, results of operations, or cash flows. The
Company has not made any provision for any loss that may result upon resolution
of these matters in the accompanying consolidated financial statements. Dollar
amounts below are in thousands.
ANTITRUST LITIGATION
The Company, VISX, and certain of their affiliates (including Pillar
Point Partners, a partnership between affiliates of the Company and VISX) are
involved in a number of antitrust lawsuits which, among other things, allege
price-fixing in connection with per-procedure patent royalties charged by the
Company and VISX. These suits are pending in both federal and state court, on
behalf of both direct purchasers from the Company and VISX and
patients/consumers, and include both purported class actions and individual
actions. Most of the federal lawsuits have been transferred for pretrial
purposes to the U.S. District Court for the District of Arizona by the Judicial
Panel on Multidistrict Litigation as In re: Pillar Point Partners Antitrust and
Patent Litigation.
FEDERAL ANTITRUST LITIGATION
Cases Consolidated for Pre-Trial Proceedings
- ---------------------------------------------
In April 1998, The Eye Professionals, P.A. commenced an action in the
U.S. District Court for the District of New Jersey against the Company and VISX.
The case purported to be a class action on behalf of all individuals or entities
that have paid a per-procedure fee directly to either defendant for use of a
Summit or VISX laser to perform laser vision correction surgery at any time
after November 1, 1995. The complaint alleged, inter alia, price-fixing in
violation of Section 1 of the Sherman Act. The action sought treble damages,
costs of suit, attorneys' fees, and various forms of declaratory and injunctive
relief. Similar actions were also filed in May 1998 by Metropolitan Eye Center
and Outpatient Surgical Facility, Inc. in the U.S. District Court for the
Northern District of California against the Company, VISX, Summit Partner and
VISX Partner and by New England Laser Vision, Inc. in the U.S. District Court
for the District of New Jersey against the Company and VISX. In August 1998,
David R. Shapiro, M.D., filed another similar purported class action against the
Company and VISX in the U.S. District Court for the District of Arizona.
Plaintiffs in these cases have agreed to consolidation of the four purported
class actions and filed a single consolidated amended complaint in the U.S.
District Court for the District of Arizona. It purports to be a class action on
behalf of all persons and entities (excluding governmental entities, defendants
subsidiaries and affiliates of defendants) in the United States who paid a
per-procedure royalty to any defendant or any alleged co-conspirator or any
subsidiary or affiliate thereof, at any time after September 1995. The
Consolidated Amended Class Action Complaint seeks, among other things,
unspecified treble damages on behalf of plaintiffs and the alleged class, along
with attorneys' fees, costs, and injunctive and declaratory relief.
In September 1998, Laser Eye Center of Texas, L.L.P. and Warren D.
Cross, M.D., filed a purported class action against the Company, Summit Partner,
VISX, VISX Partner and Pillar Point Partners in the U.S. District Court for the
Southern District of Texas. The suit purports to be a class action on behalf of
all persons and entities who have paid money to defendants, or any of their
subsidiaries, on a per-procedure basis for the ability to use defendants' laser
equipment or technology to perform laser vision correction surgery. Plaintiffs
allege, among other things, price-fixing and monopolization in violation of
Sections 1 and 2 of the Sherman Act. They seek, among other things, treble
damages on behalf of the alleged class, costs of suit, including attorneys'
fees, and declaratory and injunctive relief. This case was transferred to the
District of Arizona for consolidated pre-trial proceedings.
-25-
<PAGE> 26
In February 1999, Carolina Eye Associates, P.A. and Carolina-South Eye
Associates filed suit against VISX and the Company in the U.S. District Court
for the District of New Jersey. This action, like the consolidated federal
actions described above, purports to be a class action on behalf of all persons
and entities (excluding governmental entities, defendants, subsidiaries and
affiliates of defendants) in the United States who paid a per-procedure royalty
to any defendant or any alleged co-conspirator or any subsidiary or affiliate
thereof, at any time after September 1995. The complaint alleges, among other
things, price-fixing in violation of Section 1 of the Sherman Act and seeks,
among other things, compensatory damages of at least $100,000 plus $8,300 per
month from the filing of the complaint until the date of judgment, trebling of
those damages, attorneys' fees, costs, and declaratory and injunctive relief.
This case was transferred to the District of Arizona for consolidated pre-trial
proceedings.
Plaintiffs in the various class actions described above have now moved
for certification of a class including all persons in the United States who paid
a per-use royalty to any defendant or any co-conspirator or any subsidiary or
affiliate thereof, at any time after September 1995.
In June 1996, a Texas ophthalmologist, Robert G. Burlingame, sued the
Company, Summit Partner, VISX, VISX Partner and Pillar Point Partners in U.S.
District Court for the Northern District of California alleging price-fixing in
violation of Section 1 of the Sherman Act and state antitrust laws and fraud and
deceit in connection with certain of the Company's sales and marketing
activities. The plaintiff seeks, among other things, compensatory damages of at
least $30 plus $2 to $3 per month until the date of judgment, trebling of those
damages, compensatory and punitive damages on the fraud claim against the
Company of at least $500 plus $2 to $3 per month until the date of judgment,
attorneys' fees, costs and declaratory and injunctive relief. This case was
transferred to the District of Arizona for consolidated pre-trial proceedings.
In September 1996, a Nevada ophthalmologist, John R. Shepherd, through
his professional corporation, commenced a similar lawsuit against the same
parties, in the same court, alleging substantially similar antitrust claims and
seeking substantially similar relief, including damages before trebling of at
least $125 plus $13 per month until the date of judgment. This case was
transferred to the District of Arizona for consolidated pre-trial proceedings.
In May 1999, Freedom Vision Laser Center, L.P. filed suit in the United
States District Court for the Central District of California against the
Company, Autonomous, Summit Partner, VISX, VISX Partner and Pillar Point
Partners. The complaint alleges, among other things, price-fixing,
monopolization, attempted monopolization, and conspiracy to monopolize, in
violation of Sections 1 and 2 of the Sherman Act, as well as violations of the
California Business and Professions Code. Plaintiff seeks, among other things,
damages that are alleged to be more than $1,000 before trebling, disgorgement of
alleged illegal and ill-gotten gains, declaratory and injunctive relief, and
attorneys' fees and costs. This case has been transferred to the District of
Arizona for consolidated pre-trial proceedings.
Cases Not Consolidated for Pre-Trial Proceedings
- -------------------------------------------------
In April 1999, Antoine L. Garabet, M.D., Inc. and Abraham V. Shammas,
M.D., Inc., d/b/a The Laser Eye Center, filed suit in the U.S. District Court
for the Central District of California against the Company and Autonomous. The
suit alleges, among other things, that the Company's acquisition of Autonomous
may substantially lessen competition or tend to create a monopoly in violation
of Section 7 of the Clayton Act, Section 1 of the Sherman Act, and the
California Business and Professions Code. The complaint seeks, among other
things, unspecified compensatory damages, trebling of those damages, declaratory
and injunctive relief, divestiture
-26-
<PAGE> 27
in the event that the acquisition of Autonomous is consummated, restitutionary
relief, including disgorgement of alleged unlawful profits and the imposition of
a constructive trust over alleged ill-gotten gains, and attorneys' fees and
costs. Plaintiffs also threatened to seek a temporary restraining order,
preliminary injunction, and other unspecified preliminary injunctive relief
directed at the acquisition. The Company filed a counterclaim for copyright
infringement and unfair competition against the plaintiffs and Antoine L.
Garabet, M.D. and Abraham V. Shammas, M.D., individually. The parties have
agreed to a dismissal of this counterclaim, without prejudice.
COUNTERCLAIMS
The Company is the subject of additional Federal antitrust litigation
as a result of counterclaims to patent litigation initiated by Pillar Point
Partners and the Company. A discussion of those counterclaims is presented below
under "Patent Litigation."
STATE ANTITRUST LITIGATION
Beginning in March 1998, a number of actions brought by individuals
under the Cartwright Act and the California Business and Professions Code were
commenced against the Company, Summit Partner, VISX and VISX Partner in Superior
Court of Santa Clara County. In May 1998, these actions were consolidated as In
re PRK/LASIK Consumer Litigation. In June 1998, plaintiffs B.J. Snyder, Donna
McMahan, Paula Mobsby, Helen Thomas, Carmen Ocariz, Martin Hermans, Ken
Bartlett, Jackie Kirk, Grace Geniusz, Jocelyn Joseph, Andrew Stoddard, and
Cynthia Brubecker filed an Amended Consolidated Master Complaint for Damages
("Amended Complaint") in this matter against the Company, Summit Partner, VISX,
and VISX Partner. The Amended Complaint purports to be filed on behalf of all
natural persons in the United States who underwent excimer laser surgery with a
laser manufactured by the Company or VISX during the period beginning October
1995, and paid a per-procedure fee indirectly to a defendant, excluding
defendants, any unnamed co-conspirators of defendants, defendants' predecessors,
successors, parents, subsidiaries, affiliates, officers and directors,
governmental entities, and any and all judges and justices assigned to hear any
aspect of the litigation. The Amended Complaint seeks unspecified compensatory
damages, restitution and/or disgorgement of alleged ill-gotten gains,
prejudgment and postjudgment interest, costs of suit, and attorneys' fees, as
well as various forms of declaratory and injunctive relief, including an order
permitting any person or entity with which the Company or VISX or both have
entered into any agreement since June 3, 1992, for the purchase, license, or use
of any of the Pillar Point Patents to withdraw from such agreement without
penalty or obligation. James Ballard filed a similar suit against the Company,
Summit Partner, VISX, VISX Partner, Pillar Point Partners, and other individual
defendants in Superior Court of San Diego County. This suit has been transferred
to Santa Clara County and consolidated as part of In re PRK/LASIK Consumer
Litigation. The parties have stipulated to the conditional certification of a
class of natural persons in California, Alabama, Arizona, the District of
Columbia, Florida, Kansas, Maine, Michigan, Minnesota, Mississippi, New Mexico,
New York, North Carolina, North Dakota, South Dakota, Tennessee, West Virginia,
and Wisconsin who have undergone ophthalmic refractive surgery with an excimer
laser manufactured by the Company or VISX.
In April 1998, Penny S. Marks, an individual who allegedly has had
laser vision correction surgery performed, commenced an action in Florida state
court against the Company and VISX. The case purports to be a class action on
behalf of all persons who have had a PRK procedure in the State of Florida from
October 20, 1995 up to and including the date the class certification hearing
begins. The complaint alleges various violations of the Florida Deceptive and
Unfair Trade Practices Act, the Florida Antitrust Act and Section 5 of the
Federal Trade Commission Act. The complaint seeks unspecified compensatory
damages, costs and attorneys' fees, as well as declaratory and injunctive
relief. Plaintiff filed a
-27-
<PAGE> 28
motion seeking class certification. Thereafter, the parties filed a joint motion
to stay this action pending resolution of In re PRK/LASIK Consumer Litigation,
the consolidated class action litigation described immediately above. The court
has granted this motion to stay.
In June 1998, Barbara Worcester, an individual who allegedly has had
laser vision correction surgery performed, filed an action in Wisconsin state
court against the Company, Summit Partner, VISX, VISX Partner and Pillar Point
Partners. The case purports to be a class action on behalf of all Wisconsin
purchasers of refractive laser surgery procedures. The complaint alleges
violations of the antitrust laws of the State of Wisconsin. The complaint seeks
unspecified damages, trebling of those damages, attorneys' fees and costs, and
declaratory and injunctive relief. Defendants removed this action to federal
court, and it has been transferred to the District of Arizona.
Plaintiff has filed a motion seeking class certification.
In January 1999, Karen Frankson, Virginia Harmes, and Beth
Luetschwager, three individuals who allegedly have had laser vision correction
surgery performed, filed a similar purported class action in Wisconsin state
court. Defendants removed this action to federal district court in Wisconsin,
and it was transferred to the District of Arizona. The parties recently agreed
to a dismissal of this action, without prejudice.
In May 1999, Linda Brisson, an individual who allegedly has had laser
vision correction surgery performed, commenced an action in Minnesota state
court against the Company, Summit Partner, VISX, VISX Partner and Pillar Point
Partners. The case purports to be a class action on behalf of all Minnesota
purchasers of refractive laser surgery procedures. The complaint alleges, among
other things, price-fixing in violation of Minnesota antitrust law. The
complaint seeks, among other things, compensatory damages alleged to be at least
in the millions of dollars, trebling of those damages, attorneys' fees and
costs, and injunctive and other relief.
In January 2000, Antoine L. Garabet, M.D. and Abraham V. Shammas, M.D.
filed an action individually and on behalf of the general public against the
Company and VISX in Superior Court of the State of California, Santa Clara
County. The suit alleges violations of the California Unfair Business Practices
Act in connection with, among other things, per procedure fees charged by the
Company and VISX. The action seeks, among other things, disgorgement of alleged
ill-gotten gains and monies that defendants have earned by means of alleged
unlawful, unfair, and fraudulent business practices (with defendants' per
procedure revenues elsewhere alleged to be in the millions of dollars annually),
a constructive trust over such gains and monies, declaratory and injunctive
relief, and attorneys' fees and costs.
SHAREHOLDER LITIGATION
Between August 1996 and February 1997 various shareholder actions were
commenced against the Company and certain of its present or former officers in
the U.S. District Court for the District of Massachusetts claiming, among other
things, violations of Sections 10(b) and 20(a) of the Securities Exchange Act of
1934 arising out of public statements made by defendants and violations of
Section 20A of the Securities Exchange Act of 1934 arising out of alleged
insider trading by certain defendants. The actions were consolidated, by order
of the Court entered December 2, 1996, as In re Summit Technology Securities
Litigation. By order dated August 11, 1998, the Court certified the action as a
class action on behalf of all purchasers of Summit common stock, other than
defendants and certain affiliated persons and entities, between March 31, 1995
and July 3, 1996. Plaintiffs seek unspecified damages, interest, costs and
expenses, attorneys' fees and extraordinary and/or injunctive relief. Discovery
was completed in February 2000. On March 14, 2000 defendants filed a motion for
summary judgment on certain claims. Additional motions for summary judgment may
be filed as well.
-28-
<PAGE> 29
In October 1996, an additional class action was commenced in the U.S.
District Court for the District of Massachusetts against the Company, its
directors, certain of the Company's present or former officers and the four
underwriters of the Company's October 1995 common stock offering claiming
violations of Sections 11, 12(2) and 15 of the Securities Act of 1933 arising
out of alleged material misstatements of fact in the Registration Statement
issued in connection with the offering. By order dated August 11, 1998, the
Court certified the action as a class action on behalf of all purchasers of
Summit stock in the offering other than defendants and certain affiliates. The
action was coordinated with the securities litigation by order of the court
dated December 2, 1996. The action seeks unspecified compensatory damages,
interest, costs and expenses, attorneys' fees and extraordinary and/or
injunctive relief. Cross motions for summary judgment were filed in November
1999 and February 2000 with respect to certain claims. Additional motions for
summary judgment may be filed as well.
In December 1996, one of the Company's shareholders filed in the U.S.
District Court for the District of Massachusetts a derivative action,
purportedly on behalf of the Company, against the Company as nominal defendant,
directors of the Company and certain present or former officers of the Company.
This action was consolidated with the securities litigation by order of the
Court entered July 22, 1997. The complaint alleges that the conduct of the
individual defendants has exposed the Company to the liability, expense and
inconvenience of the securities litigation and has harmed the Company's
reputation, thereby limiting its access to capital markets. It also alleges
breach of fiduciary duty, gross negligence and insider trading against
individual defendants. It seeks damages, interest, costs and expenses and
attorneys' fees.
PATENT LITIGATION
Pillar Point Partners, Summit Partner and VISX Partner commenced patent
infringement litigation against an ophthalmologist believed to have used or be
using homemade laser systems not licensed under patents held by Pillar Point
Partners and one alleged manufacturer of such laser systems. These actions were
originally pending as Pillar Point Partners, et al. v. Jon G. Dishler, et al.
(U.S. District Court, District of Colorado) and Pillar Point Partners, et al. v.
Jui-Teng Lin, et al. (U.S. District Court, Middle District of Florida). Each
action was transferred to the District of Arizona. The defendants in the Dishler
action have asserted counterclaims against Summit Partner, VISX Partner, and
Pillar Point Partners seeking declarations that the patents in suit are invalid
and unenforceable. They have also raised antitrust counterclaims alleging
price-fixing, tying, monopolization, concerted refusal to deal, conspiracy to
monopolize, and attempted monopolization. Defendants seek unspecified actual
damages, trebling of those damages, attorneys' fees, costs and injunctive
relief. The parties have agreed to a resolution of the Jui-Teng Lin litigation.
In December 1998, the Company filed a patent infringement lawsuit in
the U.S. District Court for the District of Massachusetts against Nidek, whose
laser system received FDA approval in December, 1998. The suit alleges that
Nidek's excimer laser system infringes certain of the Company's U.S. patents and
seeks damages and injunctive relief. On January 29, 1999, a district court in
Tokyo, Japan ruled against the Company in a patent infringement lawsuit which
the Company initiated against Nidek in 1996. The Japanese lawsuit involved the
Japanese counterpart of one of the two U.S. patents which the Company has
alleged Nidek infringes in the U.S. lawsuit. The Tokyo district court's decision
was upheld on appeal.
In June 1999, the Company commenced a patent infringement lawsuit
against George I. Bekov in the U.S. District Court for the District of
Massachusetts. The suit alleges that Bekov has induced infringement of certain
of the Company's patents, including by disabling card readers and maintaining
systems which are not licensed by the Company, and seeks damages and injunctive
relief. This case has been transferred to the District of Arizona for
consolidated pre-trial proceedings.
-29-
<PAGE> 30
In February 1999, the Company asserted patent infringement claims
against Antoine L. Garabet, M.D., Antoine L. Garabet, M.D., Inc., Abraham V.
Shammas, M.D., Abraham V. Shammas, M.D., Inc., and the Laser Eye Center in a
case then pending in the District of Arizona. The suit alleges that these
parties have infringed certain of the Company's patents by using excimer laser
systems manufactured by the Company without having a license to do so, and seeks
damages and injunctive relief. In June 1999, the Company commenced a similar
patent infringement lawsuit against Robert T. Lin, Ferzaad Moosa, and Randa M.R.
Garrana in the U.S. District Court for the Central District of California. This
case has been transferred to the District of Arizona, and the parties have
stipulated to consolidation of these two cases. In November 1999, the parties
opposing the Company in these two actions filed a counterclaim against the
Company for declaratory relief and for fraud and deceit. The counterclaim seeks,
among other things, judgment that the patents in suit are not infringed and, in
any event, not enforceable as a result of the Company's alleged inequitable
conduct, unclean hands, and patent misuse; judgment enjoining the Company from
attempting to enforce the Pillar Point patents, including the patents in suit;
attorneys' fees and costs; judgment that the Company has committed fraud and
deceit in connection with the sale of a Summit laser system; compensatory
damages on the fraud claim of at least $49, plus prejudgment interest; and
punitive damages.
In October 1999, the Company commenced a patent infringement lawsuit
against Icon Laser Centers (U.S.), Inc. in the U.S. District Court for the
District of Delaware. The suit alleges that the defendant has infringed and/or
contributed to and/or induced infringement of certain of the Company's patents
by using the Nidek EC-5000 Excimer Laser System without having a license to do
so, and seeks damages and injunctive relief.
OTHER LITIGATION
In October 1992, Joseph Seriani brought suit against Lens Express and
certain of its former shareholders in the Florida Circuit Court. The suit
alleged violations of the Florida Civil Remedies for Criminal Practices Act --
the Florida civil RICO statute -- based on events which allegedly occurred in
the mid-1980s. Seriani's claims against Lens Express were dismissed several
times for failure to state a viable claim, but in each instance with leave to
amend and refile. On May 15, 1996, the date of the Company's acquisition of Lens
Express, Seriani and his wife Rhonda Seriani filed an amended complaint which
included the Company as an additional defendant. On November 25, 1996, the
Serianis voluntarily dismissed their action against the Company and on March 7,
1997 voluntarily dismissed their action against the remaining defendants, in
each case without prejudice. On March 24, 1997, the Serianis commenced a new
lawsuit against Lens Express and others in the U.S. District Court for the
Southern District of Illinois, alleging substantially similar claims. On October
7, 1999, the Court issued an Order to Show Cause why the case should not be
dismissed for lack of prosecution and, on November 23, 1999 the Court issued an
order dismissing the case with prejudice. By order dated January 7, 2000, the
Court denied the Serianis' motion to vacate its order of dismissal.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of security holders in the fourth
quarter of 1999.
-30-
<PAGE> 31
PART II
Item 5. MARKET FOR THE REGISTRANT'S COMMON STOCK AND RELATED SECURITY HOLDER
MATTERS
The Company's Common Stock $.01 par value ("Common Stock") is traded on the
NASDAQ National Market System, under the symbol "BEAM." The following chart sets
forth the high and low sales prices for the Common Stock during the indicated
periods.
<TABLE>
<CAPTION>
High Low
------ ------
<S> <C> <C>
1999
First quarter $ 11.56 $ 4.31
Second quarter 23.44 10.44
Third quarter 29.38 14.25
Fourth quarter 21.63 10.25
1998
First quarter $ 7.25 $ 4.56
Second quarter 7.50 4.50
Third quarter 6.88 3.06
Fourth quarter 6.13 3.00
</TABLE>
The closing price of the Common Stock on March 24, 2000 was $9.875. On
March 24, 2000, the Common Stock was held of record by 2,386 persons and
entities, including significant amounts of stock held in "street name."
ITEM 6. SELECTED FINANCIAL DATA
The Company's Selected Historical Consolidated Financial Data
(in thousands, except per share data)
The selected consolidated financial data presented below for, and as of the
end of, each of the years in the five-year period ended December 31, 1999, are
derived from the Company's audited consolidated financial statements. This
selected consolidated financial data should be read in conjunction with the
Company's audited consolidated financial statements and notes and the related
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" that are included in Item 7 of Part II of this Report.
-31-
<PAGE> 32
<TABLE>
<CAPTION>
Years Ended December 31,
-------------------------------------------------------
1999 1998 1997 1996 1995
--------- -------- ------- -------- --------
<S> <C> <C> <C> <C> <C>
STATEMENTS OF OPERATIONS DATA
Revenues .......................................... $ 111,099 $ 91,641 $79,650 $ 73,912 $ 95,258
Income (loss) from continuing operations(1) ....... (23,025) 36,730 828 (13,491) 1,575
Cumulative effect of accounting principle change(2) -- (10,103) -- -- --
Net income (loss) (3) ............................. (23,025) 27,570 21,398 (36,857) (2,967)
Basic and diluted earnings (loss) per share:
Income (loss) from continuing operations ........ $ (.57) $ 1.17 $ .03 $ (.43) $ .06
Cumulative effect of accounting principle change -- (.32) -- -- --
Net income (loss) ............................... (.57) .88 .68 (1.18) (.11)
Weighted average number of common shares--basic ... 40,436 31,244 31,400 31,174 27,892
Weighted average number of common shares--diluted . 40,436 31,292 31,591 31,174 27,892
Pro forma amounts assuming accounting principle
change had been applied retroactively:
Net income (loss) .............................. N/A $ 37,673 $22,682 $(37,772) $ (6,073)
Net income (loss) per share--basic and diluted . N/A $ 1.20 $ .72 $ (1.21) $ (.22)
</TABLE>
<TABLE>
<CAPTION>
December 31,
----------------------------------------------------
1999 1998 1997 1996 1995
-------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C>
BALANCE SHEET DATA
Working capital ....................... $ 99,830 $ 78,953 $ 67,404 $ 73,085 $108,374
Total assets .......................... 270,667 144,925 115,103 133,660 161,661
Long-term debt, less current maturities 1,986 150 6,330 11,472 537
Stockholders' equity .................. 236,168 119,334 88,987 101,947 138,239
</TABLE>
- ----------
(1) In 1999, the Company recorded one-time charges of $22,600 related to the
acquisition of Autonomous Technologies Corporation. In 1998, the Company
received a litigation settlement of $29,884, net of related taxes and
expenses.
(2) In 1998, the Company changed its method of accounting for Lens Express
membership fee revenues that were previously recognized when received.
Under the new accounting method, the Company recognizes membership fee
revenues ratably over the term of the membership, which is one to five
years.
(3) Net income (loss) includes a gain of $943 in 1998, a net gain of
$20,570 in 1997, a loss of $23,366 in 1996 and a loss of $4,542 in 1995
related to the Company's discontinued laser vision center business.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
We currently operate in two principal segments: (i) laser vision
correction which includes manufacturing, selling and servicing laser systems and
related products to correct vision disorders and collecting per procedure
license fees from users of our systems and (ii) contact lenses and related
products which are sold via mail order through our wholly-owned subsidiary, Lens
Express, Inc. ("Lens").
On February 22, 2000, our competitor, VISX, Inc. ("VISX") announced
that it was lowering its U.S. per procedure licensing fee to $100. For obvious
competitive reasons, we responded by lowering our own U.S. per procedure
licensing fee. Effective February 23, 2000, we instituted a tiered pricing
program for our customers. Our Apex Plus(TM)/Infinity(TM) excimer laser system
will be value priced and will carry a per procedure licensing fee of $100. Prior
to February 23, 2000, the list price of the licensing fee for the Apex
Plus(TM)/Infinity(TM) System was $250.00 per procedure, with actual pricing
variable based on factors including volume discounts and promotions,
participation in one of our innovative bundled pricing programs which combine
license fees with other products and services, and whether the customer is or
was one of our clinical investigators. The emphasis(R) disc used in
-32-
<PAGE> 33
conjunction with the Apex Plus(TM)/Infinity(TM) System for astigmatism and
farsightedness corrections will be priced at $25 in the U.S. and $75 in
international markets. LADARVision(R) system procedures will be premium priced
at $150 per procedure for purchased units. Customers who have acquired Apex
Plus(TM)/Infinity(TM) and/or LADARVision(R) Systems utilizing a program which
bundles the licensing fee with other products and services will receive
adjustments to their programs to reflect the reduced pricing. We expect that
these reductions in per procedure pricing will materially reduce our revenues
and revenue growth in 2000.
Information about U.S. procedure volume is based on our sale of
OmniCards to U.S. customers and procedures performed on the LADARVision(R)
excimer laser system. OmniCards are credit card-sized, data encrypted plastic
cards that must be inserted into the Apex Plus(TM)/Infinity(TM) excimer laser
system to enable customers to perform a procedure. OmniCards may be encoded with
a single procedure or with several procedures, and they are priced based on the
number of procedures they permit. We may bundle the OmniCard price with other
products and services, and/or offer volume discounts to our customers that cause
them to purchase an inventory of procedures in advance. As a result, our per
procedure pricing can vary and procedure volume data do not necessarily reflect
the actual number of procedures performed during a particular period. Procedures
are tracked on the LADARVision(R) system by internal software that enables
billing information to be processed via modem, and are thus likely to offer a
more direct correlation to actual procedure volume in any given period.
On April 29, 1999, we completed our acquisition of Autonomous
Technologies Corporation ("Autonomous") for approximately 11.2 million shares of
our common stock and $46.8 million in cash. An independent third party appraisal
company has conducted a valuation of the intangible assets that were acquired.
Goodwill of $55.3 million is being amortized over 25 years, purchased
technologies of $28.1 million are being amortized over 15 years and the other
intangible asset of $3.2 million is being amortized over five years. In
addition, we recorded a one-time charge of $19.8 million in 1999 for acquired
in-process research and development. As a result of the acquisition, we recorded
a one-time charge of $2.8 million in 1999 to write-down our inventory to its net
realizable value due to a reduction in future requirements of work-in-process
inventory and spare parts inventory. Results of operations discussed in this
section include the effects of operations of Autonomous from the effective date
of the acquisition and do not include any historical results of Autonomous.
We are continuing to evaluate our operations and strategies, which may
cause us to acquire one or more additional businesses, or to dispose of all or
part of one or more of our businesses.
RESULTS OF OPERATIONS
1999 as compared with 1998
Revenues: Revenues in 1999 increased 21% to $111.1 million from $91.6
million in 1998. Revenues from our laser vision correction business were $64.2
million in 1999 compared to $44.9 million in 1998, a 43% increase. Revenues from
system sales increased 30% in 1999 compared to 1998. System sales include
revenues from our microkeratome product line, which was acquired in the fourth
quarter of 1998. We placed 106 laser systems in 1999 compared to 51 laser
systems in 1998. In 1999, we placed 9 laser system upgrades compared to 66 laser
system upgrades in 1998, reflecting substantial completion of the upgrades of
our installed base of Apex(TM) Systems to the Apex Plus(TM) model. Revenues from
license fees, service and other increased 49% in 1999 compared to 1998. In 1999,
procedure volume in the U.S., as measured by our sales of OmniCards and by
actual LADARVision(R) procedures, increased 85% over the prior year. In 1999 and
1998, revenues from contact lens and related products were $46.9 million and
$46.8 million, respectively.
-33-
<PAGE> 34
Cost of Revenues: Excluding the $2.8 million inventory write-down, as
previously discussed in the section "General", cost of revenues as a percentage
of revenues decreased to 54% in 1999 from 57% in 1998. This decrease was
primarily attributable to the favorable impact from lower cost of revenues
associated with license fee revenues partially offset by unabsorbed
manufacturing costs. Cost of revenues in 1999 also includes the amortization of
purchased technologies related to the Autonomous acquisition. Including the
inventory write-down, cost of revenues as a percentage of revenues was 57% in
1999. In 1999, the cost of contact lens and related products revenues as a
percentage of its revenues decreased to 59% from 62% in 1998.
Operating Expenses: Selling, general and administrative expenses as a
percentage of revenues were 38% in 1999 and 33% in 1998. Selling, general and
administrative expenses in 1999 were $41.7 million compared to $30.2 million in
1998, a 38% increase. These expenses in 1999 reflect the effects of the
Autonomous acquisition, increased sales and marketing costs to grow laser vision
correction procedure volume and to grow our contact lens business and increased
legal costs. The effects of the Autonomous acquisition include eight months of
Autonomous' operations and amortization of goodwill and the other intangible
asset.
Research, development and regulatory expenses in 1999 increased to
$14.2 million from $7.2 million in the prior year, primarily due to research and
development costs associated with our LADARVision(R) system. In 1999, we also
incurred increased spending on our regulatory efforts to obtain additional Food
and Drug Administration ("FDA") approvals for the use of the Apex Plus(TM) and
LADARVision(R) system to treat a wider range of common refractive vision
disorders. In July 1999, the FDA granted us an Investigational Device Exemption
to initiate studies for customized ablations using our CustomCornea(TM)
wavefront measurement device and our LADARVision(R) system. In October 1999, the
FDA approved our Apex Plus(TM) for two new indications - treatment of
farsightedness using PRK and treatment of nearsightedness and higher degrees of
nearsightedness with or without astigmatism using LASIK. In November 1999, the
FDA accepted the filing of the Pre-market Approval Application Supplement for
the LADARVision(R) system to treat nearsightedness and farsightedness with or
without astigmatism using LASIK.
In connection with the Autonomous acquisition, we recorded a one-time
charge of $19.8 million in 1999 for in-process research and development, which
relates to Autonomous' CustomCornea(TM) research project. The valuation was
performed by an independent third-party appraisal company and was determined
using the income method. Revenue projections were completed through year 2012
and were separately identified as follows: (i) revenue derived from products
relying on current technology, (ii) revenue derived from products relying on a
new in-process research and development program -- CustomCornea(TM), and (iii)
revenue from future technologies not yet developed. Revenue generated from the
CustomCornea(TM) product has similar margin and expense levels as those
generated from the LADARVision(R) product. The projected cash flows were
discounted using a 27.5% rate. The fair value of in-process research and
development was determined separately from all other acquired assets using the
percentage of completion method. The percentage of completion ratio was
calculated by dividing total expected expenditures on CustomCornea(TM) through
the acquisition closing date by the total estimated expenditures to achieve
technological feasibility. We are responsible for the estimate of the value of
the in-process research and development.
Other Income (Expense): Interest income decreased to $3.5 million in
1999 from $4.4 million in 1998, primarily due to lower average balances of cash
and cash equivalent balances and interest-bearing investments. Interest expense
decreased to $.3 million in 1999 from $.8 million in 1998 as a result of lower
average balances of borrowings. Other income in 1999 included a $2.4 million
gain on the sale of LCA Vision Inc. ("LCA") common stock and 1998 included a
$2.0 million gain on the sale of assets. In 1998, we received a $35.0 million
payment from VISX pursuant to a settlement agreement, under which we and VISX
agreed to dissolve Pillar Point
-34-
<PAGE> 35
Partners and settle all pending litigation between the two companies. The
litigation settlement, net of related expenses, was $34.4 million.
Net Income (Loss): The net loss for 1999 was $23.0 million, or $0.57
per basic and diluted share, compared to net income of $27.6 million, or $0.88
per basic and diluted share, for 1998. The 1999 results include one-time charges
of $19.8 million for acquired in-process research and development and $2.8
million to write-down inventory related to the Autonomous acquisition. Excluding
these one-time acquisition charges of $22.6 million, the net loss for 1999 was
$0.4 million, or $0.01 per basic and diluted share.
The results for 1998 include the receipt of a $29.9 million, or $.95
per basic and diluted share, litigation settlement, net of related expenses of
$.6 million and related taxes of $4.5 million. In 1998, we reversed an accrual
related to the sale of discontinued operations which resulted in an additional
gain on the sale of discontinued operations of $.9 million, or $0.03 per basic
and diluted share. The 1998 results also include a one-time non-cash charge of
$10.1 million, or $0.32 per basic and diluted share, representing the cumulative
effect of adopting a new accounting principle as of January 1, 1998. Under the
new accounting method, we recognize Lens' membership fee revenues ratably over
the term of the membership, which is one to five years. Customers of Lens pay
membership fees, which entitle members to purchase contact lens and related
products at member prices. We believe that this method is preferable because it
spreads revenue over the period that benefits are provided to members.
Income Taxes: The provision for income taxes in 1999 was $.4 million
for state and foreign taxes. The effective tax rate for 1998 was 12%. We have
continued to provide a 100% valuation allowance against our net deferred tax
asset as of December 31, 1999.
1998 as compared with 1997
Revenues: Revenues in 1998 increased 15% to $91.6 million from $79.7
million in 1997. Revenues from our laser vision correction business increased
36% to $44.9 million in 1998 compared to $33.1 million in 1997. Revenues from
system sales, which include new placements, as well as upgrades of laser
systems, increased by 86% in 1998 compared to 1997. System sales in 1998 also
include revenues from our microkeratome product line, which was acquired in the
fourth quarter of 1998. Procedure volume in the U.S. as measured by our sales of
OmniCards increased 25% in 1998 compared to 1997. Revenues from our laser vision
correction business during 1998 were also favorably impacted by the FDA approval
in March 1998 of the Apex Plus(TM) to treat astigmatism utilizing the Company's
emphasis(TM) disc. In 1998 and 1997, revenues from contact lens and related
products were $46.8 million and $46.6 million, respectively. As discussed below
in "Accounting Principle Change", we changed our method of accounting for Lens'
membership fee revenues which resulted in a $2.6 million increase in 1998
contact lens and related products revenues.
Cost of Revenues: Cost of revenues as a percentage of revenues
decreased to 57% in 1998 from 63% in 1997. This decrease was primarily
attributable to the favorable impact from increased manufacturing levels and
lower cost of revenues associated with contact lens and related products and
license fee revenues. Cost of system revenues as a percentage of its revenue
decreased to 80% in 1998 compared to 112% in 1997. In 1997, cost of system
revenues exceeded system revenues primarily due to unabsorbed manufacturing
costs. In 1998, cost of contact lens and related products revenues as a
percentage of its revenues was 62% compared to 68% in 1997. This cost of revenue
percentage in 1997 would have been 66% assuming the newly-adopted accounting
principle had been in effect in 1997.
Operating Expenses: Selling, general and administrative expenses in
1998 were $30.2 million compared to $24.1 million in the prior year, a 25%
increase. Selling, general and administrative expenses as a percentage of
revenues were 33% and 30% in
-35-
<PAGE> 36
1998 and 1997, respectively. We have incurred significant expenditures in sales
and marketing in order to grow laser vision correction procedure volume, which
have included hiring additional personnel, increased promotions and development
of product marketing materials for users of our lasers. In 1998, increases in
general and administrative expenses were primarily attributable to higher
payroll and benefit costs associated with new management hires, which occurred
in the latter part of 1997. In 1997, we received a net payment of $4.5 million
from VISX resulting from the settlement of patent litigation. This settlement
resulted in a reduction of legal costs of $.6 million in 1998 and $2.6 million
in the second quarter of 1997. We also recorded a $1.4 million reduction in
legal expenses in 1997 resulting from the settlement of a patent litigation.
Research, development and regulatory expenses in 1998 increased to $7.2
million from $6.2 million a year ago, primarily as a result of increased
spending on our research and development efforts in developing enhancements to
the Apex Plus(TM) and increased regulatory efforts to obtain additional FDA
approvals for the use of the Apex Plus(TM) to treat farsightedness as well as a
wider range of nearsightedness.
Other Income (Expense): In 1998, we received a $35.0 million payment
from VISX pursuant to a settlement agreement, under which we and VISX agreed to
dissolve Pillar Point Partners and settle all pending litigation between the two
companies. The litigation settlement, net of related expenses was $34.4 million.
Interest income in 1998 increased slightly to $4.4 million in 1998 from $4.0
million in 1997, primarily due to higher average balances of cash and cash
equivalent balances and short and long-term investments. Interest expense
decreased to $.8 million in 1998 from $1.2 million as a result of lower
borrowings. In 1998, other income included a $2.0 million gain from the sale of
assets and in 1997 other income included a $.7 million loss on investment in
connection with the distribution of LCA common stock as discussed below.
Discontinued Operations: In January 1997, we announced our plan to
discontinue our Vision Center business owned and operated by RCII, a
wholly-owned subsidiary. Accordingly, the results of operations for this
business were classified as discontinued operations at December 31, 1996.
On August 18, 1997, we sold RCII to LCA in exchange for 16,164,361
newly issued shares of LCA common stock. The sale of the discontinued operations
resulted in a net gain of $23.9 million, which included a gain on the sale of
net assets held for discontinued operations and accruals for other estimated
costs. On December 29, 1997, we distributed 9,000,000 shares of LCA common stock
to our shareholders in the form of a dividend. Due to the distribution, we
recorded a loss on investment of $.7 million, representing the difference
between the fair market value of LCA common stock on the dividend declaration
date of $23.6 million and its cost basis of $24.3 million.
In the fourth quarter of 1998, we reversed an accrual related to the
sale of discontinued operations, which resulted in an additional gain on the
sale of discontinued operations of $.9 million.
Accounting Principle Change: Customers of Lens Express pay membership
fees which entitle members to purchase contact lens and related products at
member prices. During the fourth quarter of 1998, we changed our method of
accounting for membership fee revenues, which were previously recognized when
received. Under the new accounting method, we recognize membership fee revenues
ratably over the term of the membership, which is one to five years. We believe
that this method is preferable because it spreads revenue over the period that
benefits are provided to members. In accordance with the provision of Accounting
Principles Board Opinion No. 20 "Accounting Changes", we recorded a one-time
non-cash charge of $10.1 million, or $.32 per basic and diluted share,
representing the cumulative effect of adopting the new accounting principle as
of January 1, 1998.
-36-
<PAGE> 37
Net Income: Income from continuing operations was $36.7 million, or
$1.17 per basic and diluted share, in 1998 compared to $.8 million, or $.03 per
basic and diluted share in 1997. Excluding the $35.0 million litigation
settlement and related expenses of $.6 million and related taxes of $4.5 million
and the $1.9 million gain, net of tax, on the sale of assets, income from
continuing operations in 1998 was $4.9 million, or $.16 per basic and diluted
share compared to $2.1 million, or $.07 per basic and diluted share, in 1997
assuming that the accounting principle change had been in effect in 1997.
Net income for 1998 was $27.6 million, or $.88 per basic and diluted
share, compared to net income of $21.4 million for 1997, or $.68 per basic and
diluted share. On a pro forma basis, assuming the accounting principle change
had been in effect in 1997, net income for 1997 would have been $22.7 million,
or $.72 per basic and diluted share.
Income Taxes: The effective tax rate for 1998 was 12% compared to 14%
for 1997. We have continued to provide a 100% valuation allowance against our
net deferred tax asset of $11.3 million as of December 31, 1998. In 1998, the
valuation allowance decreased $13.8 million primarily due to usage of net
operating loss carryforwards.
LIQUIDITY AND CAPITAL RESOURCES
Our liquidity requirements have been met through external debt and
equity financing. As of December 31, 1999, our cash and cash equivalent balances
and short and long-term investments increased to $106.5 million from $89.9
million as of December 31, 1998. Shares of LCA Vision Inc. common stock included
in long-term investments as of December 31, 1999 and 1998 were valued at $30.9
million and $9.8 million, respectively. Working capital increased to $99.8
million as of December 31, 1999 from $79.0 million as of December 31, 1998. In
1999, net cash used by operating activities of $14.4 million was primarily
attributable to changes in operating assets and liabilities of $21.0 million. In
1998, net cash provided by operating activities of $30.6 million resulted
primarily from income from continuing operations of $36.7 million, which
includes the receipt of a $35.0 million litigation settlement.
In 1999, net cash used by investing activities of $6.5 million resulted
primarily from the net cash cost of the Autonomous acquisition of $46.3 million,
capital expenditures of $6.2 million offset by a net decrease in short and
long-term investments of $46.8 million. In 1998, net cash used by investing
activities of $26.1 million resulted primarily from a net decrease in short and
long-term investments of $16.5 million, purchase of patents, intangibles and
property and equipment of $7.0 million and a loan to Autonomous and deferred
acquisition costs of $3.8 million.
In 1999, net cash provided by financing activities of $59.4 million was
primarily attributable to net proceeds of $60.4 million from the issuance of
4,025,000 shares of our common stock, proceeds of $3.0 million from the issuance
of a secured promissory note and proceeds of $2.6 million from option and
warrant exercises partially offset by repayments of long-term debt of $6.3
million. We intend to use the net proceeds from the common stock offering to
fund the commercial introduction of the LADARVision(R) system in the U.S. market
and for working capital and other general corporate purposes. In addition, we
may use a portion of the net proceeds to acquire complementary businesses,
products, services or technologies; however, we currently have no commitments to
do so. In November 1999, we issued a $3.0 million secured promissory note. The
note bears interest at 10% per annum and requires a fixed monthly payment of $97
thousand over three years. The note is collateralized by certain laser equipment
leased to customers and payments due to us under these leases. We are currently
discussing with our existing and other institutions a new line of credit of
approximately $20 million to $25 million. Net cash used by financing activities
of $7.0 million in 1998 included $5.0 million
-37-
<PAGE> 38
repayments of long-term debt and repurchases of 380,500 shares of our common
stock for $1.9 million.
We believe that our existing corporate resources are adequate for at
least the next twelve months to meet working capital needs and to fund corporate
requirements.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We, in the normal course of doing business, are exposed to the risks
associated with fluctuations in the market value of our available-for-sale
investment securities, changes in foreign currency exchange rates and changes in
interest rates. Our market risk sensitive instruments are entered into for other
than trading purposes.
Our available-for-sale investment securities consist of debt
securities, primarily corporate bonds and mortgage-backed securities, and 6.6
million shares of LCA Vision Inc. common stock. The fair value of these
investment securities at December 31, 1999 was $36.6 million, which included
$5.7 million of debt securities and $30.9 million of LCA Vision Inc. common
stock with a corresponding accumulated unrealized gain of $13.1 million.
Substantially all of the unrealized gain relates to the LCA Vision Inc. common
stock, which is subject to much more market risk than our debt securities and
which has been more volatile than most market indices. A 10 percent change in
the quoted market price of one share of LCA Vision Inc. common stock as of
December 31, 1999 would have a pre-tax impact of approximately $3.1 million on
the fair value of our investment in LCA Vision Inc. common stock. This impact
would be recognized net of tax in our statement of comprehensive income. At
December 31, 1999, our debt securities consist of highly rated debt instruments.
Our investment goal surrounding debt securities is to meet liquidity needs and
to preserve the principal.
The functional currency of our foreign operations is the U.S. dollar.
We enter into forward exchange contracts to reduce exposure to exchange rate
risk associated with transactions in the ordinary course of business, primarily
payments to vendors and employees in foreign currency. The forward exchange
contracts establish a specific exchange rate at which we will sell U.S. dollars
at a future date and have maturities not exceeding 12 months. Exchange gains or
losses on forward exchange contracts are recognized in other income (expense)
when the contracts are settled. There were no outstanding forward exchange
contracts at December 31, 1999.
In November 1999, we issued a $3.0 million secured promissory note. The
note bears interest at 10% per annum and requires a fixed monthly payment of $97
thousand over three years. The note is collateralized by certain laser equipment
leased to customers and payments due to us under these leases. Changes in
interest rates may affect the fair market value of this fixed rate debt,
however, they will not affect our cash flow or earnings.
NEW ACCOUNTING STANDARDS
In December 1999, the Securities and Exchange Commission ("SEC")
released Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements." This bulletin summarizes certain views of the SEC staff on
applying generally accepted accounting principles to revenue recognition in
financial statements. We have not completed our assessment of the consolidated
financial statement impact of this bulletin. This bulletin is effective
beginning the second quarter of fiscal 2000.
In June 1998, the Financial Accounting Standards Board issued SFAS No.
133, "Accounting for Derivative Instruments and Hedging Activities" ("SFAS
133"), which establishes standards for derivative instruments and hedging
activities. It requires an entity to recognize all derivatives as either assets
or liabilities in the statement of financial position and measure those
instruments at fair value. It requires that changes in the derivative's fair
value be recognized currently in the earnings unless specific hedge accounting
criteria are met. A company must formally document, designate and assess the
effectiveness of transactions that receive hedge accounting. SFAS 133 is
currently effective for fiscal years beginning after June 15, 2000. We will
adopt SFAS 133 in the first quarter of fiscal 2001. We are currently evaluating
this statement, but do not expect the adoption of SFAS 133 to have a material
effect on our consolidated financial position or results of operations.
-38-
<PAGE> 39
YEAR 2000 ISSUE
The Year 2000 issue is the result of computer programs that are not
able to differentiate between the year 1900 and the year 2000 because they were
written using two digits instead of four digits to define the applicable year.
Currently, we are not aware of any Year 2000 issues that have had a
significant interruption in service or delays in business operations. A review
of our internal computer systems and software packages was performed to identify
the systems and software that could be affected by this issue. Installation of
and testing of Year 2000 compliant hardware and software was completed. The
costs related to these upgrades were not material and have been incurred in the
normal course of operations. Our products, which were Year 2000 compliant, have
not experienced any Year 2000 related problems. We are not aware of any of our
supplier's inability to remediate their Year 2000 issues. However, not all
vendors have been used at this date and future problems could develop.
We will continue to monitor our internal and external sources for
delayed complications or disruptions arising from the Year 2000 issue. In the
event of unforeseen or unanticipated issues related to the Year 2000, these
issues may have material adverse effect on our results of operations, financial
position or cash flow.
EURO CONVERSION
On January 1, 1999, eleven of fifteen member countries of the European
Union adopted the conversion of their national currencies to the European
Union's common currency ("Euro"). A permanent fixed conversion rate between the
existing national currencies of these countries and the Euro was established on
that date. The Euro may be used in business transactions; however, national
currencies will still remain legal tender through June 30, 2002. We do not
believe that adoption of the Euro will have a material adverse effect on our
results of operations, financial position or cash flow.
RECENT DEVELOPMENTS
On March 28, 2000, a restructuring plan was approved by the Company's
Board of Directors that will result in the termination of approximately 20
employees. The Company will record a liability and related charge of
approximately $3 million in the first quarter of 2000.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information relating to quantitative and qualitative disclosure about
market risk is included in Item 7 of Part II of this Report, entitled
"Management's Discussion and Analysis of Financial Condition and Results of
Operations."
-39-
<PAGE> 40
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
Independent Auditors' Reports ............................................................................. F-2
Consolidated Balance Sheets as of December 31, 1999 and 1998 .............................................. F-4
Consolidated Statements of Operations for the Years Ended December 31, 1999, 1998 and 1997 ................ F-5
Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 1999, 1998 and 1997 F-7
Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 1999, 1998
and 1997 ............................................................................................... F-8
Consolidated Statements of Cash Flows for the Years Ended December 31, 1999, 1998 and 1997 ................ F-10
Notes to Consolidated Financial Statements ................................................................ F-12
</TABLE>
F-1
<PAGE> 41
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
Summit Technology, Inc.:
We have audited the accompanying consolidated balance sheets of Summit
Technology, Inc. and subsidiaries (the "Company") as of December 31, 1999 and
1998 and the related consolidated statements of operations, comprehensive income
(loss), stockholders' equity, and cash flows for the years then ended. Our
audits also included the financial statement schedule for the years ended
December 31, 1999 and 1998 listed in Item 14.2. These financial statements and
the financial statement schedule are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements and the financial statement schedule based on our audits.
We conducted our audit in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, such financial statements referred to above present fairly, in
all material respects, the financial position of the Company at December 31,
1999 and 1998 and the results of their operations and their cash flows for the
years then ended, in conformity with accounting principles generally accepted in
the United States of America. Also, in our opinion, such financial statement
schedule for the years ended December 31, 1999 and 1998 when considered in
relation to the basic consolidated financial statements taken as a whole,
present fairly in all material respects the information set forth therein.
As discussed in Note 2 to the consolidated financial statements, the Company
changed its method of accounting for membership fee revenues in 1998.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
January 31, 2000
(except for the second paragraph of Note 1, as to which the date is February 23,
2000)
F-2
<PAGE> 42
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
Summit Technology, Inc.:
We have audited the accompanying consolidated statements of operations,
stockholders' equity, and cash flows of Summit Technology, Inc. and subsidiaries
for the year ended December 31, 1997. These consolidated financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these consolidated financial statements based on our
audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the results of operations and cash flows of
Summit Technology, Inc. and subsidiaries for the year ended December 31, 1997,
in conformity with generally accepted accounting principles.
/s/ KPMG LLP
KPMG LLP
Boston, Massachusetts
March 6, 1998
F-3
<PAGE> 43
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 1999 AND 1998
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
DECEMBER 31, DECEMBER 31,
1999 1998
- ------------------------------------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 69,850 $ 31,314
Short-term investments 5,730 33,295
Receivables, net of allowances of $1,042 in 1999 and $1,399 in 1998 18,777 12,764
Inventories 25,885 17,403
Other current assets 3,308 5,965
----------------------
Total current assets 123,550 100,741
Long-term investments 30,948 25,253
Property and equipment, net 20,951 8,802
Patents and other intangibles, net 9,349 7,497
Purchased technologies, net 26,851 --
Goodwill, net 53,859 --
Other assets 5,159 2,632
- ------------------------------------------------------------------------------------------------------------
TOTAL ASSETS $ 270,667 $ 144,925
- ------------------------------------------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 7,203 $ 4,132
Accrued expenses 8,859 5,081
Current maturities of long-term debt 1,203 6,431
Deferred revenue 6,455 6,144
----------------------
Total current liabilities 23,720 21,788
Deferred revenue - noncurrent 4,007 3,653
Deferred tax liabilities - noncurrent 4,786 --
Long-term debt, less current maturities 1,986 150
- ------------------------------------------------------------------------------------------------------------
Total liabilities 34,499 25,591
- ------------------------------------------------------------------------------------------------------------
Commitments and contingencies (Notes 11 and 13)
Stockholders' equity:
Preferred stock, $.01 par value. Authorized 5,000,000 shares; none issued - -
Common stock, $.01 par value. Authorized 100,000,000 shares;
issued 46,992,169 shares in 1999 and 31,322,880 shares in 1998;
outstanding 46,827,454 shares in 1999 and 31,153,765 in 1998 470 314
Additional paid-in capital 271,414 149,482
Accumulated deficit (43,244) (20,219)
Accumulated other comprehensive income (loss) 8,336 (9,411)
Treasury stock, at cost, 164,715 shares
in 1999 and 169,115 shares in 1998 (808) (832)
- ------------------------------------------------------------------------------------------------------------
Total stockholders' equity 236,168 119,334
- ------------------------------------------------------------------------------------------------------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 270,667 $ 144,925
- ------------------------------------------------------------------------------------------------------------
</TABLE>
See accompanying notes to consolidated financial statements.
F-4
<PAGE> 44
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 1999, 1998 AND 1997
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
1999 1998 1997
--------- -------- --------
<S> <C> <C> <C>
Revenues:
Systems $ 18,267 $ 14,105 $ 7,589
License fees, service and other 45,946 30,782 25,486
Contact lens and related products 46,886 46,754 46,575
--------- -------- --------
Total revenues 111,099 91,641 79,650
--------- -------- --------
Cost of revenues:
Systems 13,327 11,333 8,490
License fees, service and other 19,377 12,187 9,788
Contact lens and related products 27,758 28,800 31,721
Inventory write-down related to systems
and service 2,800 -- --
--------- -------- --------
Total cost of revenues 63,262 52,320 49,999
--------- -------- --------
Gross profit 47,837 39,321 29,651
--------- -------- --------
Operating expenses:
Selling, general and administrative expenses 41,738 30,217 24,131
Research, development and regulatory 14,201 7,223 6,213
Acquired in-process research and development 19,800 -- --
--------- -------- --------
Total operating expenses 75,739 37,440 30,344
--------- -------- --------
Operating income (loss) from continuing operations (27,902) 1,881 (693)
Litigation settlement, net of related expenses -- 34,386 --
Interest income 3,549 4,351 4,019
Interest expense (315) (780) (1,195)
Other income (expense) 2,018 1,913 (1,166)
--------- -------- --------
Income (loss) from continuing operations
before provision for income taxes (22,650) 41,751 965
Provision for income taxes 375 5,021 137
--------- -------- --------
Income (loss) from continuing operations (23,025) 36,730 828
Gain on sale of discontinued operations, net of tax -- 943 23,910
Loss from discontinued operations, net of tax -- -- (3,340)
--------- -------- --------
Income (loss) before cumulative
effect of accounting principle change (23,025) 37,673 21,398
Cumulative effect of accounting principle change, net of tax -- (10,103) --
--------- -------- --------
Net income (loss) $ (23,025) $ 27,570 $ 21,398
========= ======== ========
</TABLE>
(continued)
See accompanying notes to consolidated financial statements.
F-5
<PAGE> 45
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 1999, 1998 AND 1997
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(continued)
<TABLE>
<CAPTION>
1999 1998 1997
---------- ---------- ----------
<S> <C> <C> <C>
Basic and diluted earnings (loss) per share:
- -----------------------------------------------------
Income (loss) from continuing operations $ (0.57) $ 1.17 $ 0.03
Gain on sale of discontinued operations, net of tax -- .03 0.76
Loss from discontinued operations, net of tax -- -- (0.11)
---------- ---------- ----------
Income (loss) before cumulative
effect of accounting principle change (0.57) 1.20 0.68
Cumulative effect of accounting principle change,
net of tax -- (0.32) --
---------- ---------- ----------
Net income (loss) $ (0.57) $ 0.88 $ 0.68
========== ========== ==========
Weighted-average number of common shares outstanding:
- -----------------------------------------------------
Basic 40,436 31,244 31,400
Effect of dilutive securities outstanding -- 48 191
---------- ---------- ----------
Diluted 40,436 31,292 31,591
========== ========== ==========
Pro forma amounts assuming accounting principle
change had been applied retroactively:
- -----------------------------------------------------
Net income (loss) N/A $ 37,673 $ 22,682
Net income (loss) per share - basic N/A $ 1.20 $ 0.72
Net income (loss) per share - diluted N/A $ 1.20 $ 0.72
</TABLE>
See accompanying notes to consolidated financial statements.
F-6
<PAGE> 46
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
YEARS ENDED DECEMBER 31, 1999, 1998 AND 1997
(IN THOUSANDS)
<TABLE>
<CAPTION>
1999 1998 1997
-------- ------- --------
<S> <C> <C> <C>
Net income (loss) $(23,025) $27,570 $ 21,398
Net unrealized gain (loss) on investments, net of tax 17,747 1,873 (11,284)
Reclassification adjustment for realized
gain in net loss, net of tax (2,346) -- --
-------- ------- --------
Comprehensive income (loss) $ (7,624) $29,443 $ 10,114
======== ======= ========
</TABLE>
See accompanying notes to consolidated financial statements.
F-7
<PAGE> 47
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 1999, 1998 AND 1997
(IN THOUSANDS)
<TABLE>
<CAPTION>
Accumulated
Common Stock Additional Other Treasury Stock Total
----------------- Paid-in Accumulated Comprehensive ----------------------- Stockholders'
Shares Par Value Capital Deficit Income (Loss) Shares At Cost Equity
------ --------- ---------- ----------- ------------- ------------ --------- -------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at January 1, 1997 31,025 $311 $ 170,983 $(69,187) $ -- (6) $ (160) $ 101,947
Exercise of stock options 40 -- 214 -- -- -- -- 214
Other shares issued 235 2 335 -- -- -- -- 337
Dividend -- -- (23,625) -- -- -- -- (23,625)
Net unrealized loss
on investments -- -- -- -- (11,284) (11,284)
Net income -- -- -- 21,398 -- -- -- 21,398
------ ---- --------- -------- -------- ------- -------- ---------
Balance at December 31, 1997 31,300 313 147,907 (47,789) (11,284) (6) (160) 88,987
Exercise of stock options 7 -- 37 -- -- -- -- 37
Other shares issued 16 1 72 -- -- -- -- 73
Net unrealized gain
on investments -- -- -- -- 1,873 -- -- 1,873
Purchases of treasury stock -- -- -- -- -- (381) (1,855) (1,855)
Effect of adjustment to
Lens acquisition
exchange ratio -- -- (1,351) -- -- 218 1,183 (168)
Tax benefit related to
stock options -- -- 2,817 -- -- -- -- 2,817
Net income -- -- -- 27,570 -- -- -- 27,570
------ ---- --------- -------- -------- ------- -------- ---------
</TABLE>
(continued)
See accompanying notes to consolidated financial statements.
F-8
<PAGE> 48
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 1999, 1998 AND 1997
(IN THOUSANDS)
(continued)
<TABLE>
<CAPTION>
Accumulated
Common Stock Additional Other Treasury Stock Total
----------------- Paid-in Accumulated Comprehensive ----------------- Stockholders'
Shares Par Value Capital Deficit Income (Loss) Shares At Cost Equity
------ --------- ---------- ---------- ------------- ------ ------- -------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1998 31,323 314 149,482 (20,219) (9,411) (169) (832) 119,334
Exercise of stock options
and warrants 454 4 2,571 -- -- -- -- 2,575
Issuance of treasury stock -- -- -- -- -- 4 24 24
Net unrealized gain
on investments -- -- -- -- 17,747 -- -- 17,747
Issuance of shares for
acquisition 11,190 112 47,914 -- -- -- -- 48,026
Options and warrants
granted for acquisition -- -- 11,037 -- -- -- -- 11,037
Issuance of shares in
public offering 4,025 40 60,358 -- -- -- -- 60,398
Stock based compensation -- -- 52 -- -- -- -- 52
Net loss -- -- -- (23,025) -- -- -- (23,025)
------ ---- -------- -------- -------- --- ----- ---------
Balance at December 31, 1999 46,992 $470 $271,414 $(43,244) $ 8,336 (165) $(808) $ 236,168
====== ==== ======== ======== ======== ==== ===== =========
</TABLE>
See accompanying notes to consolidated financial statements.
F-9
<PAGE> 49
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1999, 1998 AND 1997
(IN THOUSANDS)
<TABLE>
<CAPTION>
1999 1998 1997
-------- -------- --------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $(23,025) $ 27,570 $ 21,398
Adjustments to reconcile net income (loss) to
net cash provided (used) by operating activities:
Acquired in-process research and development 19,800 -- --
Inventory write-down 2,800 -- --
Other non-cash items 76 -- --
Cumulative effect of accounting principle change -- 10,103 --
Gain on sale of discontinued operations -- (943) (23,910)
(Gain) loss on investment (2,430) -- 675
Gain on sale of assets -- (1,981) --
Depreciation and amortization 9,417 3,743 3,863
Provision for losses on accounts receivables 13 838 245
Changes in operating assets and liabilities:
Receivables (5,950) (4,706) (588)
Inventories (13,979) (2,267) (245)
Prepaid and other assets (2,266) 221 282
Accounts payable 2,882 (350) 711
Accrued expenses (2,026) 1,644 1,083
Deferred revenue 323 (3,243) (697)
Operating activities of discontinued operations -- -- (14,653)
-------- -------- --------
Net cash provided (used) by operating activities (14,365) 30,629 (11,836)
-------- -------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash consideration for acquisition (46,344) -- --
Purchases of short-term investments (3,485) (53,063) (46,196)
Purchases of long-term investments (1,797) (24,670) (9,686)
Maturities of short-term investments 7,802 39,630 26,557
Maturities of long-term investments 5,669 6,590 7,715
Sales of short-term investments 23,248 6,908 12,262
Sales of long-term investments 15,396 8,115 5,166
Additions to property and equipment (6,152) (3,664) (797)
Proceeds from sale of assets -- 1,990 --
Purchase of patents and other intangibles (375) (3,346) --
Decrease in restricted cash -- 1,264 238
Loan to acquiree and deferred acquisition costs -- (3,832) --
Note receivable and other (449) (2,000) 892
Investing activities of discontinued operations -- -- 9,948
-------- -------- --------
Net cash provided (used) by investing activities (6,487) (26,078) 6,099
-------- -------- --------
</TABLE>
(continued)
See accompanying notes to consolidated financial statements.
F-10
<PAGE> 50
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1999, 1998 AND 1997
(IN THOUSANDS)
(continued)
<TABLE>
<CAPTION>
1999 1998 1997
-------- -------- --------
<S> <C> <C> <C>
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of shares in public offering 60,398 -- --
Proceeds from issuance of long-term debt, net 2,990 -- --
Repayments of long-term debt (6,347) (5,000) (5,000)
Payments of capital lease obligations (228) (212) (246)
Proceeds from exercise of stock options and warrants 2,575 37 214
Proceeds from other shares issued -- 73 337
Purchases of treasury stock -- (1,855) --
Financing activities of discontinued operations -- -- 139
-------- -------- --------
Net cash provided (used) by financing activities 59,388 (6,957) (4,556)
======== ======== ========
Increase (decrease) in cash and cash equivalents 38,536 (2,406) (10,293)
Cash and cash equivalents, beginning of year 31,314 33,720 44,013
-------- -------- --------
Cash and cash equivalents, end of year $ 69,850 $ 31,314 $ 33,720
======== ======== ========
Supplemental cash flow information:
- -----------------------------------
Interest paid $ 284 $ 820 $ 1,108
Income taxes paid $ 179 $ 2,186 $ 106
</TABLE>
See accompanying notes to consolidated financial statements.
F-11
<PAGE> 51
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(in thousands, except share and per share amounts)
Years ended December 31, 1999, 1998, and 1997
1. Nature of Business
The operations of Summit Technology, Inc. and subsidiaries (the
"Company" or "Summit") presently consist of two operating segments: (i) laser
vision correction which includes manufacturing, selling and servicing laser
systems and related products to correct vision disorders and collecting per
procedure license fees from users of its systems and (ii) contact lenses and
related products which are sold via mail order through its wholly-owned
subsidiary, Lens Express, Inc. ("Lens"). In 1999, the Company completed its
acquisition of Autonomous Technologies Corporation ("Autonomous") (see Note 3).
On February 22, 2000, VISX, Inc. ("VISX"), a competitor, announced
that it was lowering its U.S. per procedure licensing fee to one hundred
dollars. For obvious competitive reasons, the Company responded by lowering its
own U.S. per procedure licensing fee. Effective February 23, 2000, the Company
instituted a tiered pricing program for its customers. The Company's Apex
Plus(TM)/Infinity(TM) excimer laser system will be value priced and will carry a
per procedure licensing fee of one hundred dollars. Prior to February 23, 2000,
the list price of the licensing fee for the Apex Plus(TM)/Infinity(TM) System
was two hundred and fifty dollars per procedure, with actual pricing variable
based on factors including volume discounts and promotions, participation in one
of our innovative bundled pricing programs which combine license fees with other
products and services, and whether the customer is or was one of our clinical
investigators. The emphasis(R) disc used in conjunction with the Apex
Plus(TM)/Infinity(TM) System for astigmatism and hyperopia corrections will be
priced at twenty-five dollars. Ladarvision(R) system procedures will be premium
priced at one hundred and fifty dollars per procedure for purchased units.
Customers who have acquired Apex Plus(TM)/Infinity(TM) and/or LadarVision(R)
Systems utilizing a program which bundles the licensing fee with other products
and services will receive adjustments to their programs to reflect the reduced
pricing. The Company expects that these reductions in per procedure pricing will
materially reduce its revenues and revenue growth in 2000, but will not
materially affect estimates and assumptions made with respect to the 1999
consolidated financial statements.
The Company is continuing to evaluate its operations and strategies,
which may result in the acquisition by the Company of one or more additional
businesses, or dispositions of all or part of one or more of the Company's
businesses.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of consolidated financial statements in conformity with
accounting principles generally accepted in the U.S. requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation
The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiaries after elimination of intercompany
accounts and transactions.
Revenue Recognition
The Company recognizes revenue on product sales when the products are
shipped and the customer takes ownership and assumes risk of loss. The cost of
any product upgrade obligations are accrued when the product is shipped.
Additionally, the Company provides installation, training and a one-year
warranty on its laser system. The costs to provide these services are incidental
to the sale and are accrued when the sale is recognized. Advance payments
received by the Company for products or services are recorded as
F-12
<PAGE> 52
deferred revenue. Service contract revenue is recognized ratably over the term
of the contract. The Company recognizes revenue under laser equipment operating
leases based upon the terms of the contract. Non-refundable per procedure
license fees are recognized upon shipment of OmniCards which are required to
perform laser vision correction procedures with the Company's equipment in the
U.S. The Company accounted for its interest in Pillar Point Partners ("PPP")
using the equity method of accounting and recorded its equity in the net income
of PPP as "license fees, service and other revenues" (see Note 4).
Customers of Lens pay membership fees which entitle members to purchase
contact lens and related products at member prices. During the fourth quarter of
1998, the Company changed its method of accounting for membership fee revenues
which were previously recognized when received. Under the new accounting method,
the Company recognizes membership fee revenues ratably over the term of the
membership, which is one to five years. The Company believes that this method is
preferable because it spreads revenue over the period that benefits are provided
to members. In accordance with the provisions of Accounting Principles Board
("APB") Opinion No. 20 "Accounting Changes," the Company recorded a one-time
charge of $10,103, or $.32 per basic and diluted share, representing the
cumulative effect of adopting the new accounting principle as of January 1,
1998. Adoption of the new standard resulted in a $2,583 increase in 1998 contact
lens and related products revenues.
Cash Equivalents
Cash equivalents consist of certificates of deposit and highly liquid
debt instruments with original maturities of three months or less.
Short and Long-term Investments
Short and long-term investments consist of marketable debt and equity
securities. The Company considers its investments as available-for-sale and
carries the investments at market value. Unrealized holding gains and losses,
net of the related tax effect, on available-for-sale securities are included in
other comprehensive income. Realized gains and losses from the sale of
available-for-sale securities are determined on a specific identification basis.
These investments primarily consist of U.S. government securities,
mortgage-backed securities, equity securities and investment grade corporate
bonds.
Inventories
Inventories are stated at the lower of cost or market value, cost being
determined using the first-in, first-out method.
Property and Equipment
Property and equipment is stated at cost. Property and equipment under
capital leases is stated at the lower of the present value of future minimum
lease payments or fair market value at the beginning of the lease term.
Depreciation of property and equipment is calculated using the straight-line
method over the estimated useful lives of the assets. Amortization of property
and equipment held under capital leases and leasehold improvements is calculated
using the straight-line method over the shorter of the lease term or estimated
useful life of the asset.
Useful lives for property and equipment are as follows:
Leasehold improvements 5-10 years
Manufacturing and test equipment 3-10 years
Computer, furniture and office equipment 3-10 years
Leased laser equipment 3 years
Intangible Assets
Goodwill represents the excess of purchase price over the fair value of
net assets acquired. Goodwill is being amortized using the straight-line method
over 25 years. Purchased technologies which primarily consist of Autonomous'
LADARVision(R) technology
F-13
<PAGE> 53
have been assigned a value of $28,100. The amortization of purchased
technologies is included in cost of revenues and is being recognized on a
straight line basis over 15 years. Patents consist of purchased patents and
patent application costs. Patents are being amortized using the straight-line
method over the patent's economic life ranging from nine to 20 years. Other
intangibles include purchased licenses, customer databases and other. Purchased
licenses and other intangible assets are being amortized over five years using
the straight line method and customer databases are being amortized on an
accelerated method over six years based upon expected customer turnover. The
carrying values of these intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of the
asset may not be recoverable.
Deferred Income Taxes
Deferred tax assets and liabilities have been established for the
expected future tax consequences of events that have been recognized in the
Company's consolidated financial statements and tax returns. These deferred tax
assets and liabilities are determined based on the difference between the
financial statement carrying amounts and tax basis of assets and liabilities
using currently enacted tax rates that are expected to be in effect during the
years in which the differences are anticipated to reverse.
Advertising Expense
The Company expenses advertising costs when the advertising takes
place. For the years ended December 31, 1999, 1998 and 1997 the Company's
advertising expense was $3,731, $2,741 and $3,683, respectively.
Foreign Currency Translation
The functional currency of the Company's foreign operations is the U.S.
dollar. Assets, liabilities and expenses related to foreign operations are
remeasured in U.S. dollars at the appropriate exchange rates. Gains and losses
resulting from remeasurement are included in other income (expense).
Foreign Currency Management
The Company enters into forward exchange contracts to reduce exposure
to exchange rate risk associated with transactions in the ordinary course of
business, primarily payments to vendors and employees in foreign currency. The
forward exchange contracts establish a specific exchange rate at which the
Company will sell U.S. dollars at a future date and have maturities not
exceeding 12 months. Exchange gains or losses on forward exchange contracts are
recognized in other income (expense) when the contracts are settled. There were
no forward exchange contracts outstanding at December 31, 1999. In 1998, the
Company recorded a loss of $32, representing the estimated fair value, for
outstanding forward exchange contracts at December 31, 1998 which had a notional
value of $3,000.
Fair Value
The carrying amount of cash and cash equivalents, accounts receivable and
accounts payable approximates fair value because of the short-term maturity of
these items. The fair market value of long-term debt approximates the carrying
value of long-term debt.
Concentration of Credit Risk
The Company's financial instruments subject to credit risk are
primarily cash and cash equivalents, short and long-term investments, trade
receivables and forward contracts. The Company places its investments and enters
into forward exchange contracts with major financial institutions. Investments
primarily consist of highly rated debt instruments to meet liquidity needs and
to preserve the principal. The Company limits its credit risk of U.S.
receivables by obtaining commitments from a third-party leasing company. The
Company limits its credit risk of international receivables by using
distributors with proven credit history or by requiring irrevocable letters of
credit.
F-14
<PAGE> 54
Stock Based Compensation
The Company accounts for stock based compensation in accordance with the
provisions of APB Opinion No. 25, "Accounting for Stock Issued to Employees."
Earnings Per Share
Basic earnings per share amounts are based on the weighted-average number
of common shares outstanding during the year. Diluted earnings per share amounts
include the effect of all potential common shares, if dilutive, that were
outstanding during the year. The calculation of the diluted loss per share for
the year ended December 31, 1999 excludes 1,459,299 potential common shares
because their effect would be antidilutive.
Reclassifications
Certain prior year information has been reclassified to conform with the
1999 presentation.
New Accounting Standards
In December 1999, the Securities and Exchange Commission ("SEC") released
Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements." This bulletin summarizes certain views of the SEC staff on applying
generally accepted accounting principles to revenue recognition in financial
statements. We have not completed our assessment of the consolidated financial
statement impact of this bulletin. This bulletin is effective beginning the
second quarter of fiscal 2000.
In June 1998, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards ("SFAS") No. 133, "Accounting for Derivative
Instruments and Hedging Activities", which establishes standards for derivative
instruments and hedging activities. It requires an entity to recognize all
derivatives as either assets or liabilities in the statement of financial
position and measure those instruments at fair value. It requires that changes
in the derivative's fair value be recognized currently in earnings unless
specific hedge accounting criteria are met. A company must formally document,
designate and assess the effectiveness of transactions that receive hedge
accounting. SFAS 133 is currently effective for fiscal years beginning after
June 15, 2000. The Company will adopt SFAS 133 in the first quarter of fiscal
2001. The Company is currently evaluating this statement, but does not expect
the adoption of SFAS 133 to have a material effect on the Company's consolidated
financial position or results of operations.
3. Acquisition
On April 29, 1999, the Company completed its acquisition of Orlando,
FL-based Autonomous for 11,190,306 shares of the Company's common stock and
$46,826 in cash. Autonomous is engaged in the design and development of
next-generation excimer laser instruments for laser refractive surgery.
Autonomous' LADARVision(R) System combines laser radar eye tracking with narrow
beam shaping technology.
The acquisition of Autonomous has been accounted for under the purchase
method of accounting. The issuance of 11,190,306 shares of Summit common stock
was valued at $4.2917 per share, which represents the price at which the total
share and cash consideration paid by the Company became substantially fixed. The
purchase price has been allocated to the assets acquired and to the liabilities
assumed based on their estimated fair values.
An independent third-party appraisal company has conducted a valuation of
the intangible assets that the Company acquired. These intangibles include
purchased technologies, in-process research and development and other intangible
assets. Purchased technologies primarily consist of Autonomous' LADARVision(R)
technology. The fair value of the in-process research and development of
$19,800, which relates to Autonomous' CustomCornea(TM) research project, was
recorded as an expense in the second quarter of 1999.
The valuation of these intangibles was determined using the income method.
Revenue projections were completed through year 2012 and were separately
identified as follows: (i) revenue derived from products relying on current
technology, (ii) revenue derived from products relying on a new in-process
research and development program --CustomCornea(TM), and (iii) revenue from
future technologies not yet developed. Revenue generated from the
CustomCornea(TM) product has similar margin and expense levels as those
generated from the LADARVision(R) product. The projected cash flows were
discounted using a
F-15
<PAGE> 55
27.5% rate. The fair value of in-process research and development was determined
separately from all other acquired assets using the percentage of completion
method. The percentage of completion ratio was calculated by dividing total
expected expenditures on CustomCornea(TM) through the acquisition closing date
by the total estimated expenditures to achieve technological feasibility.
Management is responsible for the estimate of the value of the in-process
research and development.
At the closing of the merger, the Company exchanged Autonomous options
and warrants for equivalent Summit stock options and warrants. This exchange
resulted in options to purchase 868,689 shares of common stock with a
weighted-average exercise price of $5.93 per share and warrants to purchase
56,713 shares of common stock with a weighted-average exercise price of $3.02
per share. The fair value of these options and warrants of $11,037 was
calculated using the Black-Scholes option pricing model with the following
assumptions for the options and warrants, respectively: expected life of 4.5
years and 2.3 years, volatility of 81.3% and 89.3%, interest rate of 5.33% and
5.1% and dividend yields of zero.
The total purchase price and allocation of the purchase price is as follows:
<TABLE>
<CAPTION>
Total Purchase Price
- --------------------
<S> <C>
Summit common stock (11,190,306 shares @ $4.2917 per share) $ 48,026
Cash paid to Autonomous equity holders 46,826
Acquisition-related fees and expenses 3,536
Fair value of Autonomous options and warrants exchanged for
equivalent Summit stock options and warrants at the closing of the merger 11,037
- ----------------------------------------------------------------------------------------------
Total purchase price $ 109,425
==============================================================================================
Allocation of Purchase Price
- ----------------------------
Net worth of Autonomous $ 2,991
Deferred tax assets, net of valuation allowance 12,520
Deferred tax liabilities (12,520)
In-process research and development 19,800
Purchased technologies 28,100
Other intangible asset 3,200
Goodwill 55,334
- ----------------------------------------------------------------------------------------------
Total $ 109,425
==============================================================================================
</TABLE>
The results of Autonomous' operations have been included in the
Company's consolidated statement of operations from the effective date of
acquisition, which was April 29, 1999. The following unaudited pro forma
information combines the results of operations of Summit and Autonomous as if
the acquisition had occurred on January 1, 1998 and excludes one-time charges of
$19,800 for acquired in-process research and development and $2,800 to
write-down inventory to its net realizable value as a result of the acquisition.
The pro forma information does not purport to represent what the consolidated
financial results of operations actually would have been if the acquisition in
fact had occurred on January 1, 1998 or to project the consolidated results of
operations of any future period.
<TABLE>
<CAPTION>
Year Ended December 31,
-------------------------
1999 1998
--------- ---------
<S> <C> <C>
Total revenues $ 111,265 $ 91,863
Net income (loss) $ (33,324) $ 5,835
Basic and diluted earning (loss) per share $ (0.76) $ 0.14
</TABLE>
F-16
<PAGE> 56
4. Pillar Point Partners
Prior to June 1998, the Company participated in per procedure license
fees from its ownership interest in PPP, a partnership formed by the Company and
VISX to hold certain U.S. patents covering excimer laser systems and procedures.
On June 4, 1998, the Company and VISX entered into a settlement agreement that
dissolved PPP and granted to each other worldwide, royalty-free cross-licenses
to all of their respective U.S. and foreign patents in the field of laser
ablation of corneal tissue, including all patents that were included or
includable in PPP. Under the terms of the settlement, the Company received a
payment from VISX of $35,000 and recorded a gain of $34,386, net of expenses
associated with the settlement. Subsequent to the dissolution of PPP, the
Company retains 100% of all per procedures fees performed on its systems.
The Company recorded as license fees, service and other revenues its
equity (approximately 44%) in the net income of PPP, which was $922 and $10,682
for the years ended December 31, 1998 and 1997, respectively.
5. Discontinued Operations
On August 18, 1997, the Company sold its Vision Center business owned
and operated by Refractive Centers International ("RCII"), a wholly-owned
subsidiary of the Company, to LCA-Vision Inc. ("LCA") in exchange for 16,164,361
newly issued shares of LCA common stock. The sale of the discontinued operations
resulted in a net gain of $23,910, which included a gain on the sale of net
assets held for discontinued operations and accruals for other estimated costs.
On December 29, 1997, the Company distributed 9,000,000 shares of LCA common
stock to its shareholders in the form of a dividend. In connection with the
distribution, the Company recorded a loss on investment of $675, representing
the difference between the fair market value of LCA common stock on the dividend
declaration date of $23,625 and its cost basis of $24,300. As of December 31,
1999 and 1998, the Company owned 12.8% and 17.3%, respectively, of LCA's
outstanding common stock, which have been classified as a long-term
available-for-sale investment.
In 1998, the Company reversed an accrual related to the sale of
discontinued operations which resulted in an additional gain on the sale of
discontinued operations of $943.
6. Inventories
Inventories consist of the following:
<TABLE>
<CAPTION>
December 31,
--------------------
1999 1998
------- -------
<S> <C> <C>
Raw materials and subassemblies $11,444 $ 5,599
Work in process 5,666 1,244
Finished goods 8,775 10,560
------- -------
Total $25,885 $17,403
======= =======
</TABLE>
7. Property and Equipment
Property and equipment consist of the following:
<TABLE>
<CAPTION>
December 31,
-----------------------
1999 1998
-------- --------
<S> <C> <C>
Leasehold improvements $ 2,200 $ 1,828
Manufacturing and test equipment 12,733 8,771
Computer, furniture and office equipment 12,674 8,585
Leased laser equipment 12,394 4,450
-------- --------
40,001 23,634
Less accumulated depreciation (19,050) (14,832)
-------- --------
Net property and equipment $ 20,951 $ 8,802
======== ========
</TABLE>
F-17
<PAGE> 57
Leased laser equipment to customers under operating leases generated
revenues of $4,027, $2,649 and $2,319 in 1999, 1998 and 1997, respectively.
Accumulated depreciation on leased laser equipment as of December 31, 1999 and
1998 was $1,895 and $1,827, respectively. Future minimum lease payments due to
the Company from operating lease agreements at December 31, 1999 were $9,078 in
2000, $9,163 in 2001 and $6,456 in 2002.
8. Intangible Assets
Patents and other intangibles consist of the following:
<TABLE>
<CAPTION>
December 31,
---------------------
1999 1998
------- -------
<S> <C> <C>
Patents $ 6,610 $ 6,610
Licenses, customer databases
and other 6,920 3,346
Less accumulated amortization (4,181) (2,459)
------- -------
$ 9,349 $ 7,497
======= =======
</TABLE>
Purchased technologies consist of the following:
<TABLE>
<CAPTION>
December 31,
-----------------------
1999 1998
-------- --------
<S> <C> <C>
Purchased technologies $ 28,100 $ --
Less accumulated amortization (1,249) --
-------- --------
$ 26,851 $ --
======== ========
</TABLE>
Goodwill consists of the following:
<TABLE>
<CAPTION>
December 31,
-------------------------
1999 1998
-------- ----------
<S> <C> <C>
Goodwill $ 55,334 $ --
Less accumulated amortization (1,475) --
-------- ----------
$ 53,859 $ --
======== ==========
</TABLE>
F-18
<PAGE> 58
9. Net Investment in Sales-Type Leases
The Company leases laser equipment to certain customers under
sales-type leases as defined by SFAS No. 13, "Accounting for Leases". The
Company's sales-type leases generally require monthly payments over 3 years and
the leased laser equipment is estimated to have no residual value at the end of
the lease term. The net investment in sales-type leases is classified as "other
assets". Future minimum lease payments receivable under noncancellable leasing
arrangement as of December 31, 1999 were as follows:
Year ending December 31:
<TABLE>
<S> <C>
2000 $ 916
2001 829
2002 577
2003 92
------
Minimum future lease receipts 2,414
Less unearned interest income 311
------
Net investment in sales-type leases $2,103
======
</TABLE>
10. Accrued Expenses
Accrued expenses consist of the following:
<TABLE>
<CAPTION>
December 31,
------ ------
1999 1998
------ ------
<S> <C> <C>
Accrued compensation and benefits $2,955 $1,322
Accrued warranty costs 663 646
Other accrued expenses 5,241 2,997
Accrued costs related to sale
of discontinued operations -- 116
------ ------
Total $8,859 $5,081
====== ======
</TABLE>
11. Lease Obligations and Financing Arrangements
Lease Obligations
Capital lease obligations consist of amounts due under equipment lease
agreements. At December 31, 1999, the cost and accumulated depreciation of the
related equipment was $857 and $602, respectively. The Company leases three main
facilities in the U.S. under operating leases expiring in 2002, 2005, and 2007.
The Company leases an office and manufacturing facility in Ireland under an
operating lease expiring in 2026. Rent expense was approximately $1,226, $732
and $751 for the years ended December 31, 1999, 1998, and 1997, respectively.
F-19
<PAGE> 59
Financing Arrangements
In November 1999, the Company issued a $3,000 secured promissory note.
The note bears interest at 10% per annum and requires a fixed monthly payment of
$97 over three years. The note is collateralized by certain laser equipment
leased to customers and payments due to the Company under these leases.
At December 31, 1999, future payments of the promissory note, capital
leases and minimum rental payments under noncancellable operating leases were as
follows:
<TABLE>
<CAPTION>
Capital Total
Promissory Lease Long-term Operating
Note Obligations Debt Leases
-------------- --------------- ------------- --------------
<S> <C> <C> <C> <C>
Year ending December 31:
2000 $1,258 $ 207 $ 1,465 $ 904
2001 1,162 104 1,266 1,006
2002 968 21 989 914
2003 - - - 720
2004 - - - 720
Thereafter - - - 1,883
-------------- --------------- ------------- --------------
Minimum future payments 3,388 332 3,720 $ 6,147
==============
Less amounts representing interest 495 36 531
-------------- --------------- -------------
Long-term debt 2,893 296 3,189
Less current maturities of long-term debt 1,020 183 1,203
============== =============== =============
Long-term debt, less current maturities $1,873 $113 $1,986
============== =============== =============
</TABLE>
12. Stockholders' Equity
Common and Preferred Stock
The Company has authorized 5,000,000 shares of preferred stock at $.01
par value and 100,000,000 shares of common stock at $.01 par value. The terms
and conditions of the preferred stock, including any preferences and dividends,
will not be established until such time, if ever, as such shares are issued by
the Company.
Stock Option Plans
In March 1987, the Company adopted a Stock Option Plan (the "1987
Plan") which permitted the Company to grant both incentive and non-incentive
stock options to employees. The 1987 Plan expired by its terms in March 1997 and
the Company adopted the 1997 Stock Option Plan (the "1997 Plan"). A total of
3,107,415 shares of common stock were authorized by the Board of Directors (the
"Board") for issuance under the 1987 Plan. In 1999, the 1997 Plan was amended to
increase the number of shares of common stock available to be issued under the
Plan from 1,500,000 shares to 3,000,000 shares. The 1997 Plan permits the
Company to grant stock options (incentive and non-incentive) and stock
appreciation rights to employees, members of the Board, consultants and
advisors. Options generally vest within 3 years of grant date and must be
exercised not later than 10 years from the date of grant.
The Company also has a Stock Option Plan for Outside Directors (the
"Directors' Plan") under which a total of 75,000 shares of common stock have
been authorized for issuance. Options granted under the Directors' Plan vest one
year from grant date and must be exercised not later than 10 years from the date
of grant.
F-20
<PAGE> 60
The following table summarizes activity under the 1987 Plan, 1997 Plan,
the Directors' Plan and options exchanged in connection with the acquisition of
Autonomous (see Note 3) (collectively, the "Plans") for each of the three years
in the period ended December 31, 1999:
<TABLE>
<CAPTION>
Number Weighted-average
of Shares Price per share
------------------- ---------------------
<S> <C> <C>
Options outstanding, January 1, 1997 1,021,916 $7.72
- ------------------------------------
Options granted 697,684 6.81
Options lapsed or canceled (195,355) 9.25
Options exercised (39,822) 5.39
-------------------
Options outstanding, December 31, 1997 1,484,423 7.16
- --------------------------------------
Options granted 627,918 3.95
Options lapsed or canceled (296,700) 8.88
Options exercised (6,850) 5.38
-------------------
Options outstanding, December 31, 1998 1,808,791 5.77
- --------------------------------------
Options granted 1,231,412 13.71
Options exchanged in connection
with acquisition 868,689 5.93
Options lapsed or canceled (87,588) 6.61
Options exercised (440,057) 5.77
-------------------
Options outstanding, December 31, 1999 3,381,247 $8.68
-------------------
</TABLE>
Options to purchase 1,396,796 shares, 780,524 shares and 622,879 shares
were exercisable under the Plans at December 31, 1999, 1998 and 1997, with a
weighted-average exercise price per share of $6.64, $6.88 and $7.92,
respectively. In 1997, options to purchase 225,000 shares, which were granted in
1989 under a separate executive stock option agreement, were exercised. In 1998,
options to purchase 100,000 shares were repriced through cancellation and
reissuance. The number of shares of common stock reserved for granting of future
options under the Plans was 873,283 shares, 321,225 shares and 829,635 shares at
December 31, 1999, 1998 and 1997, respectively. The weighted-average fair value
of options granted during 1999, 1998 and 1997 was $10.99, $2.66 and $3.94 per
option, respectively.
At December 31, 1999, warrants (see Note 3) to purchase 42,471 shares
of common stock with a weighted-average exercise price of $3.07 were
outstanding. In 1999, warrants to purchase 14,242 shares of common stock were
exercised.
The following table summarizes certain information relating to
outstanding and exercisable options under the Plans at December 31, 1999:
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
----------------------------------------------------------------- -----------------------------
Weighted- Weighted- Weighted-
Average Average Average
Ranges of Number Remaining Exercise Number Exercise
Exercise Prices of shares Contractual Life Price of shares Price
--------------- --------- ---------------- --------- --------- ---------
<S> <C> <C> <C> <C> <C>
$3.50 to $5.44 1,125,522 7.7 $ 4.51 639,226 $ 4.85
5.50 to 8.71 1,138,081 7.8 6.04 602,953 6.01
10.50 to 15.75 896,370 9.1 14.85 91,343 14.16
16.19 to 25.31 221,274 8.7 18.49 63,274 19.96
</TABLE>
F-21
<PAGE> 61
The fair value of options at date of grant was estimated using the
Black-Scholes model with the following weighted-average assumptions:
<TABLE>
<CAPTION>
1999 1998 1997
---- ---- ----
<S> <C> <C> <C>
Expected life 4 years 4 years 4 years
Interest rate 5.91% 5.02% 6.19%
Volatility 91.3% 77.6% 70.5%
Dividend yield 0% 0% 0%
</TABLE>
If the Company had recorded compensation expense for the 1987 Plan,
1997 Plan, the Directors' Plan and the Employee Stock Purchase Plan under the
provisions of SFAS No. 123, net income (loss) would have decreased (increased)
by ($4.9) million, $1.4 million and $1.2 million in 1999, 1998 and 1997,
respectively, or ($.12), $.05 and $.04 per basic and diluted share,
respectively. The fair values of the options granted are assumed to have been
recognized as compensation expense on a straight-line basis over the vesting
period of the grant.
Employee Stock Purchase Plan
In May 1991, the Company adopted an Employee Stock Purchase Plan (the
"Purchase Plan"). The Purchase Plan is available to all eligible full-time
employees, excluding those owning 5% or more of the Company's common stock.
Pursuant to the Purchase Plan, employees can purchase the Company's common
stock, at 85% of fair market value, in an amount up to 5% of the employee's
wages during the semi-annual plan purchase period. Under the Purchase Plan, the
Company sold 2,291 shares and 907 shares in 1998 and 1997, respectively. There
were no purchases under the Purchase Plan in 1999.
Shareholder Rights Plan
In March 1990, the Board adopted a Shareholder Rights Plan ("Rights
Plan") pursuant to which each stockholder of the Company holds one currently
non-exercisable right ("Right") for each share of common stock beneficially
held. The Rights become exercisable upon the occurrence of a "Distribution
Date," whereupon the holder is entitled to purchase from the Company one-quarter
of a share of common stock at the exercise price of $12.50, subject to
adjustment. Generally, a Distribution Date occurs if (a) a person or group
becomes a beneficial owner of 15% or more of the Company's outstanding shares of
common stock without the prior approval of the Board ("Acquiring Person"), or
(b) ten business days lapse following the commencement of, or announcement of an
intention to make, a tender or exchange offer for the common stock not approved
by the Board, which, if consummated, would result in a person or group becoming
a beneficial owner of 15% or more of the Company's outstanding shares of common
stock.
If a person or group becomes an Acquiring Person, a "Flip-In Event"
thereby occurs concurrently with the Distribution Date, with the effect that
each Right (other than those owned by such Acquiring Person) will entitle its
holder to obtain common stock having a market value of eight times the Right's
exercise price for a purchase price equal to four times the exercise price of
the Rights, in effect allowing a Rights holder to purchase a fixed amount of the
Company's common stock at a discount of 50% off the market price. If a person or
group becomes an Acquiring Person (hence triggering a Flip-In Event), and
thereafter the Company is involved in a merger or other business combination
with the Acquiring Person where the Company is not the surviving entity and the
holders of the Company's common stock are not the holders of all of the
surviving entity's common stock, or the sale of 50% or more of the Company's
assets and earning power to the Acquiring Person occurs (a "Flip-Over Event"),
each Right (other than those owned by the Acquiring Person) will then entitle
the holder to obtain eight times the Right's exercise price for a purchase price
equal to four times the exercise price of the Rights.
F-22
<PAGE> 62
13. Commitments and Contingencies
Commitments
During 1991, the Irish Development Authority ("IDA") agreed to
reimburse the Company up to approximately $740 for rent, training and fixed
asset acquisition costs incurred in conjunction with the opening of its
manufacturing facility in Cork, Ireland. The Company may be required to repay
the grants if the facility is closed within eight years of the final grant
drawdown. As of December 31, 1999, the Company has received approximately $662
from the IDA under these agreements.
In February 1992, the Company entered into a licensing agreement which
granted the Company use of a patent covering excimer laser ablation of tissue
under which the Company pays a royalty of 2% of the net selling price of its
Excimer Systems sold or leased in the U.S. and certain other countries. The
Company also licenses certain laser patents under which it pays royalties of up
to 6% of the net selling price. The Company also pays royalties based upon the
net selling price of its microkeratomes. Royalty expense related to laser system
and microkeratome sales were $927, $153 and $37 in 1999, 1998 and 1997,
respectively.
Contingencies
The Company is a party to various litigation matters as described
below. The Company has denied, or will deny, the substantive allegations in each
of these actions, and intends to defend them vigorously. The Company may be
served with additional complaints of a similar nature in the future. The Company
may not prevail in the pending or any possible additional actions, and the
resolutions of the actions, individually or in the aggregate, may have a
material adverse effect on the Company's financial position, results of
operations, or cash flows. The Company has not made any provision for any loss
that may result upon resolution of these matters in the accompanying
consolidated financial statements. Dollar amounts below are in thousands.
Antitrust Litigation
The Company, VISX, and certain of their affiliates (including Pillar
Point Partners, a partnership between affiliates of the Company and VISX) are
involved in a number of antitrust lawsuits which, among other things, allege
price-fixing in connection with per-procedure patent royalties charged by the
Company and VISX. These suits are pending in both federal and state court, on
behalf of both direct purchasers from the Company and VISX and
patients/consumers, and include both purported class actions and individual
actions. Most of the federal lawsuits have been transferred for pretrial
purposes to the U.S. District Court for the District of Arizona by the Judicial
Panel on Multidistrict Litigation as In re: Pillar Point Partners Antitrust and
Patent Litigation.
Federal Antitrust Litigation
Cases Consolidated for Pre-Trial Proceedings
- ---------------------------------------------
In April 1998, The Eye Professionals, P.A. commenced an action in the
U.S. District Court for the District of New Jersey against the Company and
VISX. The case purported to be a class action on behalf of all individuals or
entities that have paid a per-procedure fee directly to either defendant for
use of a Summit or VISX laser to perform laser vision correction surgery at
any time after November 1, 1995. The complaint alleged, inter alia,
price-fixing in violation of Section 1 of the Sherman Act. The action sought
treble damages, costs of suit, attorneys' fees, and various forms of
declaratory and injunctive relief. Similar actions were also filed in May 1998
by Metropolitan Eye Center and Outpatient Surgical Facility, Inc. in the U.S.
District Court for the Northern District of California against the Company,
VISX, Summit Partner and VISX Partner and by New England Laser Vision, Inc. in
the U.S. District Court for the District of New Jersey against the Company and
VISX. In August 1998, David R. Shapiro, M.D., filed another similar purported
class action against the Company and VISX in the U.S. District Court for the
District of Arizona. Plaintiffs in these cases have agreed to consolidation of
F-23
<PAGE> 63
the four purported class actions and filed a single consolidated amended
complaint in the U.S. District Court for the District of Arizona. It purports to
be a class action on behalf of all persons and entities (excluding governmental
entities, defendants subsidiaries and affiliates of defendants) in the United
States who paid a per-procedure royalty to any defendant or any alleged
co-conspirator or any subsidiary or affiliate thereof, at any time after
September 1995. The Consolidated Amended Class Action Complaint seeks, among
other things, unspecified treble damages on behalf of plaintiffs and the alleged
class, along with attorneys' fees, costs, and injunctive and declaratory relief.
In September 1998, Laser Eye Center of Texas, L.L.P. and Warren D.
Cross, M.D., filed a purported class action against the Company, Summit Partner,
VISX, VISX Partner and Pillar Point Partners in the U.S. District Court for the
Southern District of Texas. The suit purports to be a class action on behalf of
all persons and entities who have paid money to defendants, or any of their
subsidiaries, on a per-procedure basis for the ability to use defendants' laser
equipment or technology to perform laser vision correction surgery. Plaintiffs
allege, among other things, price-fixing and monopolization in violation of
Sections 1 and 2 of the Sherman Act. They seek, among other things, treble
damages on behalf of the alleged class, costs of suit, including attorneys'
fees, and declaratory and injunctive relief. This case was transferred to the
District of Arizona for consolidated pre-trial proceedings.
In February 1999, Carolina Eye Associates, P.A. and Carolina-South Eye
Associates filed suit against VISX and the Company in the U.S. District Court
for the District of New Jersey. This action, like the consolidated federal
actions described above, purports to be a class action on behalf of all persons
and entities (excluding governmental entities, defendants, subsidiaries and
affiliates of defendants) in the United States who paid a per-procedure royalty
to any defendant or any alleged co-conspirator or any subsidiary or affiliate
thereof, at any time after September 1995. The complaint alleges, among other
things, price-fixing in violation of Section 1 of the Sherman Act and seeks,
among other things, compensatory damages of at least $100,000 plus $8,300 per
month from the filing of the complaint until the date of judgment, trebling of
those damages, attorneys' fees, costs, and declaratory and injunctive relief.
This case was transferred to the District of Arizona for consolidated pre-trial
proceedings.
Plaintiffs in the various class actions described above have now moved
for certification of a class including all persons in the United States who paid
a per-use royalty to any defendant or any co-conspirator or any subsidiary or
affiliate thereof, at any time after September 1995.
In June 1996, a Texas ophthalmologist, Robert G. Burlingame, sued the
Company, Summit Partner, VISX, VISX Partner and Pillar Point Partners in U.S.
District Court for the Northern District of California alleging price-fixing in
violation of Section 1 of the Sherman Act and state antitrust laws and fraud and
deceit in connection with certain of the Company's sales and marketing
activities. The plaintiff seeks, among other things, compensatory damages of at
least $30 plus $2 to $3 per month until the date of judgment, trebling of those
damages, compensatory and punitive damages on the fraud claim against the
Company of at least $500 plus $2 to $3 per month until the date of judgment,
attorneys' fees, costs and declaratory and injunctive relief. This case was
transferred to the District of Arizona for consolidated pre-trial proceedings.
In September 1996, a Nevada ophthalmologist, John R. Shepherd, through
his professional corporation, commenced a similar lawsuit against the same
parties, in the same court, alleging substantially similar antitrust claims and
seeking substantially similar relief, including damages before trebling of at
least $125 plus $13 per month until the date of judgment. This case was
transferred to the District of Arizona for consolidated pre-trial proceedings.
In May 1999, Freedom Vision Laser Center, L.P. filed suit in the United
States District Court for the Central District of California against the
Company, Autonomous, Summit Partner, VISX, VISX Partner and Pillar Point
Partners. The complaint alleges, among other things, price-fixing,
monopolization, attempted monopolization, and conspiracy to monopolize, in
violation of Sections 1 and 2 of the Sherman Act, as well as
F-24
<PAGE> 64
violations of the California Business and Professions Code. Plaintiff seeks,
among other things, damages that are alleged to be more than $1,000 before
trebling, disgorgement of alleged illegal and ill-gotten gains, declaratory and
injunctive relief, and attorneys' fees and costs. This case has been transferred
to the District of Arizona for consolidated pre-trial proceedings.
Cases Not Consolidated for Pre-Trial Proceedings
- -------------------------------------------------
In April 1999, Antoine L. Garabet, M.D., Inc. and Abraham V. Shammas,
M.D., Inc., d/b/a The Laser Eye Center, filed suit in the U.S. District Court
for the Central District of California against the Company and Autonomous. The
suit alleges, among other things, that the Company's acquisition of Autonomous
may substantially lessen competition or tend to create a monopoly in violation
of Section 7 of the Clayton Act, Section 1 of the Sherman Act, and the
California Business and Professions Code. The complaint seeks, among other
things, unspecified compensatory damages, trebling of those damages, declaratory
and injunctive relief, divestiture in the event that the acquisition of
Autonomous is consummated, restitutionary relief, including disgorgement of
alleged unlawful profits and the imposition of a constructive trust over alleged
ill-gotten gains, and attorneys' fees and costs. Plaintiffs also threatened to
seek a temporary restraining order, preliminary injunction, and other
unspecified preliminary injunctive relief directed at the acquisition. The
Company filed a counterclaim for copyright infringement and unfair competition
against the plaintiffs and Antoine L. Garabet, M.D. and Abraham V. Shammas,
M.D., individually. The parties have agreed to a dismissal of this counterclaim,
without prejudice.
Counterclaims
The Company is the subject of additional Federal antitrust litigation
as a result of counterclaims to patent litigation initiated by Pillar Point
Partners and the Company. A discussion of those counterclaims is presented below
under "Patent Litigation."
State Antitrust Litigation
Beginning in March 1998, a number of actions brought by individuals
under the Cartwright Act and the California Business and Professions Code were
commenced against the Company, Summit Partner, VISX and VISX Partner in Superior
Court of Santa Clara County. In May 1998, these actions were consolidated as In
re PRK/LASIK Consumer Litigation. In June 1998, plaintiffs B.J. Snyder, Donna
McMahan, Paula Mobsby, Helen Thomas, Carmen Ocariz, Martin Hermans, Ken
Bartlett, Jackie Kirk, Grace Geniusz, Jocelyn Joseph, Andrew Stoddard, and
Cynthia Brubecker filed an Amended Consolidated Master Complaint for Damages
("Amended Complaint") in this matter against the Company, Summit Partner, VISX,
and VISX Partner. The Amended Complaint purports to be filed on behalf of all
natural persons in the United States who underwent excimer laser surgery with a
laser manufactured by the Company or VISX during the period beginning October
1995, and paid a per-procedure fee indirectly to a defendant, excluding
defendants, any unnamed co-conspirators of defendants, defendants' predecessors,
successors, parents, subsidiaries, affiliates, officers and directors,
governmental entities, and any and all judges and justices assigned to hear any
aspect of the litigation. The Amended Complaint seeks unspecified compensatory
damages, restitution and/or disgorgement of alleged ill-gotten gains,
prejudgment and postjudgment interest, costs of suit, and attorneys' fees, as
well as various forms of declaratory and injunctive relief, including an order
permitting any person or entity with which the Company or VISX or both have
entered into any agreement since June 3, 1992, for the purchase, license, or use
of any of the Pillar Point Patents to withdraw from such agreement without
penalty or obligation. James Ballard filed a similar suit against the Company,
Summit Partner, VISX, VISX Partner, Pillar Point Partners, and other individual
defendants in Superior Court of San Diego County. This suit has been transferred
to Santa Clara County and consolidated as part of In re PRK/LASIK Consumer
Litigation. The parties have stipulated to the conditional certification of a
class of natural persons in California, Alabama, Arizona, the District of
Columbia, Florida, Kansas, Maine, Michigan, Minnesota, Mississippi, New Mexico,
New York, North Carolina, North Dakota, South Dakota, Tennessee, West Virginia,
and Wisconsin
F-25
<PAGE> 65
who have undergone ophthalmic refractive surgery with an excimer laser
manufactured by the Company or VISX.
In April 1998, Penny S. Marks, an individual who allegedly has had
laser vision correction surgery performed, commenced an action in Florida state
court against the Company and VISX. The case purports to be a class action on
behalf of all persons who have had a PRK procedure in the State of Florida from
October 20, 1995 up to and including the date the class certification hearing
begins. The complaint alleges various violations of the Florida Deceptive and
Unfair Trade Practices Act, the Florida Antitrust Act and Section 5 of the
Federal Trade Commission Act. The complaint seeks unspecified compensatory
damages, costs and attorneys' fees, as well as declaratory and injunctive
relief. Plaintiff filed a motion seeking class certification. Thereafter, the
parties filed a joint motion to stay this action pending resolution of In re
PRK/LASIK Consumer Litigation, the consolidated class action litigation
described immediately above. The court has granted this motion to stay.
In June 1998, Barbara Worcester, an individual who allegedly has had
laser vision correction surgery performed, filed an action in Wisconsin state
court against the Company, Summit Partner, VISX, VISX Partner and Pillar Point
Partners. The case purports to be a class action on behalf of all Wisconsin
purchasers of refractive laser surgery procedures. The complaint alleges
violations of the antitrust laws of the State of Wisconsin. The complaint seeks
unspecified damages, trebling of those damages, attorneys' fees and costs, and
declaratory and injunctive relief. Defendants removed this action to federal
court, and it has been transferred to the District of Arizona. Plaintiff has
filed a motion seeking class certification.
In January 1999, Karen Frankson, Virginia Harmes, and Beth
Luetschwager, three individuals who allegedly have had laser vision correction
surgery performed, filed a similar purported class action in Wisconsin state
court. Defendants removed this action to federal district court in Wisconsin,
and it was transferred to the District of Arizona. The parties recently agreed
to a dismissal of this action, without prejudice.
In May 1999, Linda Brisson, an individual who allegedly has had laser
vision correction surgery performed, commenced an action in Minnesota state
court against the Company, Summit Partner, VISX, VISX Partner and Pillar Point
Partners. The case purports to be a class action on behalf of all Minnesota
purchasers of refractive laser surgery procedures. The complaint alleges, among
other things, price-fixing in violation of Minnesota antitrust law. The
complaint seeks, among other things, compensatory damages alleged to be at least
in the millions of dollars, trebling of those damages, attorneys' fees and
costs, and injunctive and other relief.
In January 2000, Antoine L. Garabet, M.D. and Abraham V. Shammas, M.D.
filed an action individually and on behalf of the general public against the
Company and VISX in Superior Court of the State of California, Santa Clara
County. The suit alleges violations of the California Unfair Business
Practices Act in connection with, among other things, per procedure fees
charged by the Company and VISX. The action seeks, among other things,
disgorgement of alleged ill-gotten gains and monies that defendants have
earned by means of alleged unlawful, unfair, and fraudulent business practices
(with defendants' per procedure revenues elsewhere alleged to be in the
millions of dollars annually), a constructive trust over such gains and
monies, declaratory and injunctive relief, and attorneys' fees and costs.
Shareholder Litigation
Between August 1996 and February 1997 various shareholder actions were
commenced against the Company and certain of its present or former officers in
the U.S. District Court for the District of Massachusetts claiming, among other
things, violations of Sections 10(b) and 20(a) of the Securities Exchange Act of
1934 arising out of public statements made by defendants and violations of
Section 20A of the Securities Exchange Act of 1934 arising out of alleged
insider trading by certain defendants. The actions were consolidated, by order
of the Court entered December 2, 1996, as In re Summit Technology Securities
Litigation. By order dated August 11, 1998, the Court certified the action as a
class action on behalf of all purchasers of Summit common stock, other
F-26
<PAGE> 66
than defendants and certain affiliated persons and entities, between March 31,
1995 and July 3, 1996. Plaintiffs seek unspecified damages, interest, costs and
expenses, attorneys' fees and extraordinary and/or injunctive relief. Discovery
was completed in February 2000. On March 14, 2000 defendants filed a motion for
summary judgment on certain claims. Additional motions for summary judgment may
be filed as well.
In October 1996, an additional class action was commenced in the U.S.
District Court for the District of Massachusetts against the Company, its
directors, certain of the Company's present or former officers and the four
underwriters of the Company's October 1995 common stock offering claiming
violations of Sections 11, 12(2) and 15 of the Securities Act of 1933 arising
out of alleged material misstatements of fact in the Registration Statement
issued in connection with the offering. By order dated August 11, 1998, the
Court certified the action as a class action on behalf of all purchasers of
Summit stock in the offering other than defendants and certain affiliates. The
action was coordinated with the securities litigation by order of the court
dated December 2, 1996. The action seeks unspecified compensatory damages,
interest, costs and expenses, attorneys' fees and extraordinary and/or
injunctive relief. Cross motions for summary judgment were filed in November
1999 and February 2000 with respect to certain claims. Additional motions for
summary judgment may be filed as well.
In December 1996, one of the Company's shareholders filed in the U.S.
District Court for the District of Massachusetts a derivative action,
purportedly on behalf of the Company, against the Company as nominal defendant,
directors of the Company and certain present or former officers of the Company.
This action was consolidated with the securities litigation by order of the
Court entered July 22, 1997. The complaint alleges that the conduct of the
individual defendants has exposed the Company to the liability, expense and
inconvenience of the securities litigation and has harmed the Company's
reputation, thereby limiting its access to capital markets. It also alleges
breach of fiduciary duty, gross negligence and insider trading against
individual defendants. It seeks damages, interest, costs and expenses and
attorneys' fees.
Patent Litigation
Pillar Point Partners, Summit Partner and VISX Partner commenced patent
infringement litigation against an ophthalmologist believed to have used or be
using homemade laser systems not licensed under patents held by Pillar Point
Partners and one alleged manufacturer of such laser systems. These actions were
originally pending as Pillar Point Partners, et al. v. Jon G. Dishler, et al.
(U.S. District Court, District of Colorado) and Pillar Point Partners, et al. v.
Jui-Teng Lin, et al. (U.S. District Court, Middle District of Florida). Each
action was transferred to the District of Arizona. The defendants in the Dishler
action have asserted counterclaims against Summit Partner, VISX Partner, and
Pillar Point Partners seeking declarations that the patents in suit are invalid
and unenforceable. They have also raised antitrust counterclaims alleging
price-fixing, tying, monopolization, concerted refusal to deal, conspiracy to
monopolize, and attempted monopolization. Defendants seek unspecified actual
damages, trebling of those damages, attorneys' fees, costs and injunctive
relief. The parties have agreed to a resolution of the Jui-Teng Lin litigation.
In December 1998, the Company filed a patent infringement lawsuit in
the U.S. District Court for the District of Massachusetts against Nidek, whose
laser system received FDA approval in December, 1998. The suit alleges that
Nidek's excimer laser system infringes certain of the Company's U.S. patents and
seeks damages and injunctive relief. On January 29, 1999, a district court in
Tokyo, Japan ruled against the Company in a patent infringement lawsuit which
the Company initiated against Nidek in 1996. The Japanese lawsuit involved the
Japanese counterpart of one of the two U.S. patents which the Company has
alleged Nidek infringes in the U.S. lawsuit. The Tokyo district court's
decision was upheld on appeal.
In June 1999, the Company commenced a patent infringement lawsuit
against George I. Bekov in the U.S. District Court for the District of
Massachusetts. The suit alleges that Bekov has induced infringement of certain
of the Company's patents, including by disabling card readers and maintaining
systems which are not licensed by the Company, and
F-27
<PAGE> 67
seeks damages and injunctive relief. This case has been transferred to the
District of Arizona for consolidated pre-trial proceedings.
In February 1999, the Company asserted patent infringement claims
against Antoine L. Garabet, M.D., Antoine L. Garabet, M.D., Inc., Abraham V.
Shammas, M.D., Abraham V. Shammas, M.D., Inc., and the Laser Eye Center in a
case then pending in the District of Arizona. The suit alleges that these
parties have infringed certain of the Company's patents by using excimer laser
systems manufactured by the Company without having a license to do so, and seeks
damages and injunctive relief. In June 1999, the Company commenced a similar
patent infringement lawsuit against Robert T. Lin, Ferzaad Moosa, and Randa M.R.
Garrana in the U.S. District Court for the Central District of California. This
case has been transferred to the District of Arizona, and the parties have
stipulated to consolidation of these two cases. In November 1999, the parties
opposing the Company in these two actions filed a counterclaim against the
Company for declaratory relief and for fraud and deceit. The counterclaim seeks,
among other things, judgment that the patents in suit are not infringed and, in
any event, not enforceable as a result of the Company's alleged inequitable
conduct, unclean hands, and patent misuse; judgment enjoining the Company from
attempting to enforce the Pillar Point patents, including the patents in suit;
attorneys' fees and costs; judgment that the Company has committed fraud and
deceit in connection with the sale of a Summit laser system; compensatory
damages on the fraud claim of at least $49, plus prejudgment interest; and
punitive damages.
In October 1999, the Company commenced a patent infringement lawsuit
against Icon Laser Centers (U.S.), Inc. in the U.S. District Court for the
District of Delaware. The suit alleges that the defendant has infringed and/or
contributed to and/or induced infringement of certain of the Company's patents
by using the Nidek EC-5000 Excimer Laser System without having a license to do
so, and seeks damages and injunctive relief.
Other Litigation
In October 1992, Joseph Seriani brought suit against Lens Express and
certain of its former shareholders in the Florida Circuit Court. The suit
alleged violations of the Florida Civil Remedies for Criminal Practices Act --
the Florida civil RICO statute -- based on events which allegedly occurred in
the mid-1980s. Seriani's claims against Lens Express were dismissed several
times for failure to state a viable claim, but in each instance with leave to
amend and refile. On May 15, 1996, the date of the Company's acquisition of Lens
Express, Seriani and his wife Rhonda Seriani filed an amended complaint which
included the Company as an additional defendant. On November 25, 1996, the
Serianis voluntarily dismissed their action against the Company and on March 7,
1997 voluntarily dismissed their action against the remaining defendants, in
each case without prejudice. On March 24, 1997, the Serianis commenced a new
lawsuit against Lens Express and others in the U.S. District Court for the
Southern District of Illinois, alleging substantially similar claims. On October
7, 1999, the Court issued an Order to Show Cause why the case should not be
dismissed for lack of prosecution and, on November 23, 1999 the Court issued an
order dismissing the case with prejudice. By order dated January 7, 2000, the
Court denied the Serianis' motion to vacate its order of dismissal.
14. Income Taxes
The domestic and foreign components of income (loss) from continuing
operations before provision for income taxes are as follows:
<TABLE>
<CAPTION>
December 31,
---------------------------
1999 1998 1997
------- ------- -------
<S> <C> <C> <C>
Domestic $(23,979) $39,245 $ 1,475
Foreign 1,329 2,506 (510)
------- ------ -------
$(22,650) $41,751 $ 965
======= ======= =======
</TABLE>
F-28
<PAGE> 68
The provision for income taxes is summarized as follows:
<TABLE>
<CAPTION>
December 31,
-----------------------------
1999 1998 1997
--------- -------- --------
<S> <C> <C> <C>
Current:
Federal $ - $ 789 $ (60)
State 300 1,314 195
Foreign 75 105 2
-------- ------- -------
375 2,208 137
-------- ------- -------
Deferred:
Federal (4,849) 14,293 (4,873)
State (693) (470) (510)
Tax benefit of stock
options - 2,817 -
-------- ------- -------
(5,542) 16,640 (5,383)
-------- ------- -------
Change in valuation allowance 5,542 (13,827) 5,383
-------- ------- -------
Total $ 375 $ 5,021 $ 137
======== ======= =======
</TABLE>
The appropriate tax effect of each type of temporary difference and
carryforward that gives rise to the deferred tax assets and liabilities are as
follows:
<TABLE>
<CAPTION>
December 31,
-------------------
1999 1998
-------- --------
<S> <C> <C>
Deferred tax asset:
Net operating loss $ 19,586 $ 1,552
Deferred revenue 3,169 3,155
Unrealized loss on marketable securities - 3,764
Research and development credit 684 684
Alternative minimum tax credit 789 789
Inventory reserves 4,031 1,205
Other temporary differences 2,030 1,023
-------- --------
Subtotal 30,289 12,172
Less valuation allowance (16,793) (11,251)
-------- --------
13,496 921
Deferred tax liability:
Patent costs 427 427
Depreciation 1,219 494
Unrealized gain on marketable securities 4,786 -
Purchased intangible assets 11,850 -
-------- --------
18,282 921
-------- --------
Net deferred tax liability $ 4,786 $ -
======== ========
</TABLE>
F-29
<PAGE> 69
Due to the uncertainty of the Company generating future taxable income,
the Company has recorded a valuation allowance against its deferred tax assets.
The increase in the valuation allowance in 1999 of $5,542 was primarily due to
deferred taxes established in connection with the Autonomous acquisition, offset
by the tax effect of the unrealized gain on marketable securities. At December
31, 1999, the valuation allowance included $5,746 of tax benefits which will
result in a reduction of goodwill when they are realized. The decrease in the
valuation allowance in 1998 of $13,827 was primarily due to utilization of net
operating loss carryforwards. The provision for income taxes differs from the
amount computed by applying the federal income tax rate of 35% as a result of
the following:
<TABLE>
<CAPTION>
December 31,
--------------------------------------
1999 1998 1997
--------------------------------------
<S> <C> <C> <C>
Expected expense (benefit)
at federal income tax rate (7,928) $ 14,613 $ 338
Non-deductible expenses 7,528 -- --
Foreign, state, and other taxes, net of
federal benefit 109 920 53
Change in valuation allowance for deferred
tax assets allocated to income tax expense 691 (11,010) (490)
Other (25) 498 236
-------- -------- --------
Provision for income tax $ 375 $ 5,021 $ 137
======== ======== ========
</TABLE>
At December 31, 1999, the Company had an operating loss carryforward of
$55,960, of which $50,230 was acquired from Autonomous, and tax credit
carryforwards of $1,473 available to offset future federal taxable income. Use
of the net operating loss acquired from Autonomous is limited to approximately
$11,000 per year. The tax benefit of the net operating loss and tax credit
carryforwards related to stock options of $4,441 will be credited to additional
paid-in capital when realized. The operating loss carryforward will expire in
varying amounts principally between 2011 and 2019. Research and experimentation
credit carryforwards of approximately $684 expire in the years 2001 through 2008
and the alternative minimum tax credit of $789 does not expire.
There are no unremitted earnings in the Company's foreign subsidiaries.
The Massachusetts Department of Revenue is currently in the process of
an income tax examination of the members of the combined group that file in
Massachusetts for the years 1995 and 1996. The Company has no other income tax
examinations pending.
15. Retirement Plans
The Company sponsors defined contribution retirement plans (the
"retirement plans"). Employees may contribute various percentages of their
salary subject to contribution limits defined by the Internal Revenue Code. The
Company may, at its discretion, match in cash or common stock the employee's
contributions. For the years ended December 31, 1999, 1998 and 1997, the Company
contributed cash and/or common stock valued at $227, $172 and $63, respectively,
representing its matching contribution to the retirement plans.
16. Supplemental Cash Flow Information
For the year ended December 31, 1999, non-cash transactions included
items related to the acquisition of Autonomous (see Note 3), $7,288 of net
transfers from inventory to property, plant and equipment related to laser
equipment leased to customers under operating leases, $52 for stock based
compensation and $24 for the issuance of treasury stock. For the year ended
December 31, 1998, non-cash transactions included $321 for capital lease
obligations incurred, $642 of net transfers from property, plant and equipment
to inventory related to laser equipment leased to customers under operating
leases, $1,183 for treasury stock distributed to former Lens owners as an
adjustment of the exchange ratio in the Lens
F-30
<PAGE> 70
acquisition and related distribution of LCA common stock for $168 to former Lens
owners. For the year ended December 31, 1997, other non-cash transactions
include $1,599 of net transfers from inventory to property, plant and equipment
related to laser equipment leased to customers under operating leases , proceeds
of 16.2 million shares of LCA common stock valued at $43,644 from the sale of
discontinued operations and dividend distribution of 9.0 million shares of LCA
common stock valued at $23,625 on declaration date.
17. Investment Securities
The fair value of short and long-term investment securities at December 31,
1999 and 1998 were as follows:
<TABLE>
<CAPTION>
1999 1998
------------------- --------------------
<S> <C> <C>
Corporate bonds $ 2,476 $ 42,528
Mortgage-backed securities 502 3,954
Other debt securities 2,752 1,412
U.S. Government securities - 889
------------------- --------------------
Total debt securities 5,730 48,783
LCA common stock 30,948 9,765
------------------- --------------------
$ 36,678 $ 58,548
=================== ====================
</TABLE>
At December 31, 1999 and 1998, the cost of LCA common stock was $17,826 and
$19,176, respectively, and the related unrealized gain (loss), net of tax, of
$8,336 and ($9,411), respectively, was included in accumulated other
comprehensive income (loss). The cost of debt securities approximates fair value
at December 31, 1999 and 1998. The fair value of debt securities and LCA common
stock are estimated based on quoted market prices.
Gross realized gains included in other income in 1999, 1998 and 1997 were
$2,330, $22 and $185, respectively, and gross realized losses included in other
income in 1999, 1998 and 1997 were $124, $1 and $721, respectively.
Contractual maturities of debt securities at fair value at December 31, 1999 and
1998 were as follows:
<TABLE>
<CAPTION>
1999 1998
------- -------
<S> <C> <C>
Due within one year $ 2,928 $33,295
Due after one year within five years 2,802 14,838
Due after ten years -- 650
------- -------
Total debt securities $ 5,730 $48,783
======= =======
</TABLE>
F-31
<PAGE> 71
18. Business Segments
The Company is internally organized and operates in two operating
segments: laser vision correction and contact lens and related products. The
Company's laser vision correction business consists of manufacturing, selling
and servicing laser systems and related products to correct vision disorders and
collecting per procedure license fees from users of its systems. The Company's
mail order contact lens business operates under its wholly-owned subsidiary,
Lens, which is primarily a retailer and wholesaler of contact lens and related
products.
The category "Other" includes the Company's investments, deferred taxes,
interest income, interest expense and other non-operating income (expense).
<TABLE>
<CAPTION>
Contact lens
Laser vision and related
Correction products Other Total
------------ ------------- --------- ---------
<S> <C> <C> <C> <C>
1999
Revenues $ 64,213 $ 46,886 $ -- $ 111,099
Income (loss) from continuing operations
before provision for income taxes (33,664) 5,762 5,252 (22,650)
Total assets 161,194 8,748 100,725 270,667
1998
Revenues 44,887 46,754 -- 91,641
Income from continuing operations
before provision for income taxes 29,950 6,317 5,484 41,751
Total assets 47,744 10,048 87,133 144,925
1997
Revenues 33,075 46,575 -- 79,650
Income (loss) from continuing operations
before provision for income taxes (2,708) 2,015 1,658 965
Total assets 37,024 8,975 69,104 115,103
</TABLE>
For the following geographic area data, revenues are attributed to
geographic regions based on the location of the customer and property and
equipment (net) are attributed to its physical location.
<TABLE>
<CAPTION>
Year Ended December 31,
------------------------------------
1999 1998 1997
-------- -------- --------
<S> <C> <C> <C>
Revenues
United States $101,295 $ 81,909 $ 70,931
Other foreign countries 9,804 9,732 8,719
-------- -------- --------
Total revenues $111,099 $ 91,641 $ 79,650
======== ======== ========
</TABLE>
<TABLE>
<CAPTION>
December 31,
--------------------
1999 1998
------- -------
<S> <C> <C>
Property and equipment (net)
United States $19,109 $ 7,768
Ireland 1,286 1,034
Other 556 --
------- -------
Total property and equipment (net) $20,951 $ 8,802
======= =======
</TABLE>
F-32
<PAGE> 72
19. Selected Quarterly Financial Data (Unaudited)
<TABLE>
<CAPTION>
Quarter
----------------------------------------------------
First Second Third Fourth
----------------------------------------------------
<S> <C> <C> <C> <C>
1999
Revenues $ 25,684 $ 27,401 $ 28,110 $ 29,904
Gross profit 12,306 9,885 12,043 13,603
Net income (loss) 2,386 (23,935) (605) (871)
Basic and diluted earnings per share:
Net income (loss) $ 0.08 $ (0.61) $ (0.01) $ (0.02)
</TABLE>
<TABLE>
<CAPTION>
Quarter
----------------------------------------------------
First Second Third Fourth
----------------------------------------------------
<S> <C> <C> <C> <C>
1998
Revenues $ 22,040 $ 24,100 $ 23,141 $ 22,360
Gross profit 8,732 9,945 10,147 10,497
Income from continuing operations 377 31,208 1,555 3,590
Gain on sale of discontinued operations -- -- -- 943
Income before cumulative effect of
accounting principle change 377 31,208 1,555 4,533
Cumulative effect of accounting
principle change (10,103) -- -- --
Net income (loss) (9,726) 31,208 1,555 4,533
Basic and diluted earnings per share:
Income from continuing operations $ 0.01 $ 1.00 $ 0.05 $ 0.12
Gain on sale of discontinued operations -- -- -- 0.03
Income before cumulative effect of
accounting principle change 0.01 1.00 0.05 0.15
Cumulative effect of accounting
principle change (0.32) -- -- --
Net income (loss) (0.31) 1.00 0.05 0.15
</TABLE>
F-33
<PAGE> 73
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
Summit Technology, Inc.:
Under date of March 6, 1998, we reported on the consolidated statements of
operations, stockholders' equity, and cash flows of Summit Technology, Inc. and
subsidiaries for the year ended December 31, 1997, as contained in the 1997
annual report to stockholders. In connection with our audit of the
aforementioned consolidated financial statements, we also audited financial
statement Schedule II. This financial statement schedule is the responsibility
of the Company's management. Our responsibility is to express an opinion on this
financial statement schedule based on our audit.
In our opinion, such financial statement schedule, when considered in relation
to the basic consolidated financial statements taken as a whole, presents
fairly, in all material respects, the information set forth therein.
/s/ KPMG LLP
KPMG LLP
Boston, Massachusetts
March 6, 1998
F-34
<PAGE> 74
Schedule II
-----------
SUMMIT TECHNOLOGY, INC. AND SUBSIDIARIES
Valuation and Qualifying Accounts
December 31, 1997, 1998 and 1999 (unaudited)
(in thousands)
<TABLE>
<CAPTION>
December 31, 1997 Balance at Beginning Additions/ Amounts Balance at End
of Period (Deductions) Written Off of Period
-------------------- ----------- ----------- --------------
<S> <C> <C> <C> <C>
Allowance for Doubtful Accounts $897 $245 $384 $ 758
</TABLE>
<TABLE>
<CAPTION>
December 31, 1998 Balance at Beginning Additions/ Amounts Balance at End
of Period (Deductions) Written Off of Period
-------------------- ----------- ----------- --------------
<S> <C> <C> <C> <C>
Allowance for Doubtful Accounts $758 $838 $197 $1,399
</TABLE>
<TABLE>
<CAPTION>
December 31, 1999 Balance at Beginning Additions/ Amounts Balance at End
of Period (Deductions) Written Off of Period
-------------------- ----------- ----------- --------------
<S> <C> <C> <C> <C>
Allowance for Doubtful Accounts $1,399 $13 $370 $1,042
</TABLE>
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Information concerning the change in the Company's certifying accountant is
set forth in the Company's Report on Form 8-K dated June 18, 1998 and is
incorporated herein by reference.
F-35
<PAGE> 75
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information concerning the directors and executive officers of the Company
is set forth under the "Election of Directors," "Directors and Executive
Officers," "Information Concerning the Board of Directors and Its Committees"
and "Section 16(a) Beneficial Ownership Reporting Compliance" in the Company's
Proxy Statement and is incorporated herein by reference.
ITEM 11. EXECUTIVE COMPENSATION
Information concerning executive compensation is set forth under "Executive
Compensation" in the Proxy Statement and is incorporated herein by reference,
except that the Report of the Compensation Committee and the Performance Graph
are not incorporated herein for any purpose.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Information concerning security ownership of certain beneficial owners and
management is set forth under "Ownership of Securities" in the Proxy Statement
and is incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Information concerning certain relationships and related transactions is
set forth under "Other Transactions and Relationships" in the Proxy Statement
and is incorporated herein by reference.
-40-
<PAGE> 76
PART IV
ITEM 14. FINANCIAL STATEMENTS, FINANCIAL STATEMENT SCHEDULES, EXHIBITS AND
REPORTS ON FORM 8-K
1. FINANCIAL STATEMENTS
The documents listed below are included in Item 8 of Part II of this Report.
Independent Auditors' Reports
Consolidated Balance Sheets as of December 31, 1999 and 1998
Consolidated Statements of Operations for the Years Ended December 31, 1999,
1998 and 1997
Consolidated Statements of Comprehensive Income (loss) for the Years Ended
December 31, 1999, 1998 and 1997
Consolidated Statements of Cash Flows for the Years Ended December 31, 1999,
1998 and 1997
Consolidated Statements of Changes in Stockholders' Equity for the Years Ended
December 31, 1999, 1998 and 1997
Notes to Consolidated Financial Statements
2. FINANCIAL STATEMENT SCHEDULES
Included in Item 8 of Part II of this report are the following:
Independent Auditors' Report regarding Schedule
Schedule II - Valuation and qualifying accounts
Other schedules are omitted because of the absence of conditions under
which they are required or because the required information is presented in the
financial statements or notes thereto.
3. EXHIBITS
The following Exhibits are either filed herewith or were filed as exhibits
to such other document filed with the Commission as is indicated:
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
- ------------- -----------
<S> <C>
2.1 Agreement and Plan of Merger dated April 19, 1996 among the
Company, Summit Acquisition Corporation, Lens Express, Inc.,
Mordechai Golan, Creslin Limited, Menderes Akdag and Huseyin
Kizanlikli, incorporated by reference to the Company's Form
8-K dated May 15, 1996
2.2 Agreement and Plan of Merger dated October 1, 1998 among the
Company, Alpine Acquisition Corp. and Autonomous Technologies
Corporation, filed with the Commission as Exhibit 2.1 to the
Report on Form 8-K filed with the Commission on October 7, 1998.
3.1 Articles of Organization, as amended, incorporated by
reference to the Company's Annual Report on Form 10-K for the
year ended December 31, 1992, as amended (the "1992 10-K")
</TABLE>
-41-
<PAGE> 77
<TABLE>
<S> <C>
3.3 By-Laws, as amended, incorporated by reference to Exhibit 3(b)
to the Company's Annual Report on Form 10-K for the year ended
December 31, 1989
3.4 Amendment to the Articles of Organization of Summit Technology,
Inc. dated April 29, 1999, filed with the Commission as
Exhibit 3.1 to the Report on Form 8-K filed with the
Commission on July 20, 1999
4 Rights Agreement, incorporated by reference to Exhibit 1 to
the Company's Report on Form 8-A filed with the Commission on
April 2, 1990
10.1 IBM License Agreement, incorporated by reference to Exhibit
10(b) to the Company's Annual Report on Form 10-K for the year
ended December 31, 1991 (the "1991 10-K")
10.2 Waltham Lease, incorporated by reference to Exhibit 10(c) to
the Company's Annual Report on Form 10-K for the year ended
December 31, 1990
10.3 Irish facility agreement, incorporated by reference to Exhibit
10(g) to the 1991 10-K
10.4 The Industrial Development Authority grant agreements,
incorporated by reference to Exhibit 10(h) to the 1991 10-K
10.5 Formation Agreement, Summit Transfer Agreement, Summit
Contribution Agreement, Partnership Agreement and License-Back
to Summit, each dated June 3, 1992 relating to the formation
of Pillar Point Partners, Incorporated by reference to Exhibit
10(a) to the Company's Current Report on Form 8-K filed with
the Commission on June 5, 1992
10.6 Patlex License, incorporated by reference to Exhibit 10.9 to
the 1993 S-1
10.7 1992 Stock Option Plan For Outside Directors, as amended,
incorporated by reference to the Company's Annual Report on
Form 10-K for the year ended December 31, 1995*
10.8 Settlement Agreement with Visx, Inc. dated June 4, 1998 filed
with the Commission as Exhibit 2.1 to the Report on Form 8-KA
filed with the Commission on January 14, 1999 (as to which
confidential treatment has been allowed by the Commission for
certain portions)
10.9 1999 Outside Directors' Compensation Plan, filed with the
Commission as Exhibit A to the Company's 1999 Proxy Statement
on Schedule 14A
10.10 1991 Employee Stock Purchase Plan, as amended through July 28,
1999
10.11 Letter from Summit to Mr. Robert J. Palmisano dated April 15,
1997 regarding terms of employment, filed with the Commission as
Exhibit 10.2 to the Report on Form 8-K filed with the Commission
on July 20, 1999
10.12 Letter from Summit to Mr. Randy Frey dated October 1, 1998
regarding terms of employment, filed with the Commission as
Exhibit 10.2 to the Report on Form 8-K filed with the Commission
on July 20, 1999
</TABLE>
-42-
<PAGE> 78
<TABLE>
<S> <C>
11 Statement Re: Computation of Per Share Earnings
22 Subsidiaries, incorporated by reference to Exhibit 22 to the
1992 10-K
23.1 Consent of Deloitte & Touche LLP, attached hereto
23.2 Consent of KPMG Peat Marwick LLP, attached hereto
27 Financial Data Schedule (For EDGAR Filing Purposes Only)
99 Report on Form 8-K filed with the Commission on June 18, 1998
regarding change in certifying accountant
</TABLE>
4. Reports on Form 8-K
None
*Management Compensation Plan
-43-
<PAGE> 79
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
SUMMIT TECHNOLOGY, INC.
Date: March 30, 2000 By: /s/ Robert J. Palmisano
-------------- -------------------------------
Robert J. Palmisano
Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1934, this report has
been signed below by the following persons on behalf of the registrant in the
capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
- --------- ----- ----
<S> <C> <C>
/s/ Robert J. Palmisano Director and
- -------------------------- Chief Executive Officer March 30, 2000
Robert J. Palmisano
/s/ Robert J. Kelly Executive Vice President,
- -------------------------- Chief Financial Officer and March 30, 2000
Robert J. Kelly Treasurer
/s/ Randy W. Frey
- -------------------------- Director and Executive March 30, 2000
Randy W. Frey Vice President
/s/ Jeffrey A. Bernfeld
- -------------------------- Director March 30, 2000
Jeffrey A. Bernfeld
/s/ C. Glen Bradley
- -------------------------- Director March 30, 2000
C. Glen Bradley
/s/ Richard F. Miller
- -------------------------- Director March 30, 2000
Richard F. Miller
/s/ John A. Norris
- -------------------------- Director March 30, 2000
John A. Norris
/s/ Richard M. Traskos Director and
- -------------------------- Chairman of the Board March 30, 2000
Richard M. Traskos
</TABLE>
-44-
<PAGE> 1
Exhibit 10.10
SUMMIT TECHNOLOGY, INC.
1991 EMPLOYEE STOCK PURCHASE PLAN
(as amended through July 28, 1999)
ARTICLE 1: PURPOSE.
The purpose of this 1991 Employee Stock Purchase Plan (the "Plan") is
to advance the interests of Summit Technology, Inc. (the "Company") by
encouraging and enabling the acquisition of a larger personal proprietary
interest in the Company by all eligible employees of the Company and of the
participating subsidiaries of the Company. The Plan is designed to encourage
eligible employees to remain in the employ of the Company and have a personal
interest in the success of the Company. The options issued pursuant to this Plan
are intended to constitute options issued pursuant to an "employee stock
purchase plan" as defined in Section 423(b) of the Internal Revenue Code of
1986, as amended (the "Code").
ARTICLE 2: ADMINISTRATION OF THE PLAN.
The Plan shall be administered by the Company's Compensation Committee.
Subject to the provisions of the Plan, the Compensation Committee shall have the
complete authority, in its discretion, to interpret the Plan, to ascribe, amend
and rescind rules and regulations relating to the Plan, and to make all of the
determinations necessary or advisable for the administration of the Plan.
The Compensation Committee shall consist of at least two members of the
Board, each of whom shall be a disinterested person as defined in Rule 16b-3
under the Securities Exchange Act of 1934, as such Rule may be hereafter
amended. The Compensation Committee shall be appointed by the Board, which may
at any time, and from time to time, remove any member of the Compensation
Committee, with or without cause, appoint additional members to the Compensation
Committee and fill vacancies, however caused, in the Compensation Committee. A
majority of the members of the Compensation Committee shall constitute a quorum.
All determinations of the Compensation Committee shall be made by a majority of
its members. Any decision or determination of the Compensation Committee reduced
to writing and signed by all members of the Compensation Committee shall be
fully effective as if it had been made at a meeting duly called and held.
ARTICLE 3: ELIGIBLE EMPLOYEES DEFINED.
As used in the Plan, the phrase "eligible employees" means all common
law employees of the Company and of the participating subsidiaries of the
Company, except the following shall not be deemed "employees" for purposes of
the Plan: (a) employees who have been employed by the Company, or its
subsidiaries, for less than 90 days, (b) employees customarily employed for less
than 20 hours per week, and (c) employees customarily employed for less than 5
months per year. All eligible employees shall have the same rights and
obligations under this Plan. Persons who are eligible employees on the first day
of a Payment Period shall receive their options on such day. Persons who become
eligible employees during the course of a Payment Period shall first receive
their options on the first day of the next succeeding Payment Period. However,
notwithstanding any other provision of this ARTICLE 3, an employee shall not be
deemed an eligible employee for purposes of the Plan if, immediately after the
option is granted, such employee owns stock possessing 5% or more of the total
combined voting power or value of all classes of the stock of the Company, or of
any participating subsidiary of the Company. For purposes of determining this 5%
limitation, the rules of Code Section 424(d) shall apply when determining the
stock ownership of an individual, and stock which the employee may purchase
under outstanding options shall be treated as stock owned by the employee.
<PAGE> 2
ARTICLE 4: STOCK SUBJECT TO THE PLAN.
The Stock subject to the options under the Plan shall be shares of the
Company's authorized but unissued common stock, par value $.01 per share
("Stock"), or shares of Stock reacquired by the Company, including shares
purchased in the open market. The aggregate number of shares which may be issued
pursuant to the Plan is 375,000, subject to adjustment as provided in ARTICLE
12. In the event that any option granted under the Plan shall expire or
terminate for any reason without having been exercised in full or shall cease
for any reason to be exercisable in whole or in part, the unpurchased shares
subject thereto shall again be available under the Plan.
ARTICLE 5: PAYMENT PERIODS AND STOCK OPTIONS.
The six-month periods, October 1 to March 31 and April 1 to September
30, are Payment Periods during which payroll deductions will be accumulated
under the Plan. To the extent any of these days is not a business day, the
Payment Period shall begin or end, as the case may be, on the first business day
following such date. The first Payment Period under the Plan will begin on
October 1, 1999.
Twice each year, on the first business day of each Payment Period, the
Company will grant to each eligible employee who is then a participant in the
Plan an option to purchase on the last day of such Payment Period, at the Option
Price hereinafter provided for, a maximum of the number of shares of Stock
equaling the number of whole shares obtained by dividing 5% of the eligible
employee's yearly wages (or such lesser percentage as the employee shall
designate pursuant to Article 8) by the average market price on the first day of
the Payment Period (the "Maximum Share Limit"), on condition that such employee
remains eligible to participate in the Plan throughout such Payment Period. The
participant shall be entitled to exercise such option so granted only to the
extent of the participant's accumulated payroll deductions on the last day of
such Payment Period. In the event that the participant's accumulated payroll
deductions on the last day of the Payment Period would enable the participant to
purchase more than the Maximum Share Limit were it not for the Maximum Share
Limit, the excess of the amount of the accumulated payroll deductions over the
aggregate purchase price of the Maximum Share Limit shall be promptly refunded
to the participant by the Company, with such interest as is provided in ARTICLE
8.
The Option Price for each Payment Period shall be the lesser of (i) 85%
of the closing price of the Stock on the first business day of the Payment
Period, or (ii) 85% of the closing price of the Stock on the last business day
of the Payment Period, in either event rounded up to avoid fractions of a dollar
other than 1/4, 1/2 and 3/4. The foregoing limitation on the number of shares
which may be granted in any Payment Period and the Option Price per share shall
be subject to adjustment as provided in ARTICLE 12.
For purposes of this Plan, the term "closing price" on any day means
(i) the last reported sale price of the Stock on that day on the principal
national securities exchange on which the Stock is traded, if the Stock is then
traded on a national securities exchange; or (ii) the last reported sale price
(on that date) of the Stock on the Nasdaq National Market List, if the Stock is
not then traded on a national securities exchange; or (iii) the average of the
closing bid and asked prices last quoted (on that date) by an established
quotation service for over-the-counter securities, if the Stock is not reported
on a national securities exchange or on the NASDAQ National Market List. If the
Stock is not publicly traded at the time the option is granted under this Plan,
"closing price" shall mean the fair market value of the Stock as determined by
the Compensation Committee after taking into consideration all the factors which
it deems appropriate, including, without limitation, recent sale and offer
prices of the Stock in private transactions negotiated at arm's length.
For purposes of this Plan, the term "business day" means a day on which
there is trading on the NASDAQ National Market System or on the aforementioned
national securities exchange, whichever is applicable pursuant to the preceding
paragraph.
No employee shall be granted an option which permits the employee's
right to purchase Stock under the Plan, and under all other Section 423(b)
employee stock purchase
<PAGE> 3
plans of the Company or any parent or subsidiary corporations, to accrue at a
rate which exceeds $25,000 of fair market value of Stock (determined at the time
such option is granted) for each calendar year in which such option is
outstanding at any time. The purpose of the limitation in the preceding sentence
is to comply with Code Section 423(b)(8).
ARTICLE 6: EXERCISE OF OPTION.
Each eligible employee who continues to be a participant in the Plan on
the last business day of a Payment Period shall be deemed to have exercised
his/her option on such date and shall be deemed to have purchased from the
Company such number of full shares of Stock reserved for the purpose of the Plan
as his/her accumulated payroll deductions plus additional payments on such date
will pay for at the Option Price, subject to the Maximum Share Limit on the
option. If a participant is not an employee on the last business day of a
Payment Period, he/she shall not be entitled to exercise his/her option. Only
full shares of Stock may be purchased under the Plan. Unused payroll deductions
remaining in an employee's account at the end of a Payment Period (other than
amounts refunded to the employee pursuant to ARTICLE 5) will be carried forward
to the succeeding Payment Period.
ARTICLE 7: AUTHORIZATION FOR ENTERING THE PLAN.
The Compensation Committee shall develop regulations concerning the
procedure which each employee must follow to become a participant of the Plan.
ARTICLE 8: AMOUNT OF PAYROLL DEDUCTIONS.
Subject to the limitations on stock purchases set forth in this Plan,
at the time specified in regulations issued pursuant to ARTICLE 7 an eligible
employee may designate the percentage of his/her wages during each Payment
Period that the employee wishes to have deducted and applied to the Plan;
provided, however, that the Compensation Committee may set such minimum and/or
maximum payroll deductions as the Compensation Committee, in its sole
discretion, deems appropriate. Any minimum and/or maximum payroll deductions
mandated by the Compensation Committee shall apply equally to all eligible
employees.
The Company will accumulate and hold for the employee's account the
amounts deducted from his/her pay. No interest will be paid on these amounts,
unless the Compensation Committee, in its sole discretion, determines that
interest should be paid on the amounts deducted from eligible employees' wages.
If the Compensation Committee decides that interest should be paid on the
amounts deducted from eligible employees' wages, the Compensation Committee may
set that interest rate at whatever rate the Compensation Committee, in its sole
discretion, deems appropriate, and may change that rate at whatever time, and to
whatever rate, the Compensation Committee, in its sole discretion, deems
appropriate.
ARTICLE 9: CHANGE IN PAYROLL DEDUCTIONS.
Deductions may not be increased or decreased during a Payment Period.
However, an employee may withdraw in full from the Plan, to the extent such
withdrawal is permitted by ARTICLE 10 of the Plan.
ARTICLE 10: WITHDRAWAL FROM THE PLAN.
An employee may withdraw from the Plan, in whole but not in part, by
delivering a withdrawal notice to the Compensation Committee not less than 10
days prior to the last business day of a Payment Period, in which event the
Compensation Committee shall promptly refund without interest the entire balance
of the employee's payroll deductions not previously used to purchase Stock under
the Plan. An employee who is an officer or director of the Company who withdraws
from the Plan may not participate in the Plan during the next succeeding Payment
Period.
<PAGE> 4
ARTICLE 11: ISSUANCE OF STOCK.
Certificates for Stock issued to participants will be delivered as soon
as practicable after each Payment Period by the Company's transfer agent.
Stock purchased under the Plan will be issued only in the name of the
employee, or if his/her authorization so specifies, in the name of the employee
and another person of legal age as joint tenants with rights of survivorship.
ARTICLE 12: ADJUSTMENTS.
Upon the happening of any of the following described events, an
optionee's rights under options granted under the Plan shall be adjusted as
hereinafter provided:
A. In the event shares of Stock shall be subdivided or
combined into a greater or smaller number of shares or if, upon a
reorganization, split-up, liquidation, recapitalization or the like of
the Company, the shares of the Stock shall be exchanged for other
securities of the Company, each optionee shall be entitled, subject to
the conditions herein stated, to purchase such number of shares of
stock or amount of other securities of the Company as were exchangeable
for the number of shares of Stock which such optionee would have been
entitled to purchase except for such action, and appropriate
adjustments shall be made in the purchase price per share to reflect
such subdivision, combination or exchange; and
B. In the event the Company shall issue any of its shares as a
stock dividend upon or with respect to the Stock, each optionee upon
exercising an option shall be entitled to receive (for the purchase
price paid upon such exercise) the shares as to which he/she is
exercising his/her option and, in addition thereto (at no additional
cost), such number of shares of the class or classes in which such
stock dividend or dividends were declared or paid, and such amount of
cash in lieu of fractional shares, as is equal to the number of shares
thereof and the amount of cash in lieu of fractional shares,
respectively, which he/she would have received if he/she had been the
holder of the shares as to which he/she is exercising his/her option at
all times between the date of the granting of such option and the date
of its exercise.
Upon the happening of any of the foregoing events, the class and
aggregate number of shares set forth in ARTICLE 4 hereof which are subject to
options which have been or may be granted under the Plan and the Maximum Share
Limit set forth in ARTICLE 5 shall also be appropriately adjusted to reflect the
events specified in paragraphs A and B above. Notwithstanding the foregoing, any
adjustments made pursuant to paragraphs A and B shall be made only to the extent
that the Compensation Committee, based on advice of counsel for the Company,
determines that such adjustments will not constitute a change requiring
stockholder approval under Code Section 423(b)(2).
If the Company is to be consolidated with or acquired by another entity
in a merger, or undergo a sale of all or substantially all of the Company's
assets or otherwise (all such events collectively referred to as an
"Acquisition"), the Compensation Committee shall, with respect to options then
outstanding under this Plan, (i) make appropriate provision for the continuation
of such options by arranging for the substitution on an equitable basis for the
shares then subject to such options the consideration payable with respect to
the outstanding shares of the Stock in connection with the Acquisition; (ii)
terminate all outstanding options in exchange for a cash payment equal to the
excess of the fair market value of the shares subject to the options (determined
as of the date of the Acquisition) over the Option Price thereof (determined
with reference only to the first business day of the applicable Payment Period)
if such fair market value exceeds such Option Price; or (iii) terminate all
outstanding options and promptly refund without interest the balance of employee
deductions not used to purchase Stock under the Plan in the event that the fair
market value of the shares subject to the options (determined as of the date of
the Acquisition) is less than the Option Price thereof (determined with
reference only to the first business day of the applicable Payment Period).
<PAGE> 5
The Compensation Committee shall determine the adjustments to be made
under this ARTICLE 12, and its determination shall be conclusive.
ARTICLE 13: NO TRANSFER OR ASSIGNMENT OF EMPLOYEE'S RIGHTS.
An employee's option rights under the Plan are the employee's alone and
may not be transferred or assigned to, or availed of by, any other person other
than by will or the laws of descent and distribution. Any option granted under
the Plan to an employee may be exercised, during the employee's lifetime, only
by the employee.
ARTICLE 14: TERMINATION OF EMPLOYEE'S RIGHTS.
An employee's rights under the Plan will terminate when he/she ceases
to be an employee of the Company or of a participating subsidiary of the Company
(other than as a result of death or an Approved Leave of Absence, as defined
below). A withdrawal notice will be considered as having been received from the
employee on the day his/her employment so ceases, and all payroll deductions not
used to purchase Stock will be refunded without interest.
If an employee's payroll deductions are interrupted by any legal
process, a withdrawal notice will be considered as having been received from the
employee on the day the interruption occurs.
ARTICLE 15: DEATH OF AN ELIGIBLE EMPLOYEE.
Upon an eligible employee's death, his or her beneficiary may elect to
(i) withdraw the accumulated balance of the employee's payroll deductions during
a Payment Period, or (ii) apply such balance at the end of the Payment Period to
the purchase of Stock. The beneficiary must make this election by written notice
to the Board of Directors within the earlier of 60 days of the participant's
death, or the end of the Payment Period. Failure to make a timely election in
accordance with this Article shall result in the application of the balance of
the employee's payroll deductions to the purchase of Stock. The Company shall
not be obligated to deliver any Stock or cash to a beneficiary until the Company
shall have received proof satisfactory to the Company of his or her identity,
existence and valid designation.
ARTICLE 16: APPROVED LEAVES OF ABSENCE.
An eligible employee may continue to participate in the Plan during a
leave of absence from his or her employment with the Company or a participating
subsidiary of the Company for which he or she obtains prior approval (an
"Approved Leave of Absence"). During an Approved Leave of Absence that is paid,
an employee's participation in the Plan will continue in the same manner as
before such leave of absence began. An Approved Leave of Absence that is paid
shall mean one in which regular payroll disbursements to the eligible employee
from the Company or a participating subsidiary of the Company, and payroll
deductions under the Plan, continue to occur as before such leave of absence.
During all other Approved Leaves of Absence, an eligible employee may (in lieu
of payroll deductions) make contributions under the Plan from disability, sick
or vacation pay, or in cash, for the first 90 days of the Approved Leave of
Absence; provided, however, that the aggregate amount of such contributions made
during this period shall not exceed the aggregate amount of payroll deductions
that otherwise would be permitted during this period under the Plan. After this
period, a participant may make no further contributions under the Plan until the
Approved Leave of Absence has ended and he or she has returned to employment
with the Company or a participating subsidiary of the Company.
ARTICLE 17: TERMINATION AND AMENDMENTS TO PLAN.
The Plan may be terminated at any time by the Company's Board of
Directors but such termination shall not affect options then outstanding under
the Plan. The Plan will terminate in any case when all or substantially all of
the unissued (or issued but not outstanding) shares of Stock reserved for the
purposes of the Plan have been purchased. If at any time shares of Stock
reserved for the purpose of the Plan remain available for purchase but not in
sufficient number to satisfy all then unfilled purchase requirements,
<PAGE> 6
the available shares shall be apportioned among participants in proportion to
their options and the Plan shall terminate. Upon such termination or any other
termination of the Plan, all payroll deductions not used to purchase Stock will
be refunded without interest.
The Board of Directors may from time to time adopt amendments to the
Plan provided that, without the approval of the shareholders of the Company, no
amendment may materially increase the benefits accruing to participants under
the Plan, materially increase the number of shares that may be issued under the
Plan, or materially modify the requirements for eligibility for participation in
the Plan.
ARTICLE 18: LIMITS ON SALE OF STOCK PURCHASED UNDER THE PLAN.
The Plan is intended to provide shares of Stock for investment and not
for resale. SHARES OF STOCK PURCHASED UNDER THE PLAN MAY NOT BE SOLD,
TRANSFERRED OR ASSIGNED FOR 90 DAYS FROM THE DATE OF PURCHASE. Except for such
limitation, the Company does not intend to restrict or influence any employee in
the conduct of his/her own affairs. An employee may, therefore, sell Stock
purchased under the Plan at any time the employee chooses after 90 days from the
date of purchase, subject to compliance with any applicable Federal or state
securities laws; provided, however, that because of certain Federal tax
requirements, each employee agrees by entering the Plan promptly to give the
Company notice of any such stock disposed of within two years after the date of
grant of the applicable option showing the number of such shares disposed of.
THE EMPLOYEE ASSUMES THE RISK OF ANY MARKET FLUCTUATIONS IN THE PRICE OF THE
STOCK.
ARTICLE 19: PARTICIPATING SUBSIDIARIES.
The term "participating subsidiary" shall mean any subsidiary of the
Company, as that term is defined in Section 425(f) of the Code, which is
designated from time to time, by the Board of Directors to participate in the
Plan. The Board of Directors shall have the power to make such designation
before or after the Plan is approved by the shareholders.
ARTICLE 20: OPTIONEES NOT SHAREHOLDERS.
Neither the granting of an option to an employee nor the deductions
from his/her pay shall constitute such employee a shareholder of the shares
covered by an option until such shares have been actually purchased by the
employee.
ARTICLE 21: APPLICATION OF FUNDS.
The proceeds received by the Company from the sale of Stock pursuant to
options granted under the Plan will be used for general corporate purposes.
ARTICLE 22: GOVERNMENTAL REGULATIONS.
The Company's obligation to sell and deliver shares of the Stock under
this Plan is subject to the approval of any governmental authority required in
connection with the authorization, issuance or sale of such shares, including
the Securities and Exchange Commission and the Internal Revenue Service.
ARTICLE 23: APPROVAL OF SHAREHOLDERS.
The Plan shall be subject to approval by the holders of a majority of
the shares of the Company present or represented by proxy at a duly called
meeting of shareholders, which approval must occur within twelve months before
or after the date on which this Plan was adopted by the Board of Directors.
Prior to such approval no shares shall be issued to participants under the Plan.
In the event that the approval of the shareholders is not received within twelve
months before or after the date of the adoption of this Plan, any and all
options previously granted shall be rescinded, and the Company will promptly
refund the entire balance of each participating employee's deductions without
interest.
<PAGE> 1
Exhibit 11
SUMMIT TECHNOLOGY, INC.
STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
(IN THOUSANDS, EXCEPT PER SHARE AMOUNT) 1999 1998 1997
- ----------------------------------------------------------------------------------------
<S> <C> <C> <C>
Income (loss) from continuing operations $(23,025) $ 36,730 $ 828
Gain on sale of discontinued operations, net of tax -- 943 23,910
Loss from discontinued operations, net of tax -- -- (3,340)
-------- ------- --------
Income (loss) before cumulative
effect of accounting principle change (23,025) 37,673 21,398
Cumulative effect of accounting principle
change, net of tax -- (10,103) --
-------- ------- --------
Net income (loss) $(23,025) $ 27,570 $21,398
======== ======= ========
BASIC EARNINGS (LOSS) PER SHARE:
- - --------------------------------
Weighted average common shares 40,436 31,244 31,400
-------- ------- --------
Income (loss) from continuing operations $ (0.57) $ 1.17 $ 0.03
Gain on sale of discontinued operations, net of tax -- 0.03 0.76
Loss from discontinued operations, net of tax -- -- (0.11)
-------- ------- --------
Income (loss) before cumulative
effect of accounting principle change (0.57) 1.20 0.68
Cumulative effect of accounting principle
change, net of tax -- (0.32) --
-------- ------- --------
Net income (loss) $ (0.57) $ 0.88 $ 0.68
======== ======= ========
DILUTED EARNINGS (LOSS) PER SHARE:
- - ----------------------------------
Weighted average common shares 40,436 31,244 31,400
Effect of dilutive securities outstanding 1,459 48 191
-------- ------- --------
Total 41,895 31,292 31,591
======== ======= ========
Income (loss) from continuing operations $ (0.55) $ 1.17 $ 0.03
Gain on sale of discontinued operations, net of tax -- 0.03 0.76
Loss from discontinued operations, net of tax -- -- (0.11)
-------- ------- --------
Income (loss) before cumulative
effect of accounting principle change (0.55) 1.20 0.68
Cumulative effect of accounting principle
change, net of tax -- (0.32) --
-------- ------- --------
Net income (loss) $ (0.55)(A) $ 0.88 $ 0.68
======== ======= ========
</TABLE>
(A) This computation is submitted as an exhibit to the Company's Form 10-K in
accordance with Regulation S-K Item 601(b) (11), although presenting the
computation is not in accordance with Statement of Financial Accounting
Standards No. 128, Earnings per Share, because the computation produces an
antidilutive result
<PAGE> 1
Exhibit 23.1
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in Registration Statement Nos.
33-25169, 33-41451, 33-49162, 333-25142 and 333-41583 on Form S-8 of Summit
Technology, Inc. and subsidiaries (the "Company") of our report dated January
31, 2000, except for the second paragraph of Note 1, as to which the date is
February 23, 2000, (which expresses an unqualified opinion and includes an
explanatory paragraph relating to a change in accounting principle described in
Note 2 to the consolidated financial statements), appearing in this Annual
Report on Form 10-K of the Company for the year ended December 31, 1999.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 30, 2000
<PAGE> 1
Exhibit 23.2
CONSENT OF INDEPENDENT ACCOUNTANTS
The Board of Directors
Summit Technology, Inc.:
We consent to incorporation by reference in the Registration Statement Nos.
33-25169, 33-41451, 33-49162, 333-25142 and 333-41583 on Form S-8 of Summit
Technology, Inc. and subsidiaries of our report dated March 6, 1998, relating to
the consolidated statements of operations, stockholders' equity, and cash flows
and related schedule for the year ended December 31, 1997, which report appears
in this Annual Report on Form 10-K of Summit Technology, Inc., dated March 30,
2000.
/s/ KPMG LLP
Boston, Massachusetts
March 30, 2000
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE DECEMBER
31, 1999 CONSOLIDATED FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> DEC-31-1999
<CASH> 69,850
<SECURITIES> 5,730
<RECEIVABLES> 19,819
<ALLOWANCES> 1,042
<INVENTORY> 25,885
<CURRENT-ASSETS> 123,550
<PP&E> 40,001
<DEPRECIATION> 19,050
<TOTAL-ASSETS> 270,667
<CURRENT-LIABILITIES> 23,720
<BONDS> 1,986
0
0
<COMMON> 470
<OTHER-SE> 235,698
<TOTAL-LIABILITY-AND-EQUITY> 270,667
<SALES> 111,099
<TOTAL-REVENUES> 111,099
<CGS> 63,262
<TOTAL-COSTS> 139,001
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 13
<INTEREST-EXPENSE> 315
<INCOME-PRETAX> (22,650)
<INCOME-TAX> 375
<INCOME-CONTINUING> (23,025)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (23,025)
<EPS-BASIC> (.57)
<EPS-DILUTED> (.57)
</TABLE>
